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Chapter 1 
General introduction 
1.1 Pathophysiology of migraine 
Migraine may manifest itself in many ways and the syndrome is afflicting 
approximately ten percent of the worlds population. The peak incidence of the 
syndrome occurs in adolescents and young adults, and the prevalence is about tlu:ee 
times as high among females than males (Staffa et al., 1994). The diversity of 
symptoms and the potential confusion with other types of headaches, such as 
tension-type headache and cluster headache, has lead to the formulation of diagnostic 
criteria by the International Headache Society (Olesen et al., 1988). These criteria 
discern between two main types of migraine. The first, migraine without aura, was 
previously known as common migraine and is characterized by recurrent attacks of 
intense headache lasting 4 to 72 hours. The headache is commonly unilateral, pulsatile 
and throbbing in nature. The pain is often accompanied by anorexia, nausea and 
vomiting, as well as aversion to noise and light (phonophobia and photophobia). In the 
second type, previously known as classical migraine, headache is preceded by 
neurological symptoms called aura symptoms. The classic aura includes visual 
disturbances, like scintillating scotoma and fortification spectra, that drift across the 
visual field. In addition, somatosensory symptoms may occur as a feeling of numbness 
(pins and needles) slowly ascending fi'om the fingertips to the shoulder (Spierings, 
1988; Blau, 1992). The duration of the aura phase is often limited to 60 minutes, but 
may outlast into the headache phase. 
The clinical forms of migraine attacks suggest that migraine represents in fact two 
different types of disease. This view is supported by experimental data, demonstrating 
that cerebral blood flow is usually reduced in migraine with aura but not in migraine 
without aura (Olesen et al., 1981; Lauritzen, 1994). The difference between the two 
forms may be attributed to individual variations in reactivity towards the same initial 
trigger. 
Despite detailed descriptions of the events occurring during the actual attack, little 
is known about the stimulus initiating the sequence of events. A number of prodromal 
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symptoms have been related to migraine, which include episodes of emotional and 
physical stress, sleep deprivation, enheightened sensory perception and craving for 
specific foods (Blau, 1992). The wide variety of these prodromes seems to preclude 
a common generator of migraine, although some of these stimuli could affect specific 
brain areas. 
The aura 
The occurrence of cerebral hypoperfusion during the migraine aura has been 
documented but the underlying mechanism remains a matter of ongoing debate. At the 
very beginning of migraine attacks regional cerebral blood flow decreases in the 
posterior part of the brain. Subsequently, the low flow region spreads into the parietal 
and temporal lobes at a rate of 2-3 mm min-! (Olesen et al., 1981; for review see, 
Lauritzen, 1994). It has been argued that this spreading oligemia can not account for 
the focal symptomes of migraine aura. The spreading oligemia continues after the 
symptoms of aura have vanished and blood flow reduction is too moderate to cause 
neuronal dysfunction. Furthermore, the propagation of visual disturbances occurs at a 
similar rate as cortical spreading depression, a process of cortical neuronal 
depolarization which can be observed in animals following noxious stimuli, suggesting 
a neuronal rather than a vascular origin of migraine aura (for review see Lauritzen, 
1994). However, re-evaluation of blood flow data taking into account the 
methodological implications of Compton scatter, that is the contribution of radiation 
from surrounding tissues to local blood flow analysis, suggested that cerebral blood 
flow can reach ischaemic levels and thus cause neuronal changes (Olsen & Lassen, 
1989). Moreover, cortical spreading depression is not easily observed in humans (Piper 
e/ al., 1991). 
The headache 
The pulsatile and throbbing nature of the headache suggests that a dilatation of 
large cranial and extracranial vessels is involved in the headache phase of migraine. 
Indeed, dilatation and enhanced vascular pulsations of the temporal and occipital 
branches of the external carotid artery, on the side of the headache, were described 
already in 1938 by Graham and Wolff. Headache relief, obtained with ergotamine, was 
associated with a reduction in vascular pulsatility. In contrast, administration of 
histamine caused headache and increased the amplitude of pulsations in the temporal 
artery (Graham & Wolff, 1938). Reviewing their experimental data, Drummond and 
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Lance (1988) concluded that an increase in vascular pulse amplitude in the 
frontotemporal region is observed in approximately one-third of the patients suffering 
unilateral migraine. More recently, transcranial Duplex-Doppler methods have been 
applied to monitor changes in blood flow velocity during migraine attacks. In 1990, 
Iversen reported that the lumen of the superficial temporal artery was wider on the side 
of headache than on the other side. Likewise, Thie et a!. (1990) observed a reduction 
of blood flow velocity with increased pulse wave amplitudes, in a number of cranial 
arteries during attacks of migraine without aura. However, evidence of middle cerebral 
artery dilatation, on the side of migraine headache is still conflicting. A reduction of 
blood flow velocity without concomitant change in total cerebral blood flow, indicating 
vasodilatation in this artery, has been observed in a small group of patients (Friberg 
et al., 199 I). In contrast, no changes in middle cerebral artery blood flow velocity 
were found during and between attacks in patients without aura (Zwetsloot et al., 
1993). Despite these equivocal changes, an increase in blood flow velocity in large 
cranial arteries has been observed after acute treatment with the antimigraine drug 
sumatriptan (Friberg et al., 1991; Caekebeke et al., 1992). 
In order to explain the changes in blood flow and the facial pallor observed in 
some migraine patients, Heyck hypothesized that erulanced shunting of blood through 
arteriovenous anastomoses may lead to passive increases in blood flow through large 
(extra)cranial arteries. At the same time, increased arterial pulsations will propagate, 
unattenuated, to precapillary vessels as well as the venous side of the circulation 
(Heyck et al., 1969). This postulate is largely based on the observation that the 
difference in oxygen content of arterial and venous blood obtained fi'om the ipsilateral 
side of the head was reduced. Moreover, restoration of the difference in oxygen 
saturation was observed following either spontaneous or ergotamine-induced headache 
relief. In line with this view, antimigraine drugs like ergotamine, dihydroergotamine 
and sumatriptan cause a constriction of arteriovenous anastomoses and large atteries 
in the porcine carotid circulation (Den Boer et al., 1991, (993). Heyck's hypothesis 
is suppOlted by recent observations indicating that human peripheral arteriovenous 
anastomoses are indeed dilated during migraine attacks and a therapeutic dose of 
sumatriptan can reduce sodium nitroprusside-induced elavated anastomotic blood flow 
in the human finger vasculature (Van Es et al., (995). 
Although evidence indicating a direct link between the vascular changes and the 
incidence of pain is absent, local vasodilatation together with increased vascular 
pulsations may cause headache via a depolarization of perivascular sensory nerves. 
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An alternative theory on the pathogenesis of migraine has been put forward by 
Moskowitz (1992) stating that an unknown trigger causes activation of trigeminal nerve 
endings on the cranial vasculature leading to antidromic release of vasoactive 
neuropeptides. Such neuropeptides, like substance P and calcitonin gene-related peptide 
(CORP), present in adventitial nerves surrounding cranial arteries (Uddman et al. 1986; 
Suzuki et al., 1989), may induce a temporary aseptic inflammatory process, finally 
resulting in pain. These peptides are potent vasodilators (Brain el al., 1985; this thesis, 
chapter 7) and may, therefore, give rise to a concomitant dilatation of large cranial 
arteries and alieriovenous anastomoses. The possible pathophysiological changes during 
migraine attacks are sUllllnarized in figure 1.1. 
Arteriovenous anastomoses 
Alieriovenous anastomoses are precapillary blood vessel elements connecting 
alieries and veins. The localization of these cOllllnunications enables the blood flow to 
bypass the capillary bed. These structures have been localized in various tissues 
including the human and porcine skin, tongue and dura mater. In contrast, no 
arteriovenous anastomoses have been detected in the brain (Rowbothan & Little, 1965; 
Kerbel' & Newton 1973; Den Boer el al., 1992a). Within the skin, alieriovenous 
anastomoses contribute to the exchange of body heat, whereas in other tissues they may 
serve to regulate local blood flow. In the open state, the lumen of arteriovenous 
anastomoses may exceed the diameter of the capillaries and large amounts of blood can 
be directed either fi'om deep layers to the surface or from the arterial towards the 
venous side of the circulation. 
Depending on the type of tissue, arteriovenous anastomoses are innervated by 
catecholaminergic nerves, containing noradrenaline, dopamine and/or neuropeptide Y, 
and cholinergic nerves, containing acetylcholine and vasoactive intestinal peptide (for 
reviews see Hales & Molyneux, 1988; Den Boer, 1993). In addition, histochemical 
studies in the dog and sheep tongue have shown the presence of peptidergic nerve 
fibres, containing CORP and substance P, around the walls of arteriovenous 
anastomoses (Molyneux & Haller, 1987; Hino e/ al., 1993). Preliminary observations 
indicate that CORP may also contribute to the regulation of blood flow throngh 
arteriovenous anastomoses in the sheep limb (Mogg e/ al., 1992). Finally, arteriovenous 
anastomoses may also be under hormonal constrictor influences, since 5-HT and related 
agonists constrict arteriovenous anastomoses (Saxena & Verdouw, 1982). 
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Figure 1.1 Possible changes in migraine. Migraine attacks are initiated by an unknown 
generator. Cerebral blood flow is reduced during the pre-headache phase, whereas dilatation 
of extracerebral cephalic arteries and arteriovenous anastomoses occurs during headache. 
Activation of the trigeminal nervous system (5th cranial nerve) and central pathways may 
evoke typical migraine symptoms and the release of vasoactive neuropeptides (modified from 
Saxena, 1994). 
1.2 Local regulation of vascular tone; endothelium-derived factors 
Introduction 
Because of its key localization and physiological functions, the vascular 
endothelium has been recognized as a regulatory organ rather than a simple sheet of 
cells aligning the vascular smooth muscle. Vascular endothelium has a variety of 
physiological functions which include, among others, a selective barrier function, 
regulation of inflammatory responses and cell proliferation. In addition, the 
endothelium maintains a nonadhesive luminal surface and, regulates platelet 
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aggregation and leucocyte adhesion (Radomski el al., 1987; Kubes el al., 1991). 
Furthermore, endothelial cells contribute to cardiovascular homeostasis via the release 
of a number of vasoactive substances with opposite actions to regulate the underlying 
smooth muscle tone and hence local blood flow. Similar to other major organs, 
endothelial cells receive input from their enviromnent, that is, via circulating or locally 
produced vasoactive substances and mediators derived from blood cells like platelets 
and leucocytes. Moreover, the vascular endothelium is stimulated by mechanical forces 
like shear stress and pressure, provoked by the circulating fluid stream. 
Interest in the regulatory functions of endothelial cells was increased substantially 
by the observation of Furchgott and Zawadzki (1980) that the presence of vascular 
endothelium is a prerequisite for the vasorelaxant action of acetylcholine. Removal of 
the endothelial layer from the isolated rabbit aorta prevented acetylcholine-induced 
relaxations in this vessel and, as relaxations did not depend on the release of 
cyclo-oxygenase derivatives, it was proposed that other diffusible factor(s) were 
released by the endothelium. This factor was later termed endothelium-derived relaxing 
factor (EDRF) and its chemical nature has been examined in detail. The preponderance 
of evidence suggests that EDRF is chemically related to the nitric oxide radical. In 
addition to EDRF, the existence of other endothelium-derived relaxing factors have 
been recognized which include the endothelium-derived hyperpolarizing factor (Garland 
el al., 1995) as well as the metabolite of arachidonic acid, prostacyclin (Vane el al., 
1990). In parallel with the discovery of endothelium-derived relaxing factors a host of 
contracting factors (EDCFs), have been postulated in the last decade. Apart from a 
number of unidentified constrictor substances, two major categories can be recognized. 
The first group includes products of the cyclo-oxygenase pathway such as 
thromboxane, prostaglandin H, and superoxide anions (Vane el al., 1990; Liischer 
el al., 1992). The second group consists of the family of potent vasoconstrictor 
isopeptides, the endothelins (Yanagisawa el al., 1988). 
The simultaneous release of relaxing and contracting factors, stimulated by the 
same naturally occurring substances, gives rise to a variety of interactions, and their 
opposite actions seem to imply a delicate balance under physiological conditions. As 
a consequence, local changes in endothelial function may have considerable 
implications on local blood vessel tone and blood flow. 
The following sections summarize the various endothelium-derived contracting 
and relaxing factors with special emphasis on the current knowledge of the vascular 
physiology of nitric oxide. 
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Endothelium-derived constricting factors 
Prosfanoids 
In a variety of blood vessels, endogenous agonists evoke endothelium-dependent 
contractions which can be blocked by inhibitors of the enzyme cyclooxygenase. This 
suggests that the endothelial cell is the source of these mediators. The major 
vasoconstrictor product of cyclooxygenase is thromboxane A,. Its formation from 
endoperoxides is catalyzed by the enzyme thromboxane synthetase (Moncada & Vane, 
1979). Since the production of thromboxane A, cannot explain all endothelium-
dependent contractions, other metabolites of arachidonic acid have been proposed to 
be involved. For example, in the dog cerebral artery contractions have been attributed 
to the precursor ofthromboxane A" prostaglandin H, (Toda ef al., 1988), whereas in 
the canine basilar artery superoxide anions produced by the cyclooxygenase-pathway 
seem to mediate contraction via inactivation of endothelium-derived relaxing factor 
(Katusic & Vanhoutte, 1989). 
Endofhelins 
This group of vasoactive isopeptides is probably one of the most impressive 
representatives of the EDCFs. The members of this family, denoted ET-I, ET-2 and 
ET-3 respectively, are generated from the precursor molecules prepro·endothelin and 
proendothelin (big endothelin). Conversion of big endothelin to the vasoactive 
21-aminoacid peptides is mediated in endothelial cells by the metalloprotease enzyme 
endothelin-converting enzyme (ECE), which process is blocked by phosphoramidon 
(Yanagisawa ef at. 1988; Matsumura ef al., 1990). The release of endothelin from the 
vascular endothelium is provoked by vasopressor substances like angiotensin II and 
vasopressin, the coagulation product thrombin as well as by brief periods of anoxia and 
vascular stretch (Figure 1.2; for review see LUscher ef al., 1992; Macarthur ef at., 
1994). 
When injected intravenously, endothelins elicit a biphasic blood pressure response, 
that is, a brief depressor phase followed by a long-lasting pressor response (DeNucci 
ef al., 1989). The various receptors for endothelin have been cloned (Arai ef at., 1990; 
Sakurai ef at., 1990) and according to the currently held receptor classification the 
pressor response is mediated via stimulation of endothelin ETA and ET B receptor 
subtypes present on vascular smooth muscle cells (Figure 1.2). In contrast, the 
short-lasting depressor response is mediated via endothelin ET B receptors on the 
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vascular endothelium (Davenport & Maguire, 1994). The vasorelaxant action of 
endothelin has been attributed to a concomitant release of prostacyclin and EDRF 
which may limit endothelin induced vasoconstriction (DeNucci et ai., 1988; Warner 
et ai., 1992; Fozard & Part, 1992). In addition, the production of endothelin is 
regulated by inhibitory stimuli like prostacyclin, EDRF and ADP, presumably via a 
cGMP-dependent mechanism (Boulanger & LUscher, 1990; Saijonmaa et ai., 1990). 
Under normal conditions, circulating levels of endothelin are very low, which 
seem to imply that the peptide has a moderate role in the regulation of vascular tone. 
However, ET-precursor mRNA is expressed constitutively within the vascular wall and, 
the ECE inhibitor phosporamidon as well as the endothelin ETA receptor antagonist 
BQI23 have been shown to increase regional blood flow in the human forearm 
suggesting that endothelin is released continuously in the vasculature (Haynes & Webb, 
1994). Moreover, endothelin is released predominantly towards the abluminal side of 
the blood vessel and the peptide may be regarded as a local regulatory substance rather 
than a circulating hormone (LUscher el ai., 1992). The potent vasoconstrictor properties 
of endothelin have been related to a number of pathological conditions, including 
migraine (Fiirkkilii et ai., 1992; Gallai et ai., 1994). 
Angiotensin 
Though angiotensin II was initially recognized as a circulating vasoconstrictor 
peptide mainly derived from the kidneys, endothelial angiotensin convelting enzyme 
(ACE) has been implicated in the conversion of angiotensin I to angiotensin II. Inspite 
of an ongoing debate on the origin of vascular renin, major components of the 
renin-angiotensin system, like angiotensinogen, have been identified in cultured 
endothelial cells and these cells are capable to produce angiotensin II (for review see 
Dzau, 1989; Von Lutterotti et ai., 1994). In this respect, angiotensin II can also be 
regarded as an endothelium-derived contracting factor. Pharmacological evidence 
suggests that at least two different angiotensin receptor subtypes (AT, and AT,) exist 
in the peripheral circJlation and the brain (for review see Timmermans et ai., 1993). 
Vascular smooth muJcle cells predominantly express angiotensin AT, receptors and 
activation of this receptor subtype commonly produces vasoconstriction (Figure 1.2). 
In addition to its hypertensive action, angiotensin II can produce endothelium 
dependent relaxation via yet undefined receptor subtypes. 
18 
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Figure 1.2 Endothelium-derived cOlltracting factors. Stimulation of cyclooxygenase (COX) 
by agonists, partly derived from aggregating platelets, and stretch induces the release of 
thromboxane A, (TXA,), prostaglandin H, (PGH,) and superoxide anion (0,-), which mediate 
contraction. Similarly, activation of endothelin-converting enzyme (ECE) leads to the 
production of endothelin (ET-I). ET-I may activate smooth muscle endothelin ETA and ET. 
receptors to mediate contraction. Stimulation of endothelial' ET B receptors initiates the release 
of endothelium-derived relaxing factors NO and prostacyclin (PGI,), which cause 
vasorelaxation. Local conversion of angiotensin I (AJ into angiotensin II (All) by angiotensin-
converting enzyme (ACE) may induce AT, receptor mediated smooth muscle contraction. 
Abbreviations: AA, arachidonic acid; Ach, acetylcholine; A VP, arginine vasopressin; L-Arg, 
L-arginine; NOS, NO-synthase; 5-HT, 5-hydroxytryptamine; pro-ET, pro-endothelin. 
Endothelium-derived relaxing factol's 
Prostacyclin 
The potent vasorelaxant and platelet-inhibitory metabolite of arachidonic acid, 
prostacyclin, is produced by endothelial and vascular smooth muscle cells. Its 
formation involves conversion of arachidonic acid to endoperoxide prostaglandins G, 
19 
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and H, which are subsequently convelted by prostacyclin synthase to prostacyclin 
(Vane et al., 1990). The release of prostacyclin from the vascular endothelium is 
stimulated by several endogenous mediators, like bradykinin, thrombin and endothelin, 
platelet-derived substances like 5-HT and adenine nucleotides as well as by anoxia and 
physical forces such as shear stress (Figure 1.3). The endothelial production of 
prostacyclin is activated by similar stimuli as EDRFINO production, indicating that 
these substances may act in conceIt to reduce vascular tone. 
Endothelium-derived hyperpolarizing Jactor 
In arterial tissues, cholinomimetics and other agonists like histamine and 
substance P, cause vasorelaxation which is often accompanied by an increase in smooth 
muscle membrane potential. This hyperpolarization is converted into depolarization 
after removal of the endothelium, thereby suggesting the release of a hyperpolarizing 
factor from endothelial cells (Komori et al., 1988; Chen & Suzuki, 1989; for review 
see Garland ef al., 1995). The chemical identity of this factor, termed endothelium-
derived hyperpolarizing factor (EDHF) and the cellular mechanism mediating 
endothelium-dependent hyperpolarization are distinct from those of EDRF and 
cyclooxygenase products. For example, hyperpolarization in response to acetylcholine 
is largely unaffected by agents, like haemoglobin, methylene blue and inhibitors of 
NO-synthase, known to inhibit EDRF-mediated relaxant responses (Chen & Suzuki, 
1989; Garland & McPherson, 1992). The change in smooth muscle potential evoked 
by EDHF has been associated with an increase in K+ conductance (Chen & Suzuki, 
1989) through small conductance Ca'+-activated K+ channels, although the type of 
channel involved is contentious. Comparison of agonist-evoked hyperpolarization and 
relaxation in isolated blood vessels of different size suggests that EDHF may have a 
predominant role in small arterioles. In contrast, hyperpolarization and relaxation in 
large conduit alteries has been ascribed largely to EDRF (see Garland ef al., 1995). 
The physiological role of smooth muscle hyperpolarization remains to be clarified. 
Nitric oxide 
DiscovelY 
Following the discovery ofEDRF, the labile nature of this factor became evident 
from cascade bioassay experiments in which a series of endothelium-denuded detector 
vessels relaxed following superfusion with the perfusate from endothelium-intact donor 
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blood vessels or cultured endothelial cells. Variation of the distance between donor and 
detector preparation enabled detection of its biological half-life, ranging from 4 to 6 
seconds (Griffith ef al., 1984; Rubanyi ef al., 1985; Gryglewski ef al., 1986; Palmer 
ef aI., 1987). 
Plllt(JI"t~O. 
\JUO 
~ PGI2 NO 
Shear Stress Ach, Bk, Hlst, SP 5·HT, ADP, Thrombin NPR,SNAP 
~~ 
IfndlUh6//,1 t:6//4 
~ 
Cal< l-Arg 
Icox I~ INOS t ~ ~ 
PGI, EDHF NO -~1'(.-7 
GC 
GTP-;'-cGMP 
Vasodilatation 
~ 
NO 
Figure 1.3 Endothelium-derived relaxing jactors. Various substances, partly derived from 
aggregating platelets and, shear stress may, in part via specific receptors, evoke the release 
of POI, and NO from endothelial cells. In resistance vessels, endothelium-derived 
hyperpolarizing factor (EDHF) is released. The formation ofpOl, from arachidonic acid (AA) 
is mediated by cyclooxygenase (COX). Its release leads to an increase in cAMP content of 
vascular smooth muscle cells. Calcium-dependent NO-synthase (NOS) produces NO from 
L-arginine (L-arg). NO stimulates smooth muscle guanyl cyclase (GC) to increase 
cytoplasmatic cGMP content, which action is mimicked by nitrovasodilators (nitroprusside 
sodium (NPR) and S-nitroso-N-acetylpenicillamine (SNAP». EDHF may induce 
vasorelaxation by increasing smooth muscle cell K+ conductance and subsequently reducing 
intracellular free Ca" levels. In addition, both POI, and NO inhibit platelet aggregation and 
the release of endothelin (ET-I). Abbreviations: Ach, acetylcholine; Bk, bradykinin; ECE, 
endothelin converting enzyme; ET -1, endothelin; Hist, histamine; 5-HT, 5-hydroxytryptamine; 
pro-ET, pro-cndothelin; SP, substance P. 
21 
Chapter 1 
In parallel, the smooth muscle relaxant properties of a class of nitrovasodilators 
were shown to be endothelium-independent and their action seemed to be due to the 
liberation of a labile free radical, presumably nitric oxide. In a number of tissue 
preparations, nitric oxide gas increases soluble guanylyl cyclase (GC) activity to 
elevate cGMP levels, an effect which could be mimicked using nitric oxide-generating 
compounds, such as sodium azide, hydroxylamine, sodium nitroprusside and 
S-nitrosothiols (Arnold et al., 1977; Ignarro et al., 1981). Likewise, agonist stimulated 
endothelium-dependent relaxations in the rat aorta were associated with activation of 
GC with a subsequent increase in intracellular cGMP level (Rapoport & Murad, 1983). 
Around the same time, metabolic balance stndies demonstrated that urinary nitrate 
excretion levels were in excess to dietary ingestion in both conventional and germfree 
rats as well as in humans, suggesting that nitrate is endogenously synthesized in 
mammalian cells (Green et al., 198Ia,b). 
Different pharmacological and chemical approaches were used to provide 
evidence that EDRF and NO were in fact identical: (i) in cascade bioassay 
preparations, EDRF released from intact arteries, veins and cultnred endothelial cells 
relaxed detector arteries and increased cGMP content in a similar way as authentic 
nitric oxide did (Ignarro et al., 1987; Palmer et al., 1987); (ii) the decay of EDRF 
during passage through the bioassay system resembled that of nitric oxide and the 
relaxant effect of both compounds was inhibited comparably by haemoglobin, 
erythrocytes,andmethyleneblue(Ignarro et al., 1987; Palmer et al., 1987; Gillespie & 
Sheng, 1988); (iii) similar to EDRF (Gryglewski et al., 1986; Rubanyi & Vanhoutte, 
1986), nitric oxide is stabilized by elimination of superoxide anions employing SOD 
(Ignarro et al., 1987; Palmer et al., 1987); (iv) Both EDRF and nitric oxide are 
detected by spectrophotometry after diazotization with sulphanilic acid and cause a 
characteristic shift in the absorbance spectrum of haemoglobin following their reaction 
with oxygenated haemoglobin (Ignarro et al., 1987); (v) Final support for the identity 
of EDRF was provided by chemoluminescence, which is based on the reactivity of 
nitric oxide or EDRF with ozone to generate a chemoluminescent product. Using this 
method, Palmer el al. (1987) demonstrated that nitric oxide is released from endothelial 
cells in amounts correlating with relaxations observed in bioassay preparations. Finally, 
Kelm et al. (1988), described the kinetics of nitric oxide with the difference 
spectrophotometric method and obtained a half-life of 5.6 s, essentially the same as 
reported previously for EDRF. 
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Apart from its vasorelaxant properties, NO released from vascular endothelial 
cells inhibits platelet adhesion and platelet aggregation (Radomski et al., 1987), 
properties previously attributed to EDRF (Azuma et al., 1986; Forstermann et al., 
1989). In spite of striking similarities between EDRF and NO, the chemical identity 
is still a matter of controversy. For example, the comparable vasorelaxant properties 
and half life in porcine coronary arteries as well as the "s efflux fi'om bradykinin-
stimulated bovine endothelial cells suggest that S-nitrosocysteine may serve as an 
altei'native candidate for EDRF (Myers et al., 1990; Rubanyi et al., 1991). Indeed, 
S-nitrosylation is observed with low molecular weight thiols, like cysteine and these 
potent vasodilators are more stable than NO (Ignarro et al. 1981). However, cysteine 
reduces NO-and EDRF-induced relaxations in the rabbit aorta bioassay system and 
potentiation of NO-mediated responses occurs only at high concentrations (Liu & 
Furchgott, 1993; Feelisch et al., 1994) indicating that combination with protein-bound 
thiol groups is not obligatory for biological activity. 
BiosyntheSIS 
The first indications of the source of NO originate from observations that 
activated murine macrophages, which produced substantial amounts of nitrite and 
nitrate upon stimulation with lipopolysaccharide (Stuehr & Marletta, 1985), use 
L-arginine as a substrate and form L-citmlline as a co-product (Hibbs et al., 1987; 
Iyengar et al., 1987). Porcine endothelial cells, cultured in the absence of L-arginine, 
showed a decrease in the release ofEDRF induced by bradykinin and A23187, which 
was restored by L-arginine but not D-arginine (Palmer et al., 1988a). Moreover, when 
incubated with "N-labelled L-arginine, release of "NO was observed from 
immunostimulated macrophages (Marletta et al., 1988) and porcine endothelial cells 
stimulated with bradykinin (Palmer et al., 1988b). These observations indicated a 
similar pathway in both cell types and suggest that NO originates from the terminal 
guanidino nitrogen moiety of L-arginine. Figure 1.4 illustrates the biosynthesis of NO 
fi'om L-arginine by the enzyme NO-synthase (NOS). The production of NO from the 
endogenous substrate L-arginine is associated with binding to the prosthetic haeme 
group and incorporation of molecular oxygen into NO and L-citmlline (Marletta et al., 
1988; Leone et al., 1991). This reaction resembles cytochrome P"o chemistry, involves 
a two-step electron transfer which results in the formation of the intermediate 
hydroxy-L-arginine (L-OHARG), and subsequent oxidation to L-citmlline and NO 
(Klatt et al., 1993). NOS may use L-OHARG as a substrate and this intermediate has 
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been proposed to react with NO to form a more stable vasodilator (Zembowicz el al., 
1991). In addition, L-OHARG seems to act as a paracrine molecule, since it may enter 
vascular smooth muscle cells via amino acid transporter mechanisms and is, 
independently of NOS, oxidized into NO (Schott el al., 1994). 
H2N +NH2 H,N +NHOH Y Y 
NH NH 
~ NOS ~ L-arginine 0, NQ·OH-L-arglnlne NADPH 
H,N COO' H,N COO' 
NH, r 1 
H,N a 
Y 
H2N~ N"C 
"I 
NH NH 
L-cilrulllne ~ 7 ~ N°·Oxo-L-arglnlne 
H2N + coo' NO H,N COO· 
nllrlc oxIde 
Figure 1.4 Biosynthesis o/nilric oxideji-om L-arginine. L-arginine is bound to NO-synthase 
(NOS) and molecular oxygen (0,) is incorporated into NO and L-citrulline. The reaction 
requires NADPH and involves multiple steps. L-citrulline may be reconverted into L-arginine. 
Since the initial discovery of acetylcholine-induced endothelium-dependent 
relaxations, many other vasoactive substances were found to act through the release of 
NO. These substances include, among others, bradykinin, histamine, adenine 
nucleotides, thrombin, substance P and 5-hydroxytryptamine (Figure 1.3; for review, 
see Furchgott & Vanhoutte, 1989). Apart from receptor mediated NO release, hypoxia 
as well as hydromechanic forces imposed on the blood vessel wall, induce the release 
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of NO. The tangential component of this force, known as shear stress, causes a 
deformation of the endothelial lining and the release of factors like NO and 
prostacyclin. This mechanism may serve to adapt locally to changes in blood flow and 
pressure and, may account for the basal release of NO (Pohl et al., 1991; Kuchan & 
Frangos, 1994). 
NOS-is%rllls 
The formation of NO is catalyzed in mammalian cells by a family of at least 
three isoenzymes, referred to as NOS. The major characteristics of the respective 
isoforms are summarized in table 1.1. All isoforms are NADPH-dependent haeme 
containing oxygenases, which require tetrahydrobiopterin and the flavines, FAD and 
FMN, as cofactor (Bredt et al., 1991; Ftirstermann et al., 1991). Initially, two distinct 
forms were described; a constitutive expressed form and an inducible form, denoted 
as cNOS and iNOS, respectively. The constitutive isoform is mainly present in vascular 
endothelial cells and neuronal cells, whereas the inducible enzyme is found in activated 
macrophages, hepatocytes and smooth muscle cells. Subsequently, different NOS 
isoforms were purified from rat and porcine cerebellum (Bredt & Snyder, 1990; 
Mayer et al., 1990), bovine endothelium (Ftirstermann et al., 1991) as well as human 
brain (Schmidt & Murad, 1991). 
Following purification and cloning, the constitutive enzyme appeared to consist 
of two separate isoforms encoded by different genes (Sessa et al., 1993). Isoform I 
(ncNOS) was originally purified from rat brain and is a mainly soluble enzyme, 
although a substantial portion of the enzyme appears· to be associated with the 
endoplasmatic reticulum (Bredt & Snyder, 1990; Hecker et al., 1994a). The deduced 
amino acid sequence obtained from cDNA clones shows that the molecule has 
recognition sites for NADPH, FAD, FMN and calmodulin (Bredt et al., 1991). Though 
its precise function in the regnlation of vascular tone is not yet established, this isoform 
may be involved in neurotransmission in noncholinergic-nonadrenergic (NANC) 
vasorelaxant nerves surrounding central and peripheral blood vessels (Bredt et al., 
1990; Toda et al., 1993). 
The inducible isoform (iNOS), a predominantly soluble enzyme, is expressed 
following stimulation with endotoxin and cytokines (Nathan & Xie, 1994). Unlike the 
constitutive isoforms, the activity of this isoform is not dependent on intracellular free 
Ca'+ and calmodulin binding. Its induction is associated with the formation of large 
quantities of NO and its activity is related with macrophage cytotoxicity and vascular 
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hyporeactivity to vasoconstrictors (Hevel et 01., 1991; Iulou-Schaeffer et 01., 1991; 
Stuehr et 01., 1991). 
The second constitutive isoform (isoform Ill; ecNOS) was identified as a 
membrane bound enzyme in porcine and human endothelial cells (Fiirstermann et 01., 
1991; Hecker et al., 1994b), and its activity is regulated by Ca2+ and binding of 
calmodulin. This isofonn produces small amounts of NO and may be the most 
important isoform involved in the regulation of vascular tone. 
Table 1.1 The characteristics of the constitutive and inducible isoforms of NOS. 
The descriptive nomenclature of the different isoforms is given between parenthesis. 
Source 
Type 
Activation 
NO-release 
Regulation 
Cofactors 
Feedback regulation 
Target 
I (ncNOS) 
neuronal cells 
NANC-neurons 
astrocytes 
constitutive 
glutamate 
small 
Cai+/Calmodulin 
TH4, FMN, FAD 
inhibitory 
guanylyl cyclase 
Isoform 
II (iNOS) 
macrophages 
smooth muscle cells 
inducible 
LPS 
LPS + IL-l 
LPS + TNF-a 
large, continuous 
TH4, FMN, FAD 
inhibitory 
thiols (?) 
III (ecNOS) 
endothelial cells 
constitutive 
Ach, ADP, Bk, 
5-HT, histamine, 
shear stress, pressure 
small, pulsatile 
Ca;2+/Calmodulin 
TH" FMN, FAD 
inhibitory 
guanylYI cyclase 
haemproteins 
Abbreviations: Ach, acetylcholine; ADP, adenosine diphosphate; Bk, bradykinin; FAD, 
flavin adenine dinucleotide; FMN, flavin mononucleotide; 5-HT, 5-hydroxytryptamine; 
IL-l, interleukin-l; LPS, lipopolysaccharide; NANC, non-adrenergic non-cholinergic; 
TH4• tetrahydrobiopterin; TNF-a, tumor necrosis factor-a. For details, see text. 
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A common feature of all isoforms is that their activity is regulated by feedback 
inhibition by NO. In rat cerebellum and endothelial cell homogenates, and 
macrophages, enzymatic generation of NO and L-citrulline is reduced by exogenous 
NO (Rogers & Ignarro, 1992; Assreuy et al., 1993; Buga et al., 1993). Preservation 
of NO using co-incubation with SOD further reduces NOS-activity, whereas 
inactivation of NO with oxyhaemoglobin can increase NOS activity (Rogers & Ignarro, 
1992; Buga et al., 1993). Likewise, agonist-and flow-induced relaxations of isolated 
arteries are inhibited by NO-donors (Buga et al., 1993), indicating that NOS-activity 
is regulated by one of its own endproducts. This feedback mechanism is not mediated 
by c-GMP (Assreuy et al., 1993), but may involve interaction with the prosthetic haem 
group of NOS and thereby interaction with electron transfer and substrate oxygenation. 
Mode of action and metabolism 
The lipophilic nature of NO enables a rapid diffusion across cell membranes to 
adjacent cells and body fluids. It is now generally excepted that in vascular smooth 
muscle cells endogenous NO as well as NO donors act through stimulation of GC to 
cause an increase in cGMP. The ability of NO to stimulate GC is readily explained by 
its high affinity for ferrohaem groups. The mechanism by which cGMP causes smooth 
muscle relaxation is less well defined and may involve multiple pathways. Both 
endothelium-dependent (EDRF) and independent vasorelaxations (nitrovasodilators) in 
rat aorta have been suggested to occur through a dephosphorylation of myosin light 
chain (Rapoport et al., 1983; McDaniel et al., 1992). Additionally, membrane 
hyperpolarization has been proposed to participate in smooth muscle relaxation. 
Though strongly depending on the experimental conditions, nitrovasodilators and NO 
cause hyperpolarization of vascular preparations (Tare et al., 1990; Garland & 
McPherson, 1992; Parkington et al., 1993). These hyperpolarizing responses seem to 
be distinct from those attributed to EDHF (Parkington et al., 1993; Garland et al., 
1995). Since hyperpolarization and smooth muscle relaxation are sensitive to high 
concentrations of K+ and K+ channel blockade, the effects involve opening of 
K+ channels (Garland & McPherson, 1992). Opening of these channels may be coupled 
to activation of GC as methylene blue abolished both hyperpolarizations and 
relaxations of guinea pig uterine arteries (Tare et al., 1990). FUlihermore, in rabbit 
cerebral artery smooth muscle cells hyperpolarization is mimicked by analogues of 
cGMP and cGMP-dependent protein kinase (Robertson et al. 1993). Apart from 
GC-mediated activation of K+ channels, NO has been repOlied to activate Ca'+-
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dependent K+ channels directly in smooth muscle membrane patches from rabbit aorta. 
The NO-induced relaxations of the isolated rabbit aorta was partially reduced by 
methylene blue and the remaining component of relaxation was blocked by K+ channel 
blockade (Bolotina ef ai., 1994). 
The extremely short biological half-life of NO implicates that it is rapidly 
inactivated and eliminated from the site of action. It has been speculated that a part of 
the endogenously released NO is buffered by thiols, especially serume albumin, to 
serve as a temporarily reservoir for NO (Stamler ef ai., 1992). However, the common 
belief is that NO is oxidized to NO,' in aqueous solutions containing oxygen (lgnarro 
ef ai. 1993; Wink ef ai., 1993). In contrast, in animal and human blood, NO,' 
concentration is within a low nanomolar range and is largely exceeded by the NO,' 
concentration (Castillo ef ai., 1993; Wennmalm ef ai., 1993). This apparent difference 
indicates that oxidation by molecular oxygen to NO; alone can not account for the 
entire metabolism of NO. Numerous chemical interactions in cells or tissues could 
explain further elimination, including reaction with oxyhemoglobins, superoxide anion, 
and other oxygen-derived radicals. Both haemoglobin, oxyhemoglobin, and 
erythrocytes are known to abolish NO-induced responses in functional studies (see for 
instance Gillespie & Sheng, 1988). Furthermore, oxyhemoglobin and whole blood 
catalyze the conversion of NO as well as NO; to NO,' (lgnarro ef ai., 1993; 
Wennmalm ef ai., 1993). Hence, endogenously released NO may be oxidized by 
molecular oxygen to NO,', which is subsequently incorporated in red blood cells to be 
degraded by oxyhemoglobin to NO,'. Alternatively, NO may be taken up by 
erythrocytes directly to react with oxyhemoglobin yielding NO,' and methaemoglobin. 
Irrespective of the intermediate oxidation to NO,', the final common metabolite of NO 
seems to be NO,', which is further eliminated via renal excretion. 
An additional route of inactivation is through reactivity of NO with free radicals 
such as superoxide anion (0,'). These molecules reduce vasorelant properties attributed 
to NO in bioassay systems (Gryglewski ef ai. 1986; Rubanyi & Vanhoutte, 1986). The 
main product of this interaction is peroxinitrite (ONOO'), which, in turn, decomposes 
to NO; and hydroxyl radicals. Since the formation of the highly reactive intermediate 
is dependent on the absence of reducing moieties like glutathione, this route of 
elimination may be of importance under pathophysiological conditions (Moro ef ai., 
1994). 
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Inhibition of NO-biosynthesis 
L-arginine-dependent pathways, such as in macrophage cytotoxicity (Hibbs et al., 
1988) and endothelial NO release, can be inhibited by a series of analogues of 
L-arginine, like NG-monomethyl-L-arginine (L-NMMA) and N°-nitro-L-arginine 
(L-NNA). The structure of some of these inhibitors is shown in Figure 1.5. A general 
feature of all inhibitors is the presence of a modified guanidino group, whereas 
esterification ofL-NNA leads to its water soluble congener NG-nitro-L-arginine methyl 
ester (L-NAME). These inhibitors act in an enantio-specific way and their action is 
usually overcome by an excess of L-arginine, but not D-arginine or L-citrulline. 
Binding experiments using tritiated L-NNA have shown that this compound binds 
to cNOS at a single binding site (Michel et al., 1993; Klatt et al., 1994). To date, it 
is unclear how NOS is inactivated, but these inhibitors may serve as a false substrate 
for the enzyme. 
NH, 
NH, 
A /"-.-~CO,CH, 
O,N.N ~ I 
NH, 
L-arginine 
NG-monomethyl-L-arglnlne 
(L·NMMA) 
NG-nitro-L-arglnlne 
(L·NNA) 
NG-nltro-L-arginlne methyl ester 
(L·NAME) 
Figure 1.5 Chemical structure of some NOS-inhibitors. NG-monomethyl-L-arginine, 
NG-nitro-L-arginine and its methyl ester L-NAME are derivatives of L-arginine, which contain 
a modified guanidino moiety. The commonly used abbreviations are denoted between 
parentheses. 
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The structural similarities of the NOS inhibitors with the endogenous substrate and the 
presence of a modified guanidino group, suggest that this moiety accounts for the high 
affinity for the constitutive enzyme. Furthermore, the electron drawing nitro substituent 
in L-NNA and L-NAME suggests that conformational changes at the active site of the 
enzyme may occur (MUlsch & Busse, 1990). Enzyme activity is restored more slowly 
following inhibition with L-NNA than with L-NMMA which has been related to the 
conversion of the latter to hydroxylated L-NMMA and L-HOARG, both alternate 
substrates for NOS (Olken & Marietta, 1993; Klatt et al., 1994). On the other hand, 
nitro-derivatives may fit better to the active site; 
The NOS-inhibitors possess different inhibitory potencies towards the respective 
isoforms. The nitro-analogues preferentially inhibit the constitutive isoform. For 
example, L-NNA is 300-fold more potent against brain cNOS than against macrophage 
iNOS (Furfine et al., 1993). In contrast, L-NMMA is an equipotent inhibitor of both 
cNOS and iNOS (Gross et al., 1991).Apart from their inhibitory action, some of the 
compounds possess properties not directly related to NOS. L-NMMA may compete for 
the cellular L-arginine uptake (Bogle et al., 1992). Since intracellular levels of 
L-arginine are usually well above the Km of NOS (Bredt & Snyder, 1990; Forstermann 
et al., 1991), and L-citrulline can be recycled to L-arginine (Hecker et al., 1990), this 
may only be relevant during low intracellular L-arginine concentrations, such as 
following prolonged iNOS activity. 
Radioligand binding studies have shown that alkyl esters of L-arginine can 
compete non-selectively for muscarinic receptors present in vascular tissues. 
Functionally, antimuscarinic activity could be detected with L-NAME, rather than with 
L-NMMA and L-NNA, in isolated arterial and visceral smooth muscle preparations 
(Buxton et al., 1993). The ability of L-NAME to antagonize muscarinic receptor 
mediated responses may hamper the interpretation of responses attributed to inhibition 
of NO-biosynthesis. 
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1.3 Aims of this thesis 
The objective of this thesis was to investigate the potential role of endogenous 
NO in the cardiovascular regulation in general, and in migraine more specifically. For 
this purpose, separate more specific aims were defined: 
r. To investigate the contribution of NO to the regulation of systemic 
haemodynamics and regional tissue perfusion in anaesthetized animals under 
different experimental conditions. 
2. To investigate the potential role of endogenous NO in hypotensive and 
hypertensive responses induced by known endothelium dependent agonists, in 
vivo. 
3. To identify tissues containing a.teriovenous anastomoses in pigs and to 
analyze blood flow responses of these vessel segments following inhibition of 
NO-biosynthesis. 
4. To delineate the effects of exogenous NO and calcitonin gene-related peptide 
on the distribution of blood flow in the porcine carotid circulation. 
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Chapter 2 
Haemodynamic changes and acetylcholine-induced hypotensive 
responses after NG-nitro-L-arginine methyl ester in rats and cats 
Summary 
The basal and agonist-stimulated release of nitric oxide from endothelial cells is 
inhibited by NG-nitro-L-arginine methyl ester (L-NAME). In this study, the haemo-
dynamic effects of L-NAME (1, 3, 10 and 30 mg kg· l) and its potential ability to 
attenuate the hypotensive responses to acetylcholine (0.03, 0.1, 1.0 and 3.0 Ilg kg'l) 
have been investigated in anaesthetized rats and cats. In addition, regional tissue blood 
flows were measured in cats using repeated intracardial injections with radioactive 
microspheres. 
In the rat, L-NAME elicited a dose-dependent pressor effect increasing mean 
arterial blood pressure from a baseline value of I 16 ± 4 mmHg to a maxitilllm of 
156 ± 6 mmHg. This pressor response was partly reversed by L-arginine (300 mg kg'I). 
However, the increase in blood pessure by lower doses (up to 10 mg kg'l) ofL-NAME 
was effectively reversed by L-arginine (1000 mg kg'I). 
In cats, L-NAME did not significantly modifY systemic haemodynamic variables 
(heart rate, mean arterial blood pressure, cardiac output, stroke volume or total 
peripheral resistance). Administration of L-arginine did not cause any significant effect 
in cats treated with L-NAME, but some decrease in heart rate and increases in cardiac 
output and stroke volume were observed in the saline-treated group. With the lowest 
dose, L-NAME did not affect tissue blood flows in the cat, but higher doses (3 and 
30 mg kg'l) significantly reduced blood flows to the mesentery, stomach, spleen, 
intestines, lungs and the total liver. In control (saline-treated) animals, L-arginine 
(300 mg kg'l) caused a significant increase in blood flow to the heart, mesentery, lungs 
as well as the total liver, particularly the portal fraction. L-arginine-induced changes 
in tissue blood flows (mesentery, kidneys, spleeu, lungs, total liver and pOltal blood 
Based on: Van Gelderen E.M., Heiligers J.P.C. and Saxena P.R. (1991). Haemodynamic 
changes and acetylcholine-induced hypotensive responses after NG-nitro-L-argininc methyl 
ester in rats and cats. Br. J. Pharmacol. 103; 1899-1904. 
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flow) in control animals were attenuated in animals treated with L-NAME. 
The acetylcholine-induced peak hypotensive response was not reduced in both rats 
and cats by L-NAME. However, the duration of acetylcholine-induced responses was 
attenuated by L-NAME in both species. Treatment with L-arginine (10-100 mg kg") 
did not change the acetylcholine, induced hypotension. 
These results reveal a marked difference between the haemodynamic effects of 
L-NAME in rats and cats. In contrast to rats, the role of the L-arginine-NO pathway 
in the regulation of blood pressure is rather limited in cats, although such a pathway 
may exist in several tissues. Furthermore, the hypotensive response to acetylcholine in 
both animal species seems to be largely mediated by NO-independent pathways. 
2.1 Introduction 
The vasodilator action of acetylcholine in a number of isolated blood vessels 
depends largely on the release of an endothelium-derived-relaxing factor (EDRF; 
Furchgott & Vanhoutte, 1989). EDRF has been characterized as being identical to 
nitric oxide (NO), which is cleaved from L-arginine by the action of the enzyme NOS, 
present in endothelial cells (Palmer el al., 1987, 1988). Once released, NO stimulates 
soluble guanylate cyclase to increase cGMP levels (Boulanger ef al., 1990; Kelm & 
Schrader, 1990). The biosynthesis of NO is inhibited in vitro by the arginine 
analogues, such as NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine 
methylester (L-NAME) (Palmer ef al., 1988; MUlsch & Busse, 1990). 
The local vasodilation induced by acetylcholine is reported to be inhibited by 
L-NAME in the rat perfused mesentery (Moore ef al., 1990) and by L-NMMA in 
anaesthetized rats as well as the human forearm arterial bed (Whittle ef al., 1989; 
Vallance ef al., 1989). In contrast, L-NAME has not been found to affect the 
vasodepressor action in conscious rats (Gardiner ef al., 1990b). Since most experiments 
using arginine-analogues have been performed in vitro, we studied the systemic 
haemodynamic effects of L-NAME as well as its ability to modifY the hypotensive 
responses to acetylcholine in rats and cats. In the latter animal species, tissue blood 
flows changes following the administration of L-NAME were also investigated. 
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2.2 Methods 
General 
Rals: Thirty seven male Wi star-Kyoto rats (body weight 300-350 g) were 
anaesthetized with sodium pentobarbitone (60 mg kg-I, Lp.). A trachea canula was 
inserted to facilitate ventilation. Catheters were placed in both jugular veins and the 
right carotid artery for, respectively, drug administration and blood pressure 
measurement by a pressure transducer (model P23Ac, Statham Laboratories, Hato Rey, 
Puerto Rico). Blood pressure was continuously recorded on a polygraph (model 7, 
Grass Instrument Company, Quincy, MA). Heart rate was derived from the blood 
pressure recordings. Temperature was maintained at 37 'C using an electric blanket. 
Cals: Twelve male or female cats (body weight between 2.8 and 5.0 kg) were 
anaesthetized with ketamine (12 mg kg-I, Lp.). A trachea canula was inserted for 
attificial ventilation by a respiratory pump (Loosco, Amsterdam, The Netherlands). 
Both femoral veins were catheterized for Lv. administration of drugs and blood 
sampling. Anaesthesia was maintained with sodium pentobarbitone (6 mg kg-I, Lv. 
bolus, followed by 3 mg ktl h-I, Lv. infusion). Both femoral arteries were cannulated 
for blood sampling and measurement of arterial blood pressure with a pressure 
transducer (model P23Ac, Statham Laboratories, Hato Rey, Puerto Rico). Blood 
pressure was continuously recorded on a polygraph (model 7, Grass Instrument 
Company, Quincy, MA). The right atrium was catheterized for microsphere 
administration. Finally, a flow probe was placed around the ascending aorta; cardiac 
output was calculated by adding ascending aorta blood flow and myocardial blood flow 
(see below). Body temperature was maintained at 37"C with an electric blanket and pH 
and blood gases were kept between normal limits (pO" 90-120 mmHg; pCO" 25-
35 mmHg; pH, 7.35-7.45) by adjusting respiratory rate and tidal volume. A 
stabilization period of 30-60 min was allowed. 
Regional tissue blood flows were measured with the radioactive microsphere 
technique, by use of the reference blood sample method (Heymann el al., 1977; Saxena 
el al., 1980). For each measurement, a suspension of about 200,000 microspheres 
(15 J.lm diameter, NEN Company, Dreieich, West Germany), labelled with one of the 
isotopes (1l4Ce, JJ3Sn, JOJRu, "Nb, 01' "Sc), was mixed and injected into the left atrium. 
At the end of the experiment the animals were killed and various tissues were dissected 
out, weighed and put in vials. The radioactivity in these vials was counted for 
5-10 min in a y-scintillation counter (Packard, Minaxi Autogamma 5000) using suitable 
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windows for discriminating the different isotopes. Regional blood flows and cardiac 
output were calculated with a set of computer programs especially designed for the 
radioactive microsphere teclmique (Saxena et al., 1980). 
Experimental protocol 
Rats: After.a stabilization period each rat received five increasing Lv. doses of 
acetylcholine (0.03, 0.1, 0.3, 1.0 and 3.0 Ilg kg") at intervals of 3-5 min. Peak 
hypotensive responses to acetylcholine and its duration of action, Le. the time needed 
for 50% recovery of the effect, were recorded. Due to the short-lasting action of 
acetylcholine, duration of action could only be assessed for the three highest doses. The 
rats were then divided into 4 groups which received either saline (4 times I ml kg"'; 
n~9), L-NAME (I, 3, 10 and 30 mg kg"'; n~12), L-arginine (10, 30 and 100 mg kg"'; 
n~7) or phenylephrine (40,120,220 and 330 Ilg kg" h"; n~9). In most of the animals 
(for n, see results), the different doses of saline or drugs, administered every 15-20 
min, were followed by the five doses of acetylcholine. The animals which had received 
L-NAME were administered L-arginine (300 mg kg") after the last injection of 
acetylcholine. An additional group of animals (n~6) was treated with L-NAME (I, 3 
and 10 mg kg") followed by L-arginine (1000 mg kg"). 
The dose range of phenylephrine was chosen to induce sustained increases in 
blood pressure similar to that induced with L-NAME. The magnitude and duration of 
hypotensive responses to acetylcholine after the different treatments were compared to 
the respective controls. 
Cats: A similar protocol was followed in cats as in rats for L-NAME (I, 3, 10 
and 30 mg kg") and saline. After the first series of acetylcholine injections (0.03,0.1, 
0.3, 1.0 and 3.0 Ilg kg") at baseline, the first batch of microspheres was injected in 
each animal to determine baseline values of cardiac output and regional haemodynamic 
variables. The animals then received either four doses of L-NAME (I, 3, 10 and 
30 mg kg", n~7) or saline (I ml kg", IF5) at intervals of 20 minutes. Ten minutes 
after each dose (except after 10 mg kg" L-NAME and the third dose of saline), a batch 
of microspheres was injected. Finally, a bolus injection of 300 mg kg" L-arginine was 
administered, followed ten minutes later by the last batch of microspheres for tissue 
blood flow measurements. 
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Data presentation alld analysis 
All data in the text are mentioned as mean ± s.e.mean. The values after the 
different treatments were compared to the baseline values by using Duncan' new 
multiple range test once a parametric two-way analysis of variance (randomized block 
design) had revealed that the samples represented different populations. The 
significance of the changes induced by L-NAME, L-arginine or phenylephrine as 
compared to the respective saline treatment was tested by an unpaired Student t-test. 
A P-value of 0.05 or less was considered statistically significant. 
Drugs 
The dmgs used in this study were: L-arginine hydrochloride, N"-nitro-L-arginine 
methylester (both dmgs: Signla, St Louis, U.S.A.), ketamine hydrochloride (A.U.V., 
Cuyk, The Netherlands), acetylcholine chloride, phenylephrine hydrochloride (both 
from the Department of Pharmacy, Erasmus University, Rotterdam, The Netherlands), 
sodium pentobarbital (Sanofi BV, Maassluis, The Netherlands). All drugs were 
dissolved in sterile saline. The doses mentioned in the text refer to the respective salts. 
2.3 Results 
Rats 
Haemodynamic effects 
Both mean arterial blood pressure and heart rate remained relatively stable in the 
rats receiving either saline or L-arginine injections. Both L-NAME and phenylephrine 
elicited pressor responses; from the baseline values of 116 ± 4 and 93 ± 4 mmHg, 
respectively, blood pressure increased dose-dependently to a maximum of 156 ± 6 and 
135 ± 5 mmHg, respectively, with the highest doses. Heart rate decreased significantly 
compared to baseline values with L-NAME, but the decreases were not different from 
those seen in saline-treated animals. Phenyleprine did not change heart rate 
(Figlll'e 2.1). The increase in blood pressure induced by L-NAME (30 mg kg· l ) could 
be partly reversed by the administration of L-arginine (300 mg kg· l ) (Figure 2.1). 
In an additional group of6 animals which received L-NAME up to 10 mg kg· l , 
blood pressure increased significantly from 93 ± 2 to a maximum of 142 ± 4 mmHg 
and heart rate decreased significantly from 336 ± II to 282 ± 13 beats min· l . 
L-arginine reversed the L-NAME-induced increase in blood pressure, which returned 
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to a value of 78 ± 9 mmHg (p<0.05, versus L-NAME 10 mg kg"). However, the 
bradycardia induced by L-NAME remained unchanged after L-arginine (288 ± 13 
beats min"). 
Acetylcholine responses 
Acetylcholine (0.03-3.0 /lg kg") elicited a dose-dependent fall in mean arterial 
blood pressure in rats; before any treatment the highest dose induced a fall in blood 
pressure of 52 ± 11 mmHg (n~25). The calculated dose inducing a 40 mmHg decrease 
in mean arterial blood pressure (D,,) was 0.8 ± 0.1 /lg kg" (n~25). Treatment of rats 
with the four doses of saline did not influence the hypotensive responses to 
acetylcholine (Figure 2.2). Compared to the rats treated with saline, L-NAME (3 and 
10 mg kg") increased the hypotensive effects of 0.3 to 3.0 /lg kg" acetylcholine. The 
vasodilator response to acetylcholine was also potentiated during infusions of 
phenylephrine (220 and 330 /lg kg" h"). Pretreatment with L-arginine (10-
100 mg kg") did not change the acetylcholine-induced hypotension (Figure 2.2). 
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Figure 2.1. Mean arterial blood pressure (MAP) and heart rate in rats at baseline (8) and 
after treatment with four consecutive doses of saline (I ml kg" each, n~9; 0-0), L-NAME 
(I, 3, 10 and 30 mg kg", n~12; e-e), phenylephrine (40, 120, 220 and '330 fig kg" h", 
n~9; 0-0) or L-arginine (10,30 and 100 mg kg", n~7; 0-0). L-arginine (ARG; 300 mg kg· l ) 
was injected in the animals that had received L-NAME. Data arc' given as mean ± s,c,mean. 
:+, P<O.05 versus saline; +, P<O.05 versus baseline values. 
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The duration of the depressor response to acetylcholine, assessed as the time 
needed for 50% recovery, remained unchanged after treatments with either saline, 
L-arginine or phenylephrine. However, there was some significant reduction in the 
duration of action of acetylcholine (0.3 and 1.0 Ilg kg) by L-NAME (Figure 2.3). 
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Figure 2.2 Decreases in mean arterial blood pressure (MAP) by acetylcholine (0.03-
3.0 Ilg kg") in rats before (control; 0) and after treatments with saline (1 ml kg" four times, 
IF8), L-NAME (1, 3, 10 and 30 mg kg", IF8), phenylephrine (40, 120, 220 and 
330 Ilg kg" h", n~7) or L-arginine (10, 30 and 100 mg kg", n~7). The increasing doses in 
each case are represented by the symbols 0, 6, • and ., respectively. Data are given as 
mean ± s,e,mean. *, P<O.05 versus saline. 
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Figllre 2.3 Time needed for 50% recovery in the hypotensive action of acetylcholine (0.3, I 
and 3 flg kg-I) in rats treated with saline (I ml kg-I four times, n~8), L-NAME (1,3, 10 and 
30 mg kg-I, n~8), L-arginine (10, 30 and 100 mg kg· l , n~7) or phenylephrine (40, 120, 220 
and 330 flg kg-I h· l , n~7). In each set of panels, th~ 5 columns (4 in case of L-arginine) 
represent, sequentially, the responses before and after the increasing doses of saline or drugs. 
Data are given as mean ± S.c. mean. *, P<O.05 versus saline. 
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Cats 
Haemodynamic effects 
The baseline values of the systemic and regional haemodynamic variables in the 
two groups of cats receiving, respectively, saline and L-NAME, both followed by 
L-arginine (300 mg kt') are listed in table 2.1. No significant differences were 
observed between the two groups. 
Figure 2.4 depicts the percent changes in the systemic haemodynamic variables 
caused by saline (three injections) and L-NAME (I, 3 and 30 mg kt'). Treatment with 
saline did not cause any significant change other than a small decrease in heart rate. 
Similarly, the systemic haemodynamic effects ofL-NAME in the cat were not marked. 
Table 2.1 Baseline values of systemic haemodynamic variables and organ blood flow in 
anaesthetized cats treated with saline (n~5) or L-NAME (n~7). 
Saline L-NAME 
Systemic haemodynalllic variables 
MAP (mmHg) 101.2±6.1 95.1 ± 5.6 
HR (beats lIIiff') 153.0 ± 4.9 143.3 ± 14.6 
SV (1111) 3.3 ± 0.3 3.9 ± 0.8 
co (ml miff') 503.8 ± 42.1 512.7 ± 76.9 
TPR (mmHg t' min-' ) 203.5 ± 11.4 214.4 ± 29.0 
Organ blood flow (ml min") 
Heart \3.5 ± 5.0 10.1 ± 1.5 
Brain 8.5 ± 1.8 7.1 ± 1.1 
Lungs 39.9 ± 5.7 39.8 ± 5.2 
Stomach 8.0 ± 2.1 7.2 ± 1.7 
Intestine 27.8 ± 6.0 25.6 ± 3.3 
Spleen 14.0 ± 4.6 7.1 ± 1.6 
Mesentery 7.6 ± 2.6 5.2 ± 1.1. 
Portal 68.7 ± 16.4 58.4 ± 9.5 
Total liver 86.2 ± 23.7 71.0±8.9 
Kidneys 39.2 ± 5.9 38.5 ± 4.4 
Muscle 3.8 ± 0.9 3.4 ± 0.4 
Skin 1.4 ± 0.2 1.5 ± 0.4 
Abbreviations: MAP, mean arterial blood pressure; HR, heart rate; SV, stroke volume; 
CO, cardiac output; TPR, total peripheral resistance. 
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Although there was a small increase in total peripheral resistance (29 ± 5%) after 3 mg kg·1 
L-NAME, these changes were only slightly more than those with the corresponding dose of 
saline (12 ± 5%). In the saline group, L-arginine decreased heart rate significantly (21 ± 3%), 
but cardiac output increased (12 ± 3%) due to an increase in stroke volume (42 ± 7%) 
(Figure 2.4). Administration of L-arginine did not cause any significant effect in cats treated 
with L-NAME, but the changes observed in the saline group appeared to be blunted 
(Figure 2.4). 
50 + 
Saline 
" 
25 
0001 
e> 
+ c 
'" cs'?'T'1 DOcS ODD~ .c 0 
'if' 0 
9
Q?, 
·25 
+ 
50 
L·NAME 
" 
25 ~~~ e> D~~. c * '" 
'T''I'i* .c 0 'if' 0 Yc;Jrrp, Epij~~ q--' , 
·25 HR MAP CO SV TPR 
Figure 2.4 Percentage changes from baseline in systemic haemodynamic values in cats treated 
with saline (I 011 kg·1 three times, n~5) or L-NAME (I, 3 and 30 mg kg· l, n~7). Data after 
the 3rd dose of saline or L-NAME (10 mg kg· I), where no microspheres were given (see 
Methods), were not collated. In each set of panels, the first three columns represent, 
sequentially, the increasing doses of saline or LwNAME, while the fourth colunm represents 
L-arginine (300 mg kg-I). Abbreviations: HR, heart rate; MAP, mean arterial blood pressure; 
CO, cardiac output; SV, stroke volume; TPR, total peripheral resistance. Data are given as 
mean ± s.c. mean. *, P<O.05 versus saline; +, P<O.05 versus baseline. 
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The effects of L-NAME (I, 3 and 30 mg kg") on tissue blood flows in the cat 
are shown in Figures 2.5.1 and 2.5.2. With the lowest dose no changes were observed, 
but the higher doses of L-NAME significantly reduced blood flows to several tissues 
including the mesentery, stomach, spleen, intestines, lungs and the total liver. 
L-arginine (300 mg kg") injected into the control (saline-treated) animals resulted in 
a significant increase in blood flow to the heart, mesentery, lungs as well as the total 
liver, paliicularly its portal fraction (Figure 2.5.1 and 2.5.2). The changes induced by 
L-arginine in animals treated with L-NAME were significantly different from the 
changes in saline treated animals in the mesentery, kidneys, spleen, lungs as well as 
the total liver and portal blood flow (Figure 2.5.1 and 2.5.2). 
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Figure 2.5. J Percentage changes from baseline in tissue blood flows in cats treated with 
saline (I ml kg" three times, n~5) or L-NAME (I, 3 and 30 mg kg-', n~7). As mentioned in 
Methods, tissue blood flows were not measured after the 3rd dose of saline or L-NAME 
(10 mg kg"). In each sets of panels, the first three columns, sequentially, represent the 
increasing doses of saline or L-NAME, while the fourth column represents L-arginine 
(300 mg kg-I). Data are given as mean ± s.e.mean. *, P<O.05 versus saline; +, P<O.05 versus 
baseline. 
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Figure 2.5.2 Percentage changes from baseline in tissue blood flows in cats treated with 
saline (I ml kg-I three times, n~5) or L-NAME (I, 3 and 30 mg kg-I, n~7)_ As mentioned in 
Methods, tissue blood flows were not measured after the 3rd dose of saline or L-NAME 
(10 mg kg"I). In each sets of pallels, the first three columns, sequentially, represent the 
increasing doses of saline or L-NAME, while the fourth column represents L-arginine 
(300 mg kg-I). Data are given as mean ± s,e.mean. *, P<O.05 versus saline; +, P<O.05 versus 
baseline. 
Acetylcholine responses 
Acetylcholine induced a dose-dependent hypotensive effect in anaesthetized cats 
in doses ranging from 0.03 to 3.0 !!g kg-I. The fail in mean arterial blood pressure after 
the highest dose was 62 ± 5 mmHg (n~9). The calculated dose of acetylcholine 
inducing a 40 mmHg decrease in mean blood pressure (040) was 0.11 ± 0.04 !!g kg-I 
(n~9). L-NAME (I, 3, 10 and 30 mg kg-I) did not significantly affect the fail in blood 
pressure induced by acetylcholine (Figure 2.6). However, L-NAME (from 3 mg kg-I 
and higher) was able to reduce the duration of action of acetylcholine; the time needed 
for 50% recovery in the acetylcholine responses was clearly reduced (Figure 2.7). 
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Figure 2.6 Decreases in mean arterial blood pressure (MAP) by acetylcholine (0.03· 
3.0 I-lg kg") in cats before (control;O) and after treatments with saline (\ ml kg" four times, 
n~5) or L-NAME (I, 3, 10 and 30 mg kg,l, n~6). The increasing doses in each case are 
represented by the symbols 0, 6, • and II, respectively. Data represent mean ± s.e.mean. 
No significant differences between saline and L-NAME experiments were noticed. 
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Figure 2.7 Time needed for 50% recovery in the hypotensive action of acetylcholine (0.3-
3.0 I-lg kg") in cats treated with saline (I ml kg" four times, n~5) or L-NAME (1,3,10 and 
30 mg kg'], 11=6). In each set of panels, the 5 columns represent, sequentially, the responses 
before and after increasing doses of saline or L-NAME. Data are given as mean ± s.C. mean. 
*, P<O.05 versus saline. 
45 
Chapler 2 
2.4 Discussiou 
Haemodynamic responses 
Our findings that L-NAME, when injected in pentobarbitone anaesthetized rats, 
induced a significant dose-dependent increase in blood pressure and reversal by 
L-arginine is consistent with results found in conscious as well as anaesthetized rats 
(Gardiner el al., 1990a,b,c; Rees el al., 1990). However, the concomitant fall in heart 
rate reported in anaesthetized rats by Rees el al. (1990) was comparatively less marked 
with L-NAME in our experiments as heart rate also decreased in animals treated with 
saline only. Administration of L-arginine, particularly when its dose was higher 
(100 fold) than that ofL-NAME (see also Rees e1 al., 1990), reversed the increases in 
blood pressure induced by L-NAME. 
In contrast to rats, surprisingly, no significant changes in mean arterial blood 
pressure were found with four consecutive doses ofL-NAME (I, 3, 10 and 30 mg kg") 
in cats anaesthetized with pentobarbital and ketamine (initially). This inability of 
L-NAME to elicit hypeliension has also been observed in cats anaesthetized with 
a-chloralose and pentobarbital (R. Saxena, E. Scheffel's & R. Shukla, unpublished). 
Though L-NAME had little overall effect on haemodynamics, the drug did elicit a 
dose-dependent and significant decrease in blood flow to and, therefore, an increase 
in vascular resistance in several tissues (lungs, liver, stomach, small intestine and 
mesentery), suggesting an inhibition of the release of NO by L-NAME in these organs. 
Administration of L-arginine in cats, treated with L-NAME, did not reverse the 
decrease in blood flow induced by L-NAME. In saline treated animals, however, 
L-arginine revealed a significant increase in blood flow in the lungs, mesentery, liver 
and several other organs, including the heart and ti,e kidneys. The above results suggest 
that in cats there seems to be a difference in the basal release of NO; some organs, like 
the lungs, liver and mesentery, show more basal release than other tissues like the heart 
and kidneys. The findings that neither L-NAME nor L-arginine changed the mean 
aIierial blood pressure and that L-NAME induced a decrease in blood flow in only a 
few organs suggest little contribution of the L-arginine-NO pathway to blood pressure 
regulation in the anaesthetized cat. 
Although L-arginine increased blood flow in several organs, the total peripheral 
resistance did not change. This can be due to a concomitant increase in cardiac output, 
following an enhanced stroke volume due to an improved cardiac filling. Gardiner 
el al. (I 990c ) suggest that the decrease in cardiac output by L-NAME in rats could be 
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due to a direct negative inotropic action or due to a coronary vasoconstriction. Indeed, 
L-NAME can induce coronary vasoconstriction in conscious rabbits (Humphries et al., 
1991). Our experiments in cats, however, show that despite a significant increase in 
myocardial blood flow by L-arginine, L-NAME neither decreased coronary artery 
blood flow nor decreased cardiac output. This again suggests that, unlike in the rat, 
there is little spontaneous release of NO from the cat heart. 
Acetylcholine responses 
There seems to be little doubt that the vascular smooth muscle relaxation in vitro 
or local vasodilation in several vascular beds following acetylcholine administration in 
different species is largely dependent on the release of NO and is, consequently, 
inhibited by drugs like L-NAME (Aisaka et al., 1989; Furchgott & Vanhoutte, 1989; 
Vallance et al., 1989; Whittle et al., 1989; Kontos et al., 1990; Moore et al., 1990). 
However, it has also been reported that the hypotensive response to acetylcholine in 
conscious rats is not amenable to blockade by L-NAME (Gardiner et al., 1990b). Our 
resuits, both in the anaesthetized rats and cats, are in agreement with the latter findings. 
Indeed, the' hypotensive effect of acetylcholine was even potentiated in the rat after 
treatment with 10 mg kg" L-NAME. This apparent potentiation was due to the increase 
in arterial pressure by L-NAME, since it was also observed after phenylephrine 
infusions in the rat, but not during L-NAME treatment in the cat where arterial 
pressure was not affected by the drug. Therefore, it seems likely that the magnitude of 
the hypotension elicited by acetylcholine ill vivo is not dependent on the release of NO. 
It may, however, be noted that the highest dose of L-NAME (30 mg kg") did not 
ful1her increase the depressor responses to acetylcholine in rats; on the contrary the 
magnitude of the responses were not significantly different limn those in saline-treated 
animals (see Figure 2.2), suggesting that there may be some inhibition of the 
acetylcholine depressor effects in rats at the highest dose of L-NAME. 
Despite little changes in the magnitude of the hypotensive response to 
acetylcholine, there was a significant reduction in its duration by L-NAME in both cats 
and rats; phenylephrine infusion in the rat had no effect. In contrast to experiments in 
guinea pigs with L-NMMA (Aisaka et al., 1989), L-arginine did not prolong the 
duration of the acetylcholine response in our experiments. Nevertheless, our findings 
do support the suggestions of Aisaka et al. (1989) that the first phase of the depressor 
response to acetylcholine is NO-independent. It is tempting to speculate that the second 
phase is, in pat1, due to a hyperpolarization of the vascular smooth muscle resulting 
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fi'om the release of an endothelium-dependent-hyperpolarizing-factor (EDHF). Indeed, 
in dog mesenteric arteries the hyperpolarization induced by acetylcholine, in contrast 
to the relaxation, seems to be NO-independent, since oxyhaemoglobin and methylene 
blue only prevented the latter (Komori ef al., 1988). However, in guinea pig isolated 
uterine alieries L:NMMA blocked both hyperpolarization and relaxation responses to 
acetylcholine suggesting that EDHF may be identical to NO in this species (Tare el al., 
1990). 
Lastly, it may be mentioned that acetylcholine, when applied topically, induces 
cerebral dilatation in cats by releasing an EDRF-like substance (Kontos el al., 1990). 
Our experiments, however showed no significant increase in brain blood flow by 
L-arginine or a decrease by L-NAME. These findings may indicate that, unlike large 
conducting vessels, there is only a limited contribution ofEDRFINO to cerebral blood 
flow regulation. 
In conclusion, the present in vivo experiments reveal a marked difference between 
the effects of L-NAME in rats and cats; in contrast to rats, the contribution of the 
L-arginine-NO pathway to blood pressure regulation in the cat seems to be very 
limited, although such a pathway seems to exist in several tissues. In addition, 
L-NAME does not affect the magnitude of hypotensive response to acetylcholine in 
either species, but reduces its duration. 
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Effect of NG-nitro-L-arginine methyl ester on the hypotensive 
and hypertensive responses to 5-hydroxytryptamine in the 
pithed rat 
Summary 
The haemodynamic effects ofthe NOS inhibitor N"-nitro-L-arginine methyl ester 
(L-NAME; I, 3 and 10 mg ktl) were studied in pithed rats. Furthermore, we evaluated 
the ability of this compound to modulate blood pressure responses to 
5-hydroxytryptamine (5-HT), 5-carboxamidotryptamine (5-CT) and (1-(2,5-dimethoxy-
4-iodophenyl)-2-amino propane (DOl). L-NAME elavated mean arterial blood pressure 
Ii-om 59±1 mmHg to a maximum of l26±6 mmHg, without changing heart rate. A 
comparable increase in blood pressure was observed with repeated infusions of 
phenylephrine (160, 240 and 400 Ilg kg·1 h· I); maximum 124±5 lmuHg from baseline 
54±2 mmHg. In contrast to L-NAME, phenylephrine caused tachycardia with the 
highest dose. Blood pressure responses to either L-NAME or phenylephrine were 
unaffected by pretreatment with the 5-HT,-receptor antagonistketanserin (0.1 mg ktl). 
The hypotensive responses to 5-HT in the presence ofketanserin were augmented 
by L-NAME as well as phenylephrine infusion. L-NAME also tended to prolong the 
duration of the response to 5-HT. Likewise, the hypotensive responses to 5-CT were 
potentiated. The magnitude of hypertensive responses to 5-HT was unaffected by either 
L-NAME or phenylephrine. However, in contrast to phenylephrine, L-NAME 
prolonged the duration of these responses. The magnitude and duration (middle dose 
only) of the hypertensive responses to DOl were augmented by L-NAME, whereas 
phenylephrine was ineffective. 
These results suggest that L-NAME increases blood pressure, probably by 
inhibiting the basal release of NO in animals with a low vascular tone. However, the 
Based 01/: Van Gelderen E.M. and Saxena P.R. (1992). Effect of N°-nitro-L-arginine methyl 
ester on the hypotensive and hypertensive responses to 5-hydroxytryptamine in pithed rats. 
Enr. J. Pharmacal. 222; 185-191. 
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hypotensive responses to 5-HT and 5-CT seem to be largely independent of NO-release 
by the endothelium, but the hypertensive responses to 5-HT and DOl appear to be 
limited by release of NO in the pithed rat. 
3.1 Introduction 
The vascular endothelium has been shown to regulate vascular tone by releasing 
a number of vasoactive substances. One of these substances is nitric oxide (NO), which 
is formed from L-arginine by the enzyme NO-synthase (Palmer et al., 1987, 1988). 
The production of NO can be inhibited by a number of analogues of L-arginine, 
including NG-nitro-L-arginine (L-NNA) (Dubbin et al., 1990; Miilsch & Busse, 1990). 
Its methyl ester, W-nitro-L-arginine methyl ester (L-NAME) increases blood pressure 
in both conscious and anaesthetized rats suggesting a NO-dependent vasodilator tone 
in these animals (Gardiner et al., 1990; Rees et al., 1990; chapter 2, this thesis). 
5-Hydroxytryptamine (5-HT) induces a variety of vascular effects, which may 
partially depend on intact endothelial function (Cocks & Angus, 1983; Saxena & 
Villal6n, 1990). Thus, the removal of endothelium from the rat perfused arteries 
augments the contraction (mesenteric; Dohi & LUscher, 1991) or abolishes the 
vasodilatation (coronary; Mankad et al., 1991) caused by 5-HT. Moreover, treatment 
with NO-synthase inhibitors inhibits the 5-HT-induced vasodilatation in the perfused, 
endothelium-intact coronary and renal arteries of the rat (Mankad et al., 1991; 
Verbeuren et al., 1991). Despite the undeniable evidence for a role for NO in the 
vasorelaxant responses to 5-HT in vitro, there is no information if the release of NO 
is important in such responses in vivo. Indeed, contrary to the well-known mediation 
of acetylcholine-induced vasodilatation by NO (see Furchgott & Vanhoutte, 1989), we 
have recently reported that the peak magnitude of hypotensive responses to 
acetylcholine is not reduced in the anaesthetized rat or cat by L-NAME (chapter 2, this 
thesis). Therefore, we have now investigated the putative role of NO in the hypotensive 
and hypertensive responses to 5-HT, before and after L-NAME, in the pithed rat. The 
rats were pithed to avoid the initial hypotensive response, initiated as a result of 
activation ofBezold-Jarisch reflex (see Saxena & Villal6n, 1990). For comparison, the 
5-HTJ-like receptor agonist 5-carboxamidotryptamine (5-CT) and the relative selective 
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5-HTIC12 receptor agonist {±)-I-{2,5-dimethoxy-4-iodophenyl)-2-aminopropane {~Ol) 
have also been used. According to the current view on receptor classification, 5-HTlc 
receptors have been reclassified as 5-HT,c (Hoyer et al., 1994). ' 
3.2 Methods 
General 
Male Wistar rats, body weight 350-400 g, were anaesthetized with sodium 
pentobarbitone (60 mg kg,l, Lp.). A tracheal cannula was used to allow aliificial 
respiration by a respiratory pump (Loosco, Amsterdam, The Netherlands). 
Subsequently, the animals were pithed by introducing a stainless-steel rod in the spinal 
canal via the orbit. Catheters were placed in the right jugular vein and carotid artery 
for, respectively, drug administration and blood pressure measurement using a pressure 
transducer (model P23Ac, Statham Laboratories, Hato Rey;Puelio Rico). Blood 
pressure was continuously recorded on a polygraph (model 7, Grass Instrument 
Company, Quincy, MA). Heart rate was calculated from the blood pressure recordings. 
Another catheter was placed in the left femoral vein for the infusion of phenylephrine, 
which was used as a 'control' for L-NAME. Phenylephrine induces similar changes in 
carotid, hindquarter, mesenteric and renal conductances as L-NAME (Fozard & Part, 
1992). 
Body temperature was maintained at 37'C with an electric blanket and arterial 
blood pH and gases were kept within normal limits (pO" 90-120 mm Hg; pCO" 25-35 
mm Hg; pH, 7.35-7.45) by adjusting respiratory rate and tidal volume; A stabilization 
period of at least 30 min was allowed. 
Experimental protocols 
Hypotensive responses 
5-HT induces a biphasic blood pressure response consisting of hypotension and 
hypertension in the pithed rat (Fozard & Leach, 1968). Therefore, to prevent the 
hypeliensive responses the rats (IF29) were first treated with ketanserin (0.1 mg kg· I ). 
This dose of ketanserin effectively blocks 5-HT, receptor-mediated hypertension 
without much affecting the responses to methoxamine in the pithed rat (Kalkman 'et al., 
1982). About 10-15 min later, the animals received four increasing Lv. doses of 5-HT 
(O.l, 0.3, 1.0 and 3.0 fIg kg'l) at intervals of approximately 5 min. The peak 
51 
Chapler 3 
hypotensive response t.o each dose of 5-HT was recorded. Due to the short-lasting 
action of 5-HT, the duration of actiou expressed as the time needed for 50% recovery 
of the effect (Tin) was assessed only for the two highest doses. The animals were 
subsequently divided into three groups which received Lv. either saline (3 times 
0.5 ml kg· l ; n=7), L-NAME (I, 3, 10 mg kg· l ; n=l3) or phenylephrine (160, 240 and 
400 J.lg kg· 1 h· l; n=9); the latter was used to match the hypertensive responses 
associated with L-NAME (see chapter 2, this thesis). Ten minutes after each treatment, 
the injections of 5-HT were repeated. In order to limit the duration of the experiments 
not all doses of 5-HT were injected in each animal after each dose of L-NAME, 
phenylephrine or saline. 
In four separate groups of pithed animals the hypotensive response to cumulative 
doses of 5-CT (Om to 3.0 J.lg kg· 1 Lv.) was studied after pretreatment with either 
saline (0.5 ml kg· l , Lv.; n=5) or L-NAME (I, 3 and 10 mg kg· l , Lv.; n=5 each). 
Hypertensive responses 
Thirty~one rats received three increasing Lv. doses of 5-HT (3, 10 and 30 J.lg kg· l ) 
at approximately five minutes intervals. The peak hypertensive response to and the 
duration of action (TI12) of each dose of 5-HT was recorded. Thereafter, the animals 
were also divided into three groups which received Lv. either saline (3 times 
0.5 ml kg· l ; n=8), L-NAME (I, 3 and 10 mg kg· l ; n=15) or phenylephrine (160, 240 
and 400 J.lg kg·1 h· l ; n=8). Ten minutes later, the doses of 5-HT injections were 
repeated. Again, in order to limit the duration of the experiments not all doses of5-HT 
were injected in each animal after each dose of L-NAME, phenylephrine or saline. 
In two separate groups of animals, 001 (3, 10 and 30 J.lg kg· l ) was injected Lv. 
before and after either L-NAME (3 mg kg· l , Lv.; n=5) or phenylephrine (400 J.lg kg·1 
h· l , Lv.; n=5). 
Data presentation and analysis 
All data in the text are given as means ± s.e.mean. The values after the different 
treatments were compared to the baseline values by the use of Student's I test, once 
analysis of variance had revealed that the samples represented different populations. 
The significance of changes induced by L-NAME or phenylephrine, as compared to 
the respective saline treatment, was tested by the Student Newman-Keuls test for 
multiple comparison. In case of 5-CT and 001, differences among groups were 
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compared with the Student-Newman-Keuls test for mUltiple comparison (5-CT) or 
Student's I test (001). A P value of 0.05 or less was considered statistically significant. 
Drugs 
The compounds used in this study were: 5-Carboxamidotryptamine maleate (gift: 
Glaxo Group Research, Ware, U.K.), (±)-I-(2,5-dimethoxy-4-iodophenyl)-2-amino-
propane (DOl), 5-hydroxytryptamine creatinine sulphate, NG-nitro-L-arginine methyl 
ester (all from Sigma, st. Louis, U.S.A.), ketanserin tartrate (gift: Janssen 
Pharmaceuticals, Beerse, Belgium), phenylephrine hydrochloride (Department of 
Pharmacy, Erasmus University, Rotterdam, The Netherlands), sodium pentobarbitone 
(Sanofi BV, Maassluis, The Netherlands). All compounds were dissolved in sterile 
saline. The doses mentioned in the text refer to the respective salts. 
3.3 Results 
Haemodynamics 
The blood pressure and heart rate characteristics of the three groups of pithed 
rats, used for the analysis of hypotensive (with ketanserin treatment) and hypertensive 
(without ketanserin) responses to 5-HT, are depicted in Figure 3.1. No changes in 
blood pressure occurred with saline, but dose-dependent hypertension was noticed after 
both L-NAME and phenylephrine. The increases in mean arterial blood pressure caused 
by L-NAME were similar in animals that had been treated with 0.1 mg kg" ketanserin 
(baseline, 59±2 mm Hg; maximum, 125±11 mm Hg) and those that had not (baseline, 
59±1 mm Hg; maximum, 126±6 mm Hg). Also, the pressor responses to the infusions 
of phenylephrine did not differ in the presence (baseline, 54±2 mm Hg; maximum, 
124±5 mm Hg) or absence (baseline, 50±2 mm Hg; maximum, 124±3 mm Hg) of 
ketanserin. While heart rate did not change after L-NAME, the higher doses of 
phenylephrine caused tachycardia in both ketanserin-treated and untreated rats 
(Figure 3.1). 
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Figure 3.1 Mean arterial blood pressure (MBP) and heart rate (HR) values in pithed rats with 
(left panels) or without (right panels) treatment with ketanserin in groups which received 
either saline (n~7 and 8, respectively), L-NAME (n~13 and IS, respectively) or phenylephrine 
(n~9 and 8, respectively). In each set of panels, the 4 columns from left to right represent, 
sequentially, values before and after the three doses of saline (three times 0.5 ml kg· I), 
L-NAME (I, 3 mid 10 mg kg·
'
) or phenylephrine (160, 240 and 400 fig kg·
' 
h·
'
). Data are 
given as mean ± s.e.mean. *, P<O.OS versus saline. 
Hypotensive responses to 5-HT 
The hypotensive responses elicited by 5-HT (0.1-3 J1g kg· '), after treatment with 
ketanserin (0.1 J1g kg· '), in pithed rats before and after saline, L-NAME or phenyl-
ephrine are shown in Figure 3.2. These doses of 5-HT elicited a moderate hypotensive 
response which remained unaltered after the three doses of saline. However, in the 
group treated with L-NAME hypotensive responses to 5-HT (I J1g kg"'; n~6-1O) were 
significantly augmented by 3 and 10 mg kg· ' L-NAME. The response to 5-HT 
(3 J1g kg·
'
; n~6-9) was enhanced by all three doses ofL-NAME (1, 3 and 10 mg kg· '). 
At similar blood pressure levels during phenylephrine infusions, the responses to 5-HT 
were also augmented. The changes in hypotensive responses, compared to the 
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respective control responses, were similarly potentiated in both L-NAME and phenyl-
ephrine treated animals (Figure 3.2). 
The duration of action of the hypotensive action of 5-HT in the three groups of 
animals was also studied (Figure 3.3). With the two highest doses of L-NAME the 
time to reach 50 % recovery of the response to 5-HT (1 I'g kg") was significantly 
prolonged. The dUl'ation of the responses to 5-HT (3 I'g kg") also tended to increase 
after L-NAME, but the changes were not significant. Phenylephrine did not affect the 
duration of action of 5-HT. 
Hypotensive responses to 5-CT 
As shown in Figure 3.4, compared to saline-treated animals the hypotensive 
responses to 5-CT (0.1-3.0 I'g kg") were significantly and dose-dependently potentiated 
in animals treated with L-NAME (1, 3 or 10 mg kg"). 
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Figure 3.2 Hypotensive response to 5-HT (0.1-3.0 I'g kg") in pithed rats treated with 
ketanserin (0.1 mg kg") before (0) and after treatment with saline (0.5 ml kg" three times; 
n~5-6), L-NAME (I, 3 and 10 mg kg"; n~6-IO) or phenylephrine (160, 240 and 
400 I'g kg" h"; n~6-7). The three doses in each case are represented, respectively, by the 
symbols (e), ( .. ) and (II). Data are given as mean ± s.e.mean. " P<0.05 versus saline; 
+, significant change from control response compared versus the change in saline (P<O.OS). 
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Figure 3.3 Time needed for 50% recovery (Tw) of the hypotensive action of 5-HT (I and 
3 Ilg kg·
'
) in pithed rats treated with ketanserin (0.1 mg kg· ') in groups which received either 
saline, L-NAME or phenylephrine. In each set of panels, the 4 columns from left to right 
represent, sequentially, values before (control) and after the three doses of saline (three times 
0.5 ml kg·
'
; n~5-7), L-NAME (I, 3 and 10 mg kg· l ; n~6-10) or phenylephrine (160, 240 and 
400 fig kg· ' If'; n~6-7). Data are given as mean ± s.e.mean. +, P<0.05 versus control 
responses. 
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Figure 3.4 Hypotensive responses to 5-CT (0.01-3.0 Ilg kg· l ; cumulative) in pithed rats 
treated with either saline (control;o, n~5) or L-NAME (I, 3 and IO mg kg·
'
; n~5 each). The 
three doses are represented, respectively, by the symbols (e), (.) and (III). Data are given 
as mean ± s.c.mean. *, P<O.05 versus saline. 
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Hypertensive responses to 5-HT 
Before any treatment 5-HT (3, 10 and 30 flg ktl) induced a dose-dependent 
pressor response, which in the saline group reached a peak of 52±3 mm Hg and a Till 
of 19±1 s after the highest dose. Both L-NAME (up to 10 mg kg-I) and phenylephrine 
(up to 400 flg kg-I h-I) failed to alter the magnitude of the 5-HT-induced pressor effects 
(Figure 3.5). In contrast to phenylephrine, L-NAME (3 mg kg-I) prolonged the duration 
of the responses to 5-HT (30 flg kg-I; n~7-9), compared to the corresponding baseline 
values. The highest dose of L-NAME prolonged the duration significantly, both 
compared to the corresponding baseline value as well as saline values (Figure 3.6). 
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Figure 3.5 Hypertensive responses to 5-HT (3-30 fig kg-I) in pithed rats before (control; 0) 
and after treatment with saline (0.5 ml kg- I three times; n~7-8), L-NAME (I, 3 and 
10 mg kg-I; n~7-9) or phenylephrine (160,240 and 400 flg kg- I h-I; n~6-7). The three doses 
in each case are represented, respectively, by the symbols (e), (.) and (III). Data are given 
as mean ± s.e.mean. *, P<O.05 versus the corresponding value in the saline experiments. 
57 
Chapter 3 
60 
"' 
"C 
" 0 0 
Q) 
~ 
" 0 
·in 30 
" Q) 1:: 
Q) 
c. 
>-
J: 
" ..:-
0 
Saline 
10 30 
L·NAME 
10 
+ 
30 
* + 
5·HT (~g kg·') 
Phenylephrine 
10 30 
Figure 3.6 Time needed for 50% recovery (Tin) of the hypertensive action of 5·HT (10 and 
30 flg kg·') in pithed rats in groups which received either saline, L·NAME or phenylephrine. 
In each set of panel, the 4 columns from left to right represent, sequentially, values before 
(control) and after the tlu·ee doses of saline (three times 0.5 1111 kg·'; n~7), L·NAME (I, 3 and 
10 mg kg·'; n~7·9) or phenylephrine (160,240 and 400 flg kg·' h·'; n~6·7). Data are given 
as mean ± s.e.mean. *, P<O.05 versus the corresponding value in the saline experiments. 
+, P<O.05 versus control responses. 
Hypertensive responses to DOl 
The hypertensive responses to DOl (3, 10 and 30 flg kg-') were enhanced after 
treatment of the animals with L·NAME (3 mg kg·'), but remained essentially 
unchanged after the infusion of phenylephrine (400 flg kg-' If'). The hypertensive 
effect of the two highest doses (10 and 30 flg kg"') of DOl was significantly more in 
animals treated with L·NAME than in animals treated with phenylephrine (Figure 3.7; 
upper panels). The time needed to 50% recovery of the response to DOl (10 flg kg·') 
was enhanced by L·NAME, whereas the duration of the response to the highest dose 
of DOl (30 flg kg·') was slightly reduced. In contrast, phenylephrine infusion decreased 
the duration of the hypertension action of DOl (10 and 30 flg kg·') (Figure 3.7; lower 
panels). 
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Figure 3.7 Hypertensive responses (upper panels) and time needed for 50% recovery (T,n) 
of the hypertensive responses (lower panels) induced by DOl (3-30 Ilg kg") in pithed rats 
before (control; 0 or open columns) and after (It and hatched coluums) treatment with 
L-NAME (3 mg kg"; n~5) or phenylephrine (400 fIg kg" I,.'; n~5). Data are given as mean 
± s.e.mean. "', P<O.05 versus the corresponding value in the saline experiments. +, P<O.05 
versus control responses. 
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3.4 Discussion 
Blood pressure alld heart rate challges by L-NAME 
There is increasing evidence in several species, including the rat, that NO 
maintains a basal vasodilator tone. This tone seems to be independent of the existing 
vascular tone as blood pressure was increased to a similar extent by L-NAME in pithed 
rats (present results) or anaesthetized rats (chapter 2). However, the underlying 
mechanism of the increase in blood pressure by NO-synthase inhibitors, such as 
L-NAME, is still poorly understood. In any case, a contribution of the autonomic 
nervous system or the renin-angiotensin system seems to be unlikely as the pressor 
responses to L-NNA in the rat are unaffected by blockade of the autonomic nervous 
system (Wang & Pang, 199 I) or the angiotensin I-converting enzyme (Wang and Pang, 
1991; Zambetis et al., 1991). Fmihermore, in a dose (0.1 mg kg") that is sufficient to 
block 5-HT, receptors (Kalkman et al., 1982), ketanserin failed to alter the increasesin 
blood pressure due to L-NAME in our experiments. Since the pressor responses to 
phenylephrine infusions were also similar (see Figure 3.1), the above dose of 
ketanserin apparently did not affect a,-adrenoc~ptors in our experiments. Though this 
finding is in agreement with those ofKalkman et al. (1982), Fozard (1982) did observe 
antagonism of phenylephrine-induced hypertension with similar doses of ketanserin. 
The bradycardia observed after L-NAME in both anaesthetized and conscious rats 
(Gardiner et al.,1990; Rees et al., 1990; Wang & Pang, 1991; chapter 3) is likely to 
be largely reflex-mediated. Thus, few changes in heat1rate occurred with L-NAME in 
the present experiments in pithed rats, as well as in intact rats after ganglion blockade 
(Fozard & Pati, 1991) or atropine (Widdop et al., 1992). Moreover, the bradycardia 
and decrease in renal sympathetic nerve activity induced by NG-methyl-L-arginine 
(L-NMA) in the urethane anaesthetized rat were attenuated by baroreceptor 
deafferentation (Sakuma et aI., 1992). 
Hypotellsive responses to 5-HT alld 5-CT 
It increasingly appears that there is a dissimilarity in the effects of L-NAME on 
the vasodilator responses to acetylcholine observed in experiments in vitro and in vivo. 
The vasodilator responses to acetylcholine, being susceptible to endothelial damage or 
NO-synthase inhibitors, almost exclusively depend on the release of NO in a number 
of isolated blood vessels (see Furchgott & Vanhoutte 1989), whereas this does not 
seem to be the case ill vivo as the peak hypotension induced by acetylcholine were not 
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attenuated, though the duration was somewhat decreased by L-NAME (chapter 2). One 
of the reasons of this discrepancy could be that experiments in vitro are usually 
performed on relatively large (conduit) vessels, whereas the outcome in vivo is mainly 
determined by small (resistance) vessels, i.e. arterioles. 
In the present study, hypotensive responses induced by low doses of 5-HT in the 
presence of ketanserin were not attenuated, but were even significantly enhanced, by 
L-NAME. Since the enhancement of the hypotensive response to 5-HT was also seen 
in animals treated with phenylephrine, it appears that the potentiation of the 
5-HT-induced hypotension is most likely due to an increase in blood pressure rather 
than to interference with the L-arginine-NO pathway. This finding is in contrast to the 
results obtained with 5-HT in the perfused coronary (Mallkad et al., 1991), or renal 
(Verbeuren et al., 1991) arteries ofthe rat or with a-methyl-5-HT in the rabbit isolated 
jugular vein (Martin et aI, 1992). The potentiating effect of L-NAME in our 
experiments was even more pronounced in experiments in which 5-CT was used. This 
5-HT, receptor agonist has been shown to induce endothelium-dependent as well as 
independent relaxant responses, depending on the vessel under study (Schoeffler & 
Hoyer, 1990; SUlnner, 1991; Verbeuren et al., 1991). Hence, it is not possible to 
exclude fully the release of NO in vivo, but it is likely that the hypotensive response 
to 5-HT and 5-CT is largely mediated by a direct vasodilator action on smooth muscle 
cells. 
Hypertensive responses to 5-HT and DOl 
Inhibition of the basal NO-release did not change the magnitude of the 
5-HT-induced pressor responses, but the duration of the effects was moderately 
prolonged. Therefore, it would appear that the release of NO seems to limit the 
hypertensive effects of 5-HT to some extent. The involvement of a NO-specific 
mechanism is indicated by the finding that phenylephrine failed to alter either the 
magnitude or the duration of the 5-HT effect. Indeed, the presence of intact 
endothelium has been shown to counteract contractions in response to 5-HT in the rat 
isolated mesenteric and coronary arteries (Berg-Nyborg & Mikkelsen, 1990; Dohi & 
Luscher, 1991), and treatment with NG-monomethyl-L-arginine (L-NMMA) converts 
5-HT-induced relaxations into contractions in the rat coronary artery (Mankad et aI, 
1991). Whether the contractions are opposed by basal or receptor-stimulated 
NO-release is not known. However, in the dog ped\!sed coronal), mieries contractions 
due to 5-HT are similarly augmented by L-NNA and L-NMMA, whereas contractions 
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to prostaglandin F,u remain unaffected (Cappelli-Bigazzi ef ai.,1991). Likewise, 
L-NAME enhances 5-CT and sumatriptan contractions in the dog perfhsed kidneys, but 
fails to alter those to angiotensin II (Whiting & Cambridge, 1991). Moreover, 
endothelial denudation augments contractions induced by 5-HT as well as several 
5-HT, receptor agonists in the dog isolated basilar artery (Cormor & Feniuk, 1989). 
These findings are indicative of a specific receptor mediated NO-release. 
So far, no endothelium-dependent response has been repOlied for the 5-HT,C12 
receptor agonist DOl. We now demonstrate that the magnitude of DOl responses was 
augmented by the NO-synthase inhibitor L-NAME. These responses were much more 
potentiated than the comparable hypertensive responses to 5-HT. Furthermore, the 
duration of the response to the middle dose of DOl was prolonged. Pressor effects 
elicited by 5-HT could be opposed by three possible vasodilator actions involving a 
direct arteriolar dilatation (see above) or a 5-HT, receptor-mediated or 'contraction-
induced' NO-release from the endothelium. In contrast, the responses to DOl may be 
solely opposed by the endothelial release of NO and, thus, become more pronounced 
than those to 5-HT after L-NAME. Whether NO-release is specifically related to 
5-HT2-receptor mediated pressor responses ill vivo or a more general phenomenon 
related to pressor responses per se, is still not clear. Pressor responses induced by 
phenylephrine are slightly potentiated by L-NAME in ganglion-blocked rats (Chyu 
et aI., 1992), but are unaffected by L-NNA in conscious rabbits (Du et aI., 1992). 
Fmihermore, responses to noradrenaline in pentobarbitone-anaesthetized rats are 
unaffected after L-NMMA (Gray et aI., 1991). Finally, one should bear in mind that 
the pressor responses to DOl, at least in conscious rats, are in' pa'i mediated renin 
release (Alper, 1990). 
In conclusion, L-NAMEincreases arterial blood pressure in animals with a low 
vascular tone. 5-HT- and 5-CT-induced hypotensive responses seem to be largely 
independent of NO release by the endothelium. However, the hypertensive responses 
to 5-HT and DOl appear to be limited by the release of NO in the pithed rat. 
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NG-Nitro-L-arginine methyl ester: systemic and pulmonary 
haemodynamics, tissue blood flow and arteriovenous shunting 
in the pig 
Summary 
The systemic and pulmonary haemodynamic effects ofNG-nitro-L-arginine methyl 
ester (L-NAME), an inhibitor of the endothelial nitric oxide (NO) biosynthesis, were 
evaluated in the anaesthetized pig. Coincidently, local tissue and arteriovenous 
anastomotic blood flows were investigated at baseline and following L-NAME, using 
simultaneous injections of·radioactive microspheres of two different sizes (diameter: 
15 and 50 /lm). L-NAME (I, 3 and 10 mg kg'l) reduced systemic and pulmonary 
artery conductance and cardiac output, but heart rate and mean arterial blood pressure 
remained unchanged. L-arginine (1000 mg kg'l) reversed the systemic and pulmonary 
haemodynamic changes induced by L-NAME. 
As detected with 15 /lm microspheres, L-NAME (1 and 3 mg kg'l) decreased 
tissue blood flow to and vascular conductance in the eyes, lungs, atria, kidneys, 
adrenals and liver. FUl1hermore, the difference between blood flows simultaneously 
measured with 15 and 50 /lm microsphercs, which can be equated to blood flow 
through arteriovenous anastomoses with a diameter between about 28 and 90 /lm, was 
reduced by L-NAME (3 mg kg'l) in the skin of head and gluteal regions and, as 
indicated by the microsphere content of the lungs, in the total systemic circulation. 
These results suggest that in the anaesthetized pig (i) NO is involved in the 
regulation of both systemic and pulmonary vascular conductance, (ii) the decrease in 
systemic vascular conductance is in part due to constriction of systemic arteriovenous 
anastomoses, and (iii) the decrease in pulmonary vascular conductance, leading to 
reduction of cardiac output, seems to negate the expected rise in arterial blood pressure 
observed, for example, in rats and rabbits following inhibition of NO-synthesis. 
Based 011: Van Ge1deren E.M., Den Boer M.O. and Saxena P.R. (1993). NG-nitro-L-argininc 
methyl ester: systemic and pulmonary haemodynamics. tissue blood flow and arteriovenous 
shunting in the pig. Naunyn-Sclmliedeberg's Arch. Pharmacal. 348; 417-423. 
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4.1 Introduction 
Vascular smooth muscle tone is regulated by the release of endothelium-derived 
relaxing factor (EDRF), which has now been identified as nitric oxide (NO) (Ignarro 
el al., 1987; Palmer el al., 1987) or a related nitrosothiol (Myers el al., 1990). Its 
synthesis from the precursor L-arginine is mediated by the enzyme NOS present in 
endothelial cells (Palmer el al., 1988; Forstermann el al., 1991). Analogues of 
L-arginine, including NG-nitro-L-arginine (L-NNA) and its methyl ester (L-NAME), 
have been shown to inhibit NO biosynthesis (Millseh & Busse 1990; Rees el al., 1990). 
These NOS-inhibitors induce a sustained rise in arterial blood pressure in rats 
(Gardiner el al., 1990; Rees el al., 1990; this thesis chapter 2 and 3) and rabbits 
(Humphries el al., 1991; Du el al., 1992), indicating a basal NO release mediating 
vasodilatation. In these species, blood pressure elevation is usually accompanied by a 
reflex bradycardia. Less pronounced effects on blood pressure as well as heati rate 
were found with NOS-inhibitors in lambs (Fineman el al., 1991), goats (Garcia ef al., 
1992), dogs (Richard ef al., 1991; Klabunde ef al., 1991) and cats (this thesis, chapter 
2; McMahOli ef al., 1992); in cats, microsphere content of the lungs, used as an index 
for systemic atieriovenous shunting, was decreased (this thesis, chapter 2). The reason 
for the poor pressor response following inhibition of NO synthesis in these animal 
species is not known, but it is possible that the pressor response due to rise in systemic 
vascular resistance is offset by an additional decrease in cardiac output as a 
consequence of a more marked increase in pulmonary vascular resistance. Indeed, 
NOS-inhibitors have been shown to block pulmonary vasodilator response to vagal 
stimulation in cats (McMahon ef al., 1992), attenuate endothelium-dependent 
pulmonary vasodilatation, leading to pulmonary hypeliension, in lambs (Fineman ef al., 
1991), and to produce pulmonary hypertension and reduced cardiac output in dogs 
(Klabunde ef al., 1991). The purpose of this investigation was to evaluate the effects 
ofL-NAME on systemic and pulmonary haemodynamics, tissue blood flows and total 
and regional arteriovenous shunting, using radioactive microsphere of two different 
diameters (is and 50 j.un) in anaesthetized pigs. Preliminary findings have been 
repOlied elsewhere (Van Gelderen el al., 1992). 
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4.2 Methods 
General 
Twelve male and female pigs (weight 17.8±0.3 kg) were anaesthetized with 
metomidate (120 mg, i.v.) following sedation with azaperone (150 mg, i.m.). After 
intubation, the animals were connected to a respirator (Bear 2E, BeMeds AG, Baar, 
Switzerland) for ventilation with a mixture of oxygen and room air. Arterial blood 
gases were measured (ABL-2, Radiometer, Copenhagen, Denmark) and kept within a 
physiological range (PH 7.45-7.55, PO, 90-120 mmHg, PCO, 35-45 mlnHg) by 
adjusting the ventilation rate and the oxygen-content of the mixture. Anaesthesia was 
maintained by infusing pentobarbitone sodium in the right femoral vein; 20 mg kg" If' 
during the first hour followed by 12 mg kg" If'. A catheter was introduced in the left 
femoral artery for blood pressure measurement. Cardiac output was measured with the 
help of a 6F-Swan-Ganz thermodilution catheter (Corodyn, Braun Melsungen AG, 
Melsungen, Germany), which was advanced into the pulmonary artery via the left 
femoral vein and connected to a cardiac output computer (WTI, Rotterdam, The 
Netherlands). Another catheter was placed in the left ventricle via the left connnon 
carotid miery to inject radioactive microspheres. To calibrate the radioactive 
microsphere method, arterial reference samples were collected from the aorta via a 
catheter in the right femoral artery. Blood pressures were continuously measured in the 
aorta, the pulmonary artery and the left ventricle, using pressure transducers (Statham 
P23, Hato Rey, Puelio Rico). Mean arterial blood pressure was calculated as the sum 
of the diastolic pressure and one third of the difference between systolic and diastolic 
pressure. Heart rate, left ventricular end diastolic pressure and the peak rate of rise in 
left ventricular pressure (LV dP/dt) were derived from the ventricular pulse pressure 
signal. Pulmonary capillary wedge pressure was measured by inflating the 
Swan-Ganz-balloon and pulmonary artery resistance was calculated by dividing the 
difference between mean pulmonary artery and capillary wedge pressures by cardiac 
output. In some experiments the last measurement (after L-arginine) of pulmonary 
capillary wedge pressure could not be measured and, therefore, pulmonary vascular 
resistance was not calculated. Drugs were injected into the aorta to prevent high 
concentrations of drugs reaching the heart. All catheters were filled with a heparin 
sodium solution (80 IU mi") to prevent clotting. Body temperature was kept above 
37'C and physiological saline was infhsed to compensate for fluid loss. The animals 
were allowed to stabilize for at least 45 min before the experiment started. 
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Radioactive lIIicl'Osphere technique 
The regional distribution of the cardiac output was determined with the 
radioactive microsphere technique using the reference blood smple method (Heymann 
et al., 1977), modified for use of simultaneous injection of microspheres of different 
diameter (see Saxena & Verdouw 1985; Den Boer et al., 1992a,b). The microspheres 
used in this investigation were of IS and 50 ~m diameter and labelled with either 14lCe 
(15 ~m), llJSn (50 ~lIn), lOJRu (50 ~m), "Nb (15 ~m) or "Sc (15 ~m) (NEN 
Company, Dreieich, Germany). The order of 15 and 50 ~m spheres injected before and 
after the drugs was randomized. The approximate number of microspheres given pel' 
isotope was about 1,000,000 for IS ~m and 50,000 for 50 ~m. The microspheres were 
vOliexed for about 30 s and then injected into the left ventricle against the direction 
of the blood flow to ensure uniform mixing. An arterial reference sample was 
withdrawn (rate: 10.5 mlmin·l) using a pump (Braun-Melsungen, Melsungen, 
Germany), starting about IS s before and continuing until I min after the injection of 
the microspheres. At the end of the experiment the animals were killed by an overdose 
of sodium pentobarbitone and the different tissues were dissected out, weighed and put 
in vials. The radioactivity in these vials and in the blood samples was counted for 5-10 
min in a gamma-scintillation counter (Packard, Minaxi Autogamma 5000) using 
suitable windows for discriminating the different isotopes. For each tissue, blood flow 
(QH,) was calculated using the formula: QH, ~ (iH, / I",) x 10.5, in which IH, and I", 
represent, respectively, radioactivity in the tissue and in the reference blood sample. 
Tissue vascular conductance was calculated by dividing the tissue blood flow value by 
mean alierial blood pressure. Tissue blood flow and conductance values have been 
expressed per 100 g of tissue. All data were processed by a personal computer 
(Olivetti PCS 286) using a set of specially developed computer programs, based on 
those described earlier (Saxena et al., 1980). 
As extensively discussed elsewhere (Johnston & Saxena 1978; Saxena & Verdouw 
1985; Den Boer et al., I 992a,b), not all microspheres are trapped in tissues; they 
escape entrapment via alieriovenous anastomoses to appear into the venous blood and 
are ultimately sieved in the lungs. Lung radioactivity, therefore, represents for the 
greatest part arteriovenous anastomotic blood flow, although a small pati (1-1.5% of 
cardiac output) is derived from the bronchial arteries (Bailie et al., 1982; Wu et al., 
1988). Based on the demonstration in the hamster cheek pouch that microspheres of 
IS and 24 ~m diameter are already trapped in blood vessels with a diameter of 27.7 
and 42. 7 ~m, respectively (Dickhoner et al., 1978), it may be assumed that IS ~m 
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spheres detected in a certain tissue reflect blood flow through vessels with a diameter 
smaller than about 28 11m (capillaries and small arteriovenous anastomoses), whereas 
50 11m spheres reflect blood flow through vessels under 90 11m diameter (capillaries 
and medium-sized arteriovenous anastomoses). Therefore, the difference between blood 
flow values simultaneously obtained with 15 and 50 Ilmmicrospheres may serve as an 
index of the blood flow in arteriovenous anastomoses with a diameter between 28 and 
90 11m. 
Experimental protocol 
At baseline values of systemic and pulmonary haemodynamic variables were 
collated and a mixture of 15 and 50 11m microspheres was injected in the left ventricle 
to determine baseline regional tissue blood flows. The animals were then divided at 
random into two groups (n~6 each), which were treated every 25 min with three 
consecutive doses of L-NAME (1, 3 and 10 mg kg") or saline (3 ml each). Systemic 
and pulmonary haemodynamic values were collected after each dose of L-NAME or 
saline. After the first dose 15 11m microspheres were injected, whereas after the second 
dose 15 and 50 11m spheres were injected simUltaneously. Finally, in both groups five 
animals were treated with L-arginine (1000 mg kg") and, 15 min later, the 
haemodynamic variables, except pulmonary capillary wedge pressure, were collated 
again. 
Data presentation and analysis 
All data in the text are mentioned as mean ± s.e.mean. The effects oftreatments 
were analyzed in each group using a repeated measurements analysis of variance with 
the factors size and treatment. Once the samples represented different populations, the 
values after the different treatments were compared to baseline values by use of 
Duncan's new multiple range test. In each group the difference in blood flow values 
obtained with 15 and 50 11m microspheres before and after treatment were analyzed 
with a Student's t test for paired data. The changes among the two groups were tested 
by a Student's t test. Statistical significance was accepted at P < 0.05 (two-tailed). 
Chemicals 
The drugs used in this study were: azaperone, metomidate (both from Janssen 
Pharmaceutica, Beerse, Belgium), L-arginine, NG-nitro-L-arginine methyl ester (both 
from Sigma, St. Louis, U.S.A.), pentobarbitone sodium (Narcovet, Apharmo, Arnhem, 
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The Netherlands) and heparin sodium (Thromboliqnine, Organon Teknika B.V., Boxtel, 
The Netherlands). All doses refer to the respective salts. 
4.3 Results 
Systemic and pulmonQly haemodynamics 
Systemic and pulmonary haemodynamic variables in the two groups at baseline 
and following treatment with L-NAME or saline are depicted in Figure 4.1. Apart from 
mean arterial blood pressure, which was somewhat higher in the saline group, no 
differences were observed initially between the groups. L-NAME significantly reduced 
cardiac output (by 40±2 and 45±4% after 3 and 10 mg kg", respectively) and stroke 
volume (by 28±3, 46±5 and 53±5%after the three doses, respectively), but did not 
significantly affect heart rate, mean arterial blood pressure, LV dP/dt or pulmonary 
capillary wedge pressure (both not shown in Figure 4.1). Left ventricular end diastolic 
pressure decreased significantly after 3 mg kg" L-NAME (-17±8%), whereas mean 
pulmonaty artery pressure increased significantly after the two highest doses (51±11 
and 62±1I %, respectively). L-NAME significantly reduced systemic (by 30±3, 36±6 
and 28± II % after the three doses, respectively) and pulmonary (by 65±5 and 65±2% 
after 3 and 10 mg kg", respectively) vascular conductances (Figure 4.1). 
Except for arterial blood pressure, administration L-arginine (1000 mg kg") 
pattially or fblly reversed the systemic and pulmonary haemodynamic changes induced 
by L-NAME. 
Tissue blood flow and vascular conductance 
Tissue blood flows measured with 15 !1m radioactive microspheres at baseline and 
after L-NAME are shown in Figure 4.2. L-NAME, I and 3 mg kg", respectively, 
decreased blood flow to the eyes (42±5 and 62±4%), atria (37±8 and 44±9%), lungs 
(42±8 and 68±5%), kidneys (31±2 and 51±4%), and adrenals (35±7 and 60±7%). 
When compared to baseline values, blood flow was reduced in the bones (32±5 and 
39±6%) and liver (32±l2%, I mg kg" only). L-NAME induced no significant change 
in blood flow to the brain as well as to the skin, tongue, spleen, stomach, mesentery, 
intestines 01' skeletal muscles (not shown in Figure 4.2). 
Since mean arterial blood pressure changed only moderately during the course of 
the experiment, similar changes were observed in tissue vascular conductances. 
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The vascular conductance was decreased in the adrenals (37±7 and 59±5%), eyes (45±5 
and 60±4%), kidneys (35±4 and 48±4%), bones (36±5 and 35±8%) and lungs (46±7 
and 67±5%) by L-NAME (I and 3 mg kg", respectively). Additionally, the lower dose 
of L-NAME also reduced vascular conductance in the liver (35±l2%) and heart 
(l6±5%). In the heart, the effect ofL-NAME was not observed in the ventricles and 
was confined to the atria, where vascular conductance was decreased by 42±6 and 
44±6% by I and 3 mg kg" of L-NAME, respectively. 
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Figure 4. J Systemic haemodynamics in anaesthetized pigs before (BL) and after saline (open 
circles) or L·NAME (closed circles), followed in both groups (n~6 each) by L·arginine (1000 
mg kg"; ARG). The haemodynamic variables are abbreviated: heart rate (HR), mean arterial 
blood pressure (MBP), cardiac output (CO), stroke volume (SV), mean pulmonary artery 
pressure (MP AP), left ventricular end diastolic pressure (L VEDP), systemic vascular 
conductance (SVC) and pulmonary artery conductance (PVC). Data are given as mean±s.e. 
mean, but in some cases error bars fall within the limits of the symbol. *, p<O.05 versus 
corresponding saline value; §, p<O.05 versus baseline value, in case of ARG only. 
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Figure 4.2 Tissue blood flows measured with 15 flln radioactive microspheres in pigs treated 
with either saline (upper panels; n~6) or L-NAME (lower panels; n~6). In each set ofpanels, 
baseline blood flow is shown by the open bars, whereas increasing doses of L-NAME (I and 
3 mg kg") or saline are represented by the hatched and cross hatched bars, respectively. Data 
are given as mean±s.e. mean. a, p<O.OS versus baseline only; h, p<O.05 versus saline 
experiments. 
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Total systemic and regional arteriovenous anastomotic blood flow 
The presence of a substantial number of 15 and 50 Ilm microspheres, with the 
latter in preponderance, in the lungs demonstrated that abundant systemic atieriovenous 
shunting occurs in anaesthetized pigs (Table 4.1; Figure 4.3). L-NAME (3 mg kg") 
clearly reduced the number of both 15 and 50 Ilm microspheres as well as the 
difference between these two spheres (62±6%), indicating a decrease in total systemic 
shunting through alieriovenous anastomoses between 28 and 90 Ilm diameter 
(Figure 4.3). At the tissue level, similar blood flow values were found with the two 
sizes of microspheres in all tissues dissected, except in the skin and tongue (Table 4.1). 
The difference in the blood flows measured with 15 and 50 Ilm microspheres in the 
skin and tongue reflects the presence of arteriovenous anastomoses in these tissues. 
Administration ofL-NAME (3 mg kg") significantly reduced this difference in the skin 
(by 75±5%), but not in the tongue (Figure 4.3). 
It may be noted that skin obtained Ii'om different regions showed heterogeneity 
(Figure 4.4). Thus, the head and gluteal skin exhibited a large difference between 15 
and 50 Ilm microsphere blood flow values, while those from the abdominal and back 
Table 4.1 Tissue blood flows (ml min" 100 g") at baseline measured with IS Ilm and 50 IlID 
radioactive microspheres) as well as their difference (n=12). 
Tissue Microsphere size Difference 
15 I'Dl 50 I'Dl 50 I'm - 15 I'm 
Lungs§ 210 ± 29 90 ± 15* -120 ± 17 
Brain 39 ± 1.5 41 ± 2.1 2.8 ± 1.0 
Eyes 44 ± 3.4 48 ± 3.1 4.6 ± 2.0 
Tongue 7 ± 0.4 9 ± 0.6* 1.8 ± 0.4 
Bones 6 ± 0.4 7 ± 0.6 0.6 ± 0.5 
Heali 99 ± 5.6 104 ± 4.5 5.1 ± 1.7 
Liver 21 ± 2.8 22 ± 3.2 1.6 ± 0.6 
Spleen III ± 15 119 ± 17 8.1 ± 3.3 
Stomach 18 ± 1.6 19 ± 1.8 1.0 ± 0.7 
Mesentery 3 ± 0.4 6 ± 1.4 2.5 ± 1.3 
Intestines 39 ± 1.3 40 ± 1.5 1.0 ± 0.8 
Kidneys 220 ± 13 232 ± 14 12 ± 4.5 
Adrenals 155 ± 15 153 ± 20 -2.2 ± 7.2 
Skin 5 ± 0.3 21 ± 2.4' 16 ± 2.6 
Muscles 5 + 0.4 5 + 0.4 0.4 + 0.2 
§, indicates the sum of total systemic arteriovenous anastomotic and bronchial blood flows; 
*, P<O.05 versus the corresponding 15 ~tm value. 
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region did not. The blood flow differences were significantly decreased by L-NAME 
(3 rug kg") in the gluteal and head skin by 70±5% and 70±4%, respectively 
(Figure 4.4). 
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Figure 4.3 The effect of saline (n~6) or L-NAME (3 mg kg"; n~6) on total systemic (lung) 
and regional arteriovenous anastomoses blood flow, represented by the difference in blood 
flow measured with 15 11m (open bars) and 50 flm (cross-hatched bars) radioactive 
microspheres. In each set of panels the absolute difference is depicted by the hatched bar. 
Data are given as mean ± s,c. mean. a, denotes significant difference between 15 ~nn and 
50 flm (p<0.05); b, denotes significant difference from baseline (p<0.05); c, denotes 
significant change in difference between 15 and 50 flm (p<0.05). 
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Figure 4.4 The effect of saline (n~6) or L-NAME (3 mg kg·l; IF6) on arteriovenous 
anastomoses blood flow in several skin regions, represented by the difference in blood flow 
measured with IS flm (open bars) and 50 flm (cross-hatched bars) radioactive microspheres. 
In each set of panels the absolute difference is depicted by the hatched bar. Data are given 
as mean±s.e. mean. a, denotes significant difference between IS and 50 flm (p<0.05); 
b, denotes significant difference from baseline (p<0.05); c, denotes significant change in 
difference between 15 and 50 flm (p<0.05). 
4.4 Discussion 
The present investigation was devoted to study the effects of NO-synthase 
inhibition in anaesthetized pigs using L-NAME. Recently, Buxton and coworkers 
reported that several alkyl esters of L-arginine analogues, including L-NAME, have 
atropine-like properties in both radioligand binding and functional in vitro stndies. 
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However, muscarinic cholinergic blockade is not likely to playa meaningfhl role in 
our studies. Firstly, ill vivo L-NAME is rapidly dealkylated into L-NNA, which seems 
to be responsible for the pharmacological actions in intact animals (Schwarzacher & 
Raberger, 1992), but is devoid of antimuscarinic property (Buxton el 01., 1993). 
Secondly, in our previous studies in both rats and cats, L-NAME (up to 30 mg kg") 
failed to attenuate the magnitude of hypotensive responses to acetylcholine (chapter 2). 
Lastly, the effects ofL-NAME in the present study were partly reversed by L-arginine, 
which does not affect the anti muscarinic action of L-NAME (Buxton e/ 01., 1993). 
Systemic alld pulmollmy haemodYllamics 
Several studies have demonstrated a pronounced increase in blood pressure 
following administration ofL-NNA or L-NAME to rats (Gardiner et 01., 1990; Rees 
et 01., 1990; this thesis Chapter 2 and 3) and rabbits (Wiklund e/ 01., 1990); this effect 
is thought to be due to vasoconstriction resulting from attenuation of basal NO-release. 
In contrast, the pressor responses are often quite moderate or even absent in dogs, 
goats, lambs and cats (Fineman et 01., 1991; Klabunde et 01.,1991; Garcia et 01., 1992; 
this thesis Chapter 2). Similar to our previous observations in cats (This thesis, 
chapter 2), the present experiments show that L-NAME did not increase blood pressure 
in anaesthetized pigs, though systemic vascular conductance was significantly 
decreased. Coincident with the reduction in systemic vascular conductance, pulmonary 
vascular conductance, left ventricular end diastolic pressure, stroke volume and, 
ultimately, cardiac output declined dose-dependently. It is therefore likely that the 
expected rise in mterial blood pressure due to systemic vasoconstriction was negated 
by the fall in cardiac output in the pig. A comparable fall in cardiac output has also 
been observed in the anaesthetized dog after the NOS-inhibitors, L-NNA and 
NG-monomethyl-L-arginine (Klabunde et 01., 1991; Perrella et 01., 1992). 
The reduction of stroke volume and cardiac output is best explained by the 
marked decrease in pulmonary vascular conductance, leading to high pulmonary artery 
pressure, though the reduction in systemic vascular conductance may have pattly 
contributed. Indeed, NO-release can be involved in the maintenance of a low vascular 
tone within the pulmonary circulation (Wiklund et 01., 1990; Fineman et 01., 1991; 
Perrella et 01., 1991) and exogenous NO may reverse pulmonary hypertension in man 
(Pepke-Zaba et 01., 1991). The rise in mean pulmonary artery pressure following 
L-NAME and the ability of L-arginine to reverse the changes induced by L-NAME in 
our experiments are in keeping with this view. 
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In conscious rats a direct negative inotropic action of L-NAME has been 
proposed, based upon the reduction in stroke volume, LV dP/dtma, and peak aorta blood 
flow (Gardiner el al., 1990). Though NG-methyl-L-arginine (L-NMA) decreased 
contractility and cAMP and cGMP levels in isoprenaline-stimulated rat perfused hearts, 
the compound failed to reduce LV dP/dt"a" despite a decrease in myocardial cGMP 
content in unstimulated hearts (Klabunde el al., 1992). In anaesthetized dogs, 
LV dPldtma, was only slightly decreased by L-NMA (Klabunde el al., 1991), and 
intracoronary application of L-NAME did not affect myocardial tissue perfusion 
measured with radioactive microspheres, though L-NAME did induce a local coronary 
constriction (Richard el al., 1991). Similarly, in the present experiments in pigs, no 
evidence for a major negative inotropic effect of L-NAME was uncovered as the 
compound did not lower LV dP/dt or ventricular vascular conductance significantly. 
Therefore, a reduction in myocardial oxygen supply due to coronary artery constriction 
by L-NAME is also unlikely. 
Tissue blood jlolV and vascular conducfance 
In the anaesthetized pig, L-NAME reduced tissue blood flow and vascular 
conductance in a limited number of tissues, being most apparent in the adrenals, eyes, 
kidneys and lungs. These findings differ from our previous results in cats in which a 
higher dose (30 mg kg") of L-NAME reduced blood flows to abdominal tissues 
without affecting renal blood flow (This thesis, chapter 3). Furthermore, as measured 
by the radioactive microsphere technique, reduced blood flow was observed in most 
of the tissues in rats following the NOS-inhibitor NG-monomethyl-L-arginine 
(Greenblatt ef al., 1993). These differences may be related to differences in basal 
NO-release between species and tissues or to differences in sensitivity of the vascular 
smooth muscle cells. Thus, isolated porcine renal and coronary arteries show a similar 
EDRF release but display a difference in sensitivity to the released EDRF (Christie & 
Lewis 1991). In any case, the reduced renal conductance foilowing administration of 
L-NAME, an inhibitor of NO-synthase, is in accordance with studies in rats (Gardiner 
ef al., 1990; Greenblatt ef al., 1993), rabbits (Humphries ef al., 1991) and dogs 
(Peneila ef al., 1992), and are indicative of a regulatory role for NO in the renal 
circulation. 
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Tolal systemic and regional arteriovenous shunting 
The use of radioactive microspheres to measure total systemic (Johnston & 
Saxena 1978; Saxena et al., 1980; Saxena & Verdouw 1982) and regional (Saxena & 
Verdouw 1985; Den Boer et al., 1992a,b) arteriovenous anastomotic blood flows has 
been discussed previously. Briefly, microspheres (IO 11m or larger in diameter) 
escaping entrapment in peripheral tissues and sieved by the lung capilIaries can be used 
as an index of total systemic arteriovenous shunting, whereas the difference between 
tissue blood flows simultaneously measured with microspheres of different diameters 
indicates blood flow through arteriovenous anastomoses at the tissue level. In our case, 
the difference between blood flows measured with 15 and 50 11m spheres represents 
blood flow through arteriovenous anastomoses between approximately 28 and 90 11m 
diameter, as suggested by the relative sizes of arterial microvessels and the therein 
trapped microspheres (Dickhoner et al., 1978). 
In the present experiments, 21 % of the 15 11m microspheres injected into the 
heart were detected in the lungs. Since bronchial blood flow has been shown to be only 
I to 1.5% of the cardiac output (BailIe et al., 1982; Wu el al., 1988), more than 90% 
of the micl'Ospheres sieved by the lungs had passed through arteriovenous anastomoses. 
As indicated by the difference between tissue blood flows measured simultaneously 
with 15 and 50 11m spheres, lungs seem to completely sieve microspheres escaping 
entrapment mainly in the skin, but also in the tongue and, possibly, in some other 
tissues which we did not dissect. Interestingly, skin exhibited regional heterogeneity, 
with the head and gluteal skin having a much higher arteriovenous shunting than the 
skin from the abdominal or back region. These results are in agreement with our 
previous observations (Saxena & Verdouw 1985; Den Boer et al., 1992b). L-NAME 
substantially decreased the total systemic 'arteriovenous shunting as judged by the 
decrease in the 'lung blood flow' measured with 15 11m and 50 11m microspheres as 
well as the difference between 'lung blood flow' measured with the microspheres of 
the two sizes. At the tissue level, L-NAME significantly decreased the difference 
between 15 and 50 11m sphere blood flows and, therefore, shunting in medium-sized 
atieriovenous anastomoses in the head and gluteal skin; the apparent lack of effect in 
abdominal and back skin and tongue may be due to a less pronounced shunting in these 
tissues. 
The effectiveness of L-NAME tempts us to suggest that the release of NO frolp 
endothelium regulates the tone of alieriovenous anastomoses demonstrated in porcine 
skin. Cutaneous arteriovenous anastomoses are supposed to have a role in temperature 
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and, perhaps, also in blood pressure regulation (Hales & Molyneux 1988); NO-release 
may provide a rapid mechanism to adapt to temperature changes. However, at this 
moment we cmmot fully exclude that blood flow through arteriovenous anastomoses 
following L-NAME was reduced as a result of the fall in cardiac output, causing a 
diminished blood supply to these vessels. 
In conclusion, our results demonstrate that basal NO release regulates both 
systemic and pulmonary conductance in the anaesthetized pig. The expected increase 
in blood pressure due to NO-synthase inhibition is offset by the coincident reduction 
in cardiac output. A part of the reduced vascular conductance may be attributed to a 
constriction of arteriovenous anastomoses. 
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Chapter 5 
Inhibition of nitric oxide biosynthesis and carotid arteriovenous 
anastomotic shunting in the pig 
Summary 
The role of nitric oxide (NO) biosynthesis in the regulation of blood flow through 
arteriovenous anastomoses was evaluated in the carotid circulation of the anaesthetized 
pig. For this purpose, the effect of intra carotid (Lc.) administration of the NO synthase 
inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 0.1,0.3 and 1.0 mg kg"; n~6) 
or saline (n~6) was studied on the distribution of coullnon carotid blood flow, using 
the radioactive microsphere method. 
Apati fi'om the highest dose, L-NAME caused no major changes in the systemic 
haemodynamic variables. Both cardiac output and systemic vascular conductance were 
reduced by L-NAME (I mg kg"), being reversed pattly by L-arginine (100 mg kg", 
i.c.). In both groups, L-arginine slightly reduced mean arterial blood pressure. 
Total common carotid artery blood flow as well as its distribution over the 
capillary and alieriovenolls anastomotic fraction remained stable after saline injections. 
In contrast, L-NAME caused a dose-dependent decline in common carotid artery blood 
flow and conductance and this decline was confined. entirely to its arteriovenous 
anastomotic part. 
Subsequent intracarotid injection of L-arginine (100 mg kg-') reversed the 
reduction in total carotid conductance almost completely and that in the arteriovenous 
anastomotic part partially. Additionally, L-arginine increased capillary conductance 
significantly in the L-NAME as well as the saline treated animals. 
These resuits indicate that the L-arginine-NO pathway contributes little to the 
regulation of tissue perfbsion in the porcine carotid circulation. In contrast, NO seems 
to play an important role in shunting atierial blood through atieriovenous anastomoses 
in the anaesthetized pig. 
Based 011: Van Gelderen E.M. and Saxena P.R. (1994). Inhibition of nitric oxide biosynthesis 
and carotid arteriovenous anastomotic shunting in the pig. Br. 1. Pharmacol. 111; 961-967. 
79 
Chapler 5 
5.1 Introduction 
Arteriovenous anastomoses have been found in animals and man, although their 
precise physiological function is not yet fidly understood. Cutaneous arteriovenous 
anastomoses may be implicated in the regulation of the body temperature and blood 
pressure (Hales & Molyneux, 1988). Furthermore, dilatation of cranial arteriovenous 
anastomoses has been proposed to contribute to the pathogenesis of migraine headache 
(Heyck, 1969; Saxena, 1978, 1990). 
Little is known of the mechanisms involved in opening arteriovenous 
anastomoses, which are normally under a constrictor tone. However, for several reasons 
nitric oxide (NO), which is formed from L-arginine by the calciumlcahnodulin 
dependent enzyme NOS (Palmer el ai., 1988; Bredt & Snyder, 1990; Fiirstermatm el 
ai., 1991), may be a potential candidate: (i) as indicated by the inhibition of NO 
biosynthesis using N° -nitro-L-arginine methyl ester (L-NAME), continuous production 
of NO apparently contributes to the regulation of arterial blood pressure and tissue 
perfilsion (Gardiner el ai, 1990; Rees el ai., 1990; this thesis, chapter 2); 
(ii) compounds that act via the NO system (e.g. nitroglycerine, isosorbide mononitrate) 
cause headache as well as temporal mtery dilatation in humans (Iversen, 1992; Iversen 
el ai., 1992); and (iii) as shown in chapter 4, systemic administration of L-NAME in 
anaesthetized pigs decreased the number of microspheres detected in the lungs after left 
atrial injection (Le. bronchial plus systemic arteriovenous anastomotic blood flow); 
however, in these experiments cardiac output was also concomitantly reduced (this 
thesis, chapter 4). 
The present investigation was devoted to study the effect of L-NAME, 
administered directly into the common carotid artery to avoid changes in cardiac 
output, on the distribution of the common carotid mtery blood flow into arteriovenous 
and capillary (tissue) parts in the anaesthetized pig. Furthermore, jugular venous nitrite 
content was analyzed to establish whether the inhibition of NO biosynthesis is reflected 
by a reduction in plasma nitrite (NO,) and nitrate (NO,) levels in vivo; NO is rapidly 
decomposed to finally yield nitrite and nitrate, both detected in biological fluids (Green 
el ai., 1982; Furchgott el ai., 1990; Kelm & Schrader, 1990). Preliminary data from 
the present investigation were presented at the winter meeting of the British 
Pharmacological Society (Van Gelderen & Saxena, 1993). 
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5.2 Methods 
General 
Twelve domestic pigs (Yorkshire x Landrace; 15-18 kg) were anaesthetized with 
azaperone (120 mg, i.m.) and metomidate (150 mg, i.v.), intubated and cOlmected to 
a respirator (Bear 2E, BeMeds AG, Baal', Switzerland) for intermittent positive 
pressure ventilation with a mixture of room air and oxygen. Arterial blood gas values 
were kept within physiological range (PH 7.39-7.49; pC02 37-44; p02 100-130) by 
adjusting oxygen supply, respiratory rate and tidal volume. Anaesthesia was maintained 
by continuous i.v. infhsion of pentobarbitone sodium (20 mg kg" h" during the first 
hour followed by 12 mg kg" If') in the right femoral vein. A catheter was introduced 
into the aortic arch via the left femoral artery, connected to a pressure transducer 
(Statham P23, Hato Rey, Puerto Rico) for measurement of arterial blood pressure and 
blood sample withdrawal to determine blood gases (ABL-51O, Radiometer, 
Copenhagen, Denmark). Cardiac output and pulmonary arterial blood pressure were 
measured with a 6F-Swan-Ganz thermodilution catheter (Corodyn, Braun Melsungen 
AG, Melsungen, Germany) introduced into the pulmonary artery via the left femoral 
vein and connected to a cardiac output computer (WTI, Rotterdam, The Netherlands) 
as well as to a pressure transducer. Mean arterial (MAP) and mean pulmonary artery 
(MPAP) pressures were calculated from respective systolic (SBP) and diastolic (DBP) 
blood pressures as: MAP or MP AP= DBP+(SBP-DBP)/3. Heart rate was counted from 
the blood pressure signals. Systemic and pulmonary vascular conductances were 
calculated by dividing cardiac output by MAP and MPAP, respectively, with the 
assumption that the pulmonary capillary wedge pressure remained stable throughout 
the experiment. The right common carotid artery was dissected free and the total 
carotid blood flow at the ipsilateral side was measured with a flow probe (internal 
diameter: 2.5 or 3 mm) cOl1llected to a sine-wave electromagnetic flow meter 
(Trans flow 600-system, SkalaI', Delft, The Netherlands). Two hub-less needles 
(external diameter 0.5 mm), cOlmected to a polyethylene tubing, were inserted into the 
common carotid artery against the direction of the blood flow for administration of 
radioactive microspheres or dmgs. The right jugular vein was catmulated in order to 
collect venous blood samples to determine venous blood gases and to analyze nitrite 
levels. All catheters were filled with a heparin sodium solution (80 LD. mi") to 
prevent blood clotting. During the experiment, body temperature was kept above 37°C 
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and physiological saline was infused to compensate for fluid loss. The animals were 
allowed to stabilize for at least 45 min before the start of experiments. 
Distribution of the COIl1IlIOn carotid blood flow 
The distribution of the common carotid blood flow was measured using repeated 
injections of radioactive microspheres (mean±s.d. diameter: 15±! !Jm; NEN Company, 
Dreieich, Germany) with different labels (,"Ce, 1I3Sn, lO3Ru, "Nb or 46SC) (Johnston 
& Saxena, 1978). A suspension of approximately 250,000 microspheres was vOliexed 
before each measurement and injected into the common carotid artery against the 
direction of the blood flow to ensure uniform mixing. At the end of the experiment the 
animals were killed and the heart, kidneys, lungs and the different cranial tissues were 
dissected out, weighed and put in vials. The radioactivity in these vials was counted 
for 10 min in a gamma-scintillation counter (Packard, Minaxi Autogamma 5000) using 
suitable windows for discriminating between the different isotopes. 
Tissue blood flow (capillary blood flow) was calculated by multiplying the ratio 
between tissue radioactivity and the total radioactivity with the total carotid blood flow 
at the time of injection. Since radioactivity was absent in the hea,i and kidi,eys, all 
radioactive microspheres reaching the venous side ofthe circulation had passed through 
atieriovenous anastomoses to be ultimately sieved in the lungs. Therefore, the amount 
of radioactivity in the lungs served as an index for the arteriovenous anastomotic 
fraction of the common carotid blood flow. 
Nitrite allalysis 
The nitrite content of venous blood samples, withdrawn from the ipsilateral 
jugular vein, was measured by a modification of the colorimetric procedure using the 
Griess reagent (0.5% sulfanilamide with 0.05% N-(naphthyl)-ethylenediamine in 2% 
H3P04) (Green et 01., 1982). This assay is based on the diazotization of a sulfanilamide 
by nitrite and a subsequent coupling with N-(naphthyl)-ethylenediamine to yield a 
azoclu'omophore which can be detected spectrophotometrically. Briefly, following 
centrifugation 150 !Jl of the supernatant was mixed with an equal amount of the Griess 
reagent in a 96-wells plate and incubated for 10 min at room temperature. Extinction 
was measured at 540 nm using a microplate reader (BIORAD, Model 3550) against a 
blank containing sulfanilamide. Sample nitrite concentration was calculated from a 
standard absorption curve constructed with several concentrations of sodium nitrite. 
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Since nitrite is converted rapidly to nitrate in the presence of oxygen samples were 
analyzed immediately after blood withdrawal. 
Additionally, total nitrite and nitrate content in deproteinized samples was 
measured using Griess reagent following reduction of nitrates with a Klebsiella 
pneumoniae suspension (BBD 900990, RIVM-Pharmacology, Bilthoven, The 
Netherlands) into nitrites, detected by measuring the absorbance at 540 run with a 
spectrophotometer (Perkin-Elmer lambda 15 UVNIS) against a blank (Phizackerley & 
AI-Dabbagh, 1983). 
Experimental protocol 
After the stabilization period the animals were randomly assigned to either the 
treatment or control group, finally consisting of six animals each. At the stati of the 
experiments, baseline haemodynamic parameters, venous nitrite levels, blood gases as 
well as the distribution of the common carotid blood flow was measured. Thereafter, 
the first group was treated with three consecutive doses ofL-NAME (0.1, 0.3 and 1.0 
mg kg", i.e.), whereas an equal volume of saline was injected three times into the 
control animals group. In both groups, L-arginine (100 mg kg", i.e.) was injected after 
the last dose of L-NAME or saline. Ten minutes after each dose all parameters were 
reassessed and blood samples collected. 
Data presentation and analysiS 
All data, calculated with a personal computer (Olivetti PCS 286) using a set of 
specially developed computer programs (Saxena et al., 1980), are presented in the text 
as mean±s.e. mean. The effect of treatment was analyzed in each group using a 
repeated measurement analysis of variance. When the samples represented different 
popUlations, the values after the different treatments were compared to baseline values 
by use of a Duncan's new multiple range test. Subsequently, the changes to baseline 
values among the two groups were tested using a Student's t test. Statistical 
significance was accepted at a level of p';0.05. 
Chemicals 
The chemicals used in this study were: azaperone, metomidate (both from Janssen 
Phannaceutica, Beerse, Belgium),L-arginine,N-(naphthyl)-ethylenediamine,NG-nitro-
L-arginine methyl ester (L-NAME), sulfanilamide (All from Sigma Chemical Co., St. 
Louis, U.S.A.), pentobarbitone sodium (Narcovet, Apharmo, Arnhem, The Netherlands) 
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and heparin sodium (Thromboliquine, Organon Teknika B.V., Boxtel, The 
Netherlands). Both L-arginine and L-NAME were dissolved in saline. All doses refer 
to their respective salts. 
5.3 Results 
Systemic haemodynamics 
The systemic haemodynamic variables in both groups at baseline, followed by 
either saline or L-NAME (0.1, 0.3 and 1.0 mg kg", i.c.), and L-arginine (100 mg kg", 
i.c.) are depicted in Table 5.1. There were no significant differences between the two 
groups in the systemic haemodynamic values at baseline, and no major changes were 
observed in the saline-treated animals. L-NAME also did not significantly affect heart 
rate or mean arterial blood pressure, but after the highest dose pulmonary artery 
pressure increased (l8±5%) and cardiac output decreased (-20±3%) significantly. 
Consequently, the calculated systemic (21±6%) and pulmonary (37±7%) vascular 
conductances were significantly decreased at the highest dose ofL-NAME (I mg kg"). 
L-arginine (100 mg kg", i.c.) reversed the L-NAME-induced increase in mean 
pulmonary mtery pressure as well as the reduction in systemic vascular conductance, 
and it also moderately lowered mean arterial blood pressure in both groups. 
Carotid haemodynamics 
As shown in Figure 5.1, no significant effects were observed in either total 
carotid blood flow or its distribution in saline-treated animals. In contrast, L-NAME 
caused a dose-dependent decline in total common carotid altery blood flow (maximum 
change: -37±3%). This effect was confined entirely to the arteriovenous anastomotic 
part with little change in the capillary part. The effects of L-NAME were partially 
reversed by L-arginine. 
The effects of saline and L-NAME on carotid vascular bed conductance are shown in 
Figure 5.2. While no changes were observed with saline, intracarotid injections of the 
three consecutive doses of L-NAME (0.1 to 1.0 mg kg") elicited dose-dependent 
decreases in total carotid conductance; the maximum change following the highest dose 
was -41±4%. Coincident with this reduction a decrease in arteriovenous anastomotic 
conductance was observed (-64±2%), whereas capillary conductance was unaffected. 
Subsequent intracarotid injection of L-arginine (100 mg kg") reversed the reduction 
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in total carotid conductance almost completely (93±16%) and in the arteriovenous 
anastomotic conductance partially (50±6%). Additionally, L-arginine increased 
capillary conductance significantly in the L-NAME treated animals (+50±18%), 
whereas in the saline treated animals the conductance was increased when compared 
to baseline (+55±18%; Fignre 5.2). 
Table 5.1. Systemic haemodynamic variables measured at baseline and after intracarotid 
injections of saline (control; n~6) or L-NAME (n~6), followed by L-arginine (100 mg kg· I). 
Saline or L-NAME (mg kg'l) 
Baseline 0.1 0.3 1.0 L-Arginine 
HR (beats mitf') 
Saline 93±7 9l±6 9l±6 9l±6 9l±6 
L-NAME 104±5 102±5 100±6 94±3 92±4 
MAP (mmHg) 
Saline 96±5 95±7 94±6 90±5 82±41 
L-NAME 100±2 100±5 104±6 109±8 9l±61 
MPAP (IIImHg) 
Saline 21.5±1.0 21.7±0.9 23.2±1.3 22.2±1.6 21.5±1.3 
L-NAME 20.7±0.5 21.3±0.4 23.0±0.7 24.5±1.4' 21.2±0.71 
CO (Imitf') 
Saline 2.0l±0.2 1.94±0.2 1.90±0.2 1.83±0.1 1.86±0.1 
L-NAME 2.10±0.2 1.97±0.2 1.83±0.1 1.68±0.1' 1.80±0.1 
SVC (1111 min" IIImHg") 
Saline 21.3±2.7 20.9±2.2 20.4±1.7 20.7±1.7 22.7±1.1 
L-NAME 21.1±1.9 19.6±1.4 17.7±1.6 16.2±1.0' 19.9±0.51 
PVC (ml min" mmHg") 
Saline 96.3±14 89.6±7.0 81.8±3.5 84.0±7.2 87.0±4.1 
L-NAME 102.5±1O 92.6±9.8 80.7±7.0 70.6±8.9' 84.9±5.3 
Data are given as mean±s.e. mean. *, p:S:;O.05 versus baseline; t, p:S:;O.05 L-arginine versus 
L-NAME (1.0 mg kg· l) or saline. HR, heart rate; MAP, mean arterial blood pressure; MP AP, 
mean pulmonary artery pressure; CO, cardiac output; SVC, systel.nic vascular conductance; 
PVC, pulmonary vascular conductance. 
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Figure 5.1 Total carotid, arteriovenous (AVA) and capillary blood flow at baseline (BL), 
after the three intracarotid injections with either saline (left panels; n~6) or L-NAME (right 
panels; 0.1, 0.3 and 1.0 mg kg· l ; n~6) and following L-arginine (Arg, 100 mg kg· l ; solid 
columns). In each set of panels, the hatched columns represent three increasing doses of saline 
or L~NAME. Values are given as mean±s.e. mean. +, p:::;O.05 versus BL; *, p:::;O.05 versus 
saline. 
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Figure 5.2 Total carotid, arteriovenous (AVA) and capillary vascular conductance at baseline 
(BL), after the three intracarotid injections with either saline (left panels; n~6) or L-NAME 
(right panels; 0.1, 0.3 and 1.0 mg kg"; n~6) and following L·arginine (Arg, 100 mg kg"; 
solid columns). In each set of panels, the hatched colunms represent three increasing doses 
of saline or L-NAME. Values are given as meanis.e. mean. +, p:::;O.05 versus BL; *, p:::;O.05 
versus saline. 
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Regional carotid blood flow 
Although L-NAME failed to alter total capillary blood flow, tissue blood flow 
to the eyes was reduced by L-NAME (0.3 and 1.0 mg kg-I); the maximum changes 
observed from baseline (21±4 ml min-I 100 g-I) were 52±7% and 43±17%, 
respectively. No significant changes were observed in all other dissected extracerebral 
tissues. L-arginine restored blood flow to the eyes (16±2 ml min-I 100 g-I). As depicted 
in Figure 5.3, total brain flow increased following L-NAME (261±106%), which was 
unaffected by L-arginine. A flIrther subdivision of the brain revealed a similar increase 
in all parts, also unaffected by L-arginine. 
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Figure 5.3 Blood flow distribution to cerebral and extracerebral tissues and to dura mater at 
baseline (open columns), after the three intracarotid injections with either saline (a, c; n~6) 
or L-NAME (b, d; 0.1, 0.3 and 1.0 mg kg-I; n~6) and following L-arginine (Arg, 100 mg kg-I; 
solid columns). In each set of panels, the hatched coiulmls represent three increasing doses 
of saline or L-NAME. Values are given as mean±s.e. mean. +, p50.0S versus baseline. 
88 
NOS inhibition and arteriovenous anastomotic shunting 
Similarly, L-NAME failed to alter total capillary conductance, but reduced 
vascular conductance in the eyes significantly by 54±6% (baseline: 1.6±0.3 ml min-I 
mmHg-1 x 100) following L-NAME (0.3 and 1.0 mg kg-I), whereas no significant 
changes were observed in all other dissected extra cerebral tissues. L-arginine reversed 
the vascular conductance in the eyes (1.3±0.2 ml min-I nnnHg-1 x 100). Furthermore, 
as shown in Figure 5.4, total brain conductance was enhanced by L-NAME (maximum: 
212±77%), which was unaffected by L-arginine. A further subdivision of the brain 
revealed a similar increase in all parts, also being unaffected by L-arginine 
(Figure 5.4). 
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Figure 5.4 Vascular conductance in cerebral and extracerebral tissues and dura mater at 
baseline (open columns), after three intracarotid injections with either saline (a, c; n=6) or 
L-NAME (b, d; 0.1, 0.3 and 1.0 mg kg-I; n~6) and following L-arginine (Arg, 100 mg kg-I; 
solid columns). In each set of panels, the hatched bars represent three increasing doses of 
saline or L-NAME. Values are given as mean±s.e. mean. +, p:50.05 versus baseline. 
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Arteriovenous oxygen saturation difference and nitrite content 
In both groups arterial oxygen tension and carbon dioxide tension remained stable 
throughout the experiments. The difference in arteriovenous oxygen saturation 
increased significantly following the highest dose ofL-NAME with 92±33%, whereas 
no changes were observed in the saline treated control group (Table 5.2). Similarly, a 
reduction in venous oxygen pressure was observed with this dose (l9±4%), whereas 
venous carbon dioxide pressure remained stable. At baseline, total venous nitrite and 
nitrate content was 125±20 nmol mi" (n~12; 6 each in saline and L-NAME groups), 
which remained stable throughout the experiment in both saline and L-NAME treated 
animals (Table 5.2). At baseline, plasma nitrite content varied largely between saline 
and L-NAME treated animals; the pooled nitrite level was 3.3±0.6 mnol mi" (n~8; 4 
each in saline and L-NAME groups). The nitrite level remained essentially unchanged 
in both groups, though with L-NAME (1.0 mg kg"; n~4) some decrease (34±19%) was 
observed compared to baseline values. L-arginine restored venous nitrite levels fully 
in the L-NAME treated animals, but was without effect in the control group 
(Table 5.2). 
5.4 Discussion 
Systemic haemodynamics and distribution of the common carotid blood flow 
Using the radioactive microsphere technique, we have previously shown that 
inhibition of NO biosynthesis in the anaesthetized pig by systemic administration of 
L-NAME reduces blood flow and vascular conductance in a number of tissues as well 
as the microsphere content of the lungs (Le. a sum of bronchial aliery and total 
systemic arteriovenous anastomotic flows) (this thesis, chapter 4). In these experiments 
the reduction in arteriovenous anastomotic blood flow was not unequivocal and, 
moreover, it was accompanied by a decline in cardiac output. Therefore, in the present 
study we evaluated the effects of local intra-arterial injections of L-NAME (0.1, 0.3 
and I mg kg") on the porcine carotid vascular bed, where arteriovenous anastomoses 
are abundant (Saxena & Verdouw, 1982). Indeed, the effects of Lc. application of 
L-NAME were largely confined to the carotid vascular bed, since little changes in 
systemic haemodynamic variables were observed; only the highest dose significantly 
affected mean pulmonary artery pressure, cardiac output and systemic and pulmonary 
vascular conductances. It is unlikely that these changes were due to the carotid 
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Table 5.2. Jugular venous blood pO, (V pO,), pCO, (V pCO,), difference in arterial and 
jugular venous oxygen saturation (A-V 0, sat) and jugular venous blood nitrite levels, both 
as nitrite alone (NO,) and as nitrate and nitrite (NO,) measured at baseline and after 
intracarotid injection of either saline or L-NAME and following L-arginine (100 mil kg· I). 
Saline or L-NAME (mg kg"l) 
Baseline 0.1 0.3 1.0 L-arginine 
V pO, (mmHg) 
Saline 58±3 56±4 54±5 59±4 53±5 
L-NAME 60±5 60±8 57±6 47±3* 50±4 
V peo, (mmHg) 
Saline 43±2 46±6 45±2 42±2 44±2 
L-NAME 43±1 39±2 43±1 45±2 43±2 
A-V 0, sal ("/0) 
Saline 15.2±3 17.6±4 19.1±4 14.9±3 19.3±4 
L-NAME 15.5±4 16.4±6 17.4±5 24.8±4* 18.5±4 
NOx (nn/Ol mt!) 
Saline 134±34 135±28 127±29 120±28 116±23 
L-NAME 117±23 93±29 133±32 116±26 128±27 
NO, (nn/Olmt!) 
Saline 2.4±1 2.7±1 2.7±1 2.6±1 2.3±1 
L-NAME 4.2±1 3.8±1 4.4±1 3.1±1t 3.5±1 
Data are given as mean±s.e. mean. *, p'::;;O.05 versus corresponding saline value; t, p'::;;O.05 
versus baseline value (n~4). 
haemodynamic effects of L-NAME and, therefore, it seems that pharmacologically 
effective concentrations ofL-NAME were present in the systemic circulation following 
its highest i.c. dose. These changes as well as the ability of L-arginine to reverse them 
are in accordance with our previous observations following systemic administration of 
L-NAME (this thesis, chapter 4). 
Independent of any systemic haemodynamic effect, total common carotid blood 
flow and conductance were decreased by L-NAME. Moreover, it is remarkable that 
L-NAME caused no change in the capillary part of the carotid circulation and that the 
reductions in carotid blood flow and conduction were entirely confined to the 
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arteriovenous anastomotic part. The carotid arteriovenous anastomoses have been 
localized, as demonstrated by simultaneous injections of radioactive microspheres of 
different sizes, particularly in the skin, ears and dura mater, but also in the eyes and 
tongue (Saxena & Verdouw, 1985; Den Boer ef al., 1992). Although atieriovenous 
anastomoses are anatomically distinct from the rest of the microvasculature, light and 
electron microscopy studies have shown the presence of an endothelial layer in both 
human and rabbit peripheral arteriovenous anastomoses (Gorgas ef al., 1977; Fujiwara 
& Iijima, 1990). The finding that L-arginine, the endogenous substrate for 
NO-synthase, patily reversed the L-NAME-induced reductions in the carotid 
arteriovenous anastomotic blood flow and conductance suggests that NO, released from 
the endothelium, may provide a vasodilator tone in these specialized vessels. 
Interestingly, it has also been reported that sodium nitroprusside, which releases NO 
spontaneously (Feelisch & Noack, 1987), tends to increase systemic arteriovenous 
anastomotic shunt flow in anaesthetized rabbits (Hof & Hof, 1989). 
Regional carotid blood flow 
Total capillary and extracerebral blood flow were unaffected by L-NAME and 
L-arginine caused no significant increases in blood flows to or conductances in the 
various tissues, though total capillary conductance was increased by the latter in both 
saline and L-NAME treated animals. It therefore seems that, unlike the arteriovenous 
anastomoses, a NO-dependent vascular tone is absent in the capillary part of the cranial 
circulation of the anaesthetized pig. However, it may be noted that under 
pentobarbitone anaesthesia capillary blood flow is approximately one-third of the total 
carotid blood flow (Saxena & Verdouw, 1982, 1985; Den Boer ef al., 1992; present 
results) and thus the basal release of NO may already be too low to detect a significant 
decrease. 
In contrast to a number of studies which reported a moderate reduction in 
cerebral blood flow following NO-synthase inhibition, suggesting a basal NO-release 
in this part of the cranial circulation (Kovach ef al., 1992 ; Prado ef al., 1992; 
Seligsohn & Bill, 1993), in our present experiments L-NAME failed to reduce the 
cerebral component of carotid blood flow. The absence of an endothelial NO-dependent 
dilator tone is supported by the recent finding that cultured rat brain microvessel 
endothelial cells do not show basal release of NO (Durieu-Trautmann ef al., 1993). 
Moreover in our experiments, L-NAME increased blood flow to the brain as well as 
to its constituent parts. This increase cannot be explained by hypercapnia, since arterial 
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carbon dioxide tension remained unchanged. One possible explanation may be a 
redistribution of blood from the constricted alieriovenous anastomoses towards the 
cerebral blood vessels. If this is the case, it is ofinterest that the redistribution is solely 
confined to the brain tissue without affecting extracerebral blood flow. Since the 
increase in cerebral blood flow was not sllsceptible to L-arginine, a NO-independent 
mechanism seems likely. Finally, the inability of L-NAME to reduce cerebral blood 
flow is probably not due to the low doses used, since Img kg" of L-NAME has been 
shown to block NO-production, as reflected by the increase in mean alierial blood 
pressure and blood flow reductions in a number of peripheral tissues (e.g. Gardiner 
ef al., 1990; this thesis, chapter 2 and 4). In doses up to 30 mg kg", both L-NAME 
and L-NNA are without effect on brain blood flow (this thesis, chapter 2; Faraci & 
Heistad, 1992), though in higher doses these agents can significantly reduce cerebral 
blood flow (Kovach ef al., 1992; Prado ef al., 1992; Seligsolm & Bill, 1993). It is 
tempting to speculate that at high doses NOS inhibitors may act at a different site 
within the brain. Apart from the endothelium, NOS is abundantly present in neural 
tissues including perivascular nerves surrounding cerebral vessels (Bredt ef al., 1990; 
Nozaki ef al., 1993). The activity of these nerves, denoted as nitroxidergic, is inhibited 
by L-NNA (Toda ef al., 1993) and topical application of L-NMMA reduces the 
diameter of cerebral alieries (Faraci, 1991). Hence, it is conceivable that these NOS 
inhibitors do not readily pass the blood brain barrier and can only inhibit the activity 
of nitroxidergic nerves when used in high doses. 
Changes in arteriovenolls oxygen saturation difference and nitrite content 
L-NAME caused an increase in alieriovenous oxygen saturation difference which 
is in keeping with an effect on arteriovenous anastomoses. A reduced difference 
between alierial and venous oxygen has been observed by Heyck (1969) in migraine 
patients and the difference is increased by ergot alkaloids together with a reduction in 
alieriovenous anastomoses blood flow (Johnston & Saxena, 1978; Den Boer ef al., 
1992). Since no changes were observed following L-NAME in the capillary fraction 
of the carotid blood flow, it is unlikely that the increase in percentage difference in 
arteriovenous oxygen saturation is due to an enhanced oxygen consumption in the 
capillaries. 
Concomitant with the decrement in arteriovenous anastomotic blood flow by 
L-NAME, a reduction of the plasma nitrite content in jugular venous blood was 
observed, which was restored by endogenous substrate L-arginine. Though this finding 
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is in line with the proposed competition of L-NAME and L-arginine for the enzyme 
NOS, basal plasma nitrite content was within the low micromolar range and a marked 
difference between the saline and L-NAME group was observed. Since NO may bind 
to hemeproteins or be convel1ed into nitrite and nitrate it is not clear if this is a true 
reflection of the basal endothelial NO release. In contrast, total nitrite alld nitrate 
content was approximately 40 times higher than nitrite levels and no changes were 
observed following L-NAME. In human plasma, an approximately 3-fold lower nitrate 
level was measured by Wennmahn and co-workers (1992), together with low nitrite 
concentrations. These authors suggested that NO is converted predominantly within red 
blood cells to nitrate. If this is the case, it is still unclear to which extent endothelial 
NO release contributes to the plasma nitrate content. Therefore, NOS inhibition may 
not be per se reflected by a reduction in nitrate levels. However, the inability of 
L-NAME to reduce nitrate levels in jugular venous blood samples may be explained 
in part by the reduced renal blood flow observed following L-NAME (this thesis, 
chapter 4). An augmented nitrate elimination due to a reduced renal perfbsion may 
oppose the expected reduction in plasma nitrate levels. 
In conclusion, the results of the present investigation indicate that, under resting 
conditions, the L-arginine-NO pathway has little contribution to the regulation of tissue 
perfusion within the carotid circulation of the anaesthetized pig. In contrast, NO may 
participate in controlling shunting of arterial blood through arteriovenous anastomoses. 
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The effect of nitric oxide donors on haemodynamics and blood 
flow distribution in the porcine carotid circulation 
Summary 
The role of nitric oxide (NO) in the regulation of capillary and arteriovenous 
anastomotic blood flow was evaluated in the carotid circulation of the pig. For this 
purpose, the effect of intracarotid (Lc.) infusions of saline and two NO donors, 
nitroprusside sodium (NPR) and S-nitroso-N-acetylpenicillamine (SNAP) in 
concentrations of3-100 Ilg min·1 was studied on systemic haemodynamics and carotid 
blood flow and its distribution in anaesthetized pigs with low arteriovenous 
anastomotic blood flow, by use of the radioactive microsphere method. 
Apart fi'om heali rate, which increased after both NPR and SNAP, no major 
changes in systemic haemodynamic variables were observed. In contrast to saline, both 
NPR and SNAP increased connnon carotid blood flow, vascular conductance and 
vascular pulsations dose-dependently. 
The distribution of the carotid artery blood flow over capillary and arteriovenous 
anastomotic fraction remained stable after saline infusions. Both NPR and SNAP 
enhanced total capillary blood flow and conductance. In contrast to NPR, arteriovenous 
anastomotic blood flow and conductance were increased by SNAP. At the tissue level, 
capillary blood flow increases following NPR or SNAP were reflected by an increase 
in both extra cerebral and dural blood flow without changes in total brain blood flow. 
These results indicate that both NO donors cause arteriolar dilatation together 
with enhanced vascular pulsations in the carotid circulation of the pig. Probably by 
way of a 'steal' phenomenon, this pronounced arteriolar dilatation limits the effect of 
NO donors on alieriovenous anastomoses. The finding of the present investigation 
support the contention that dilatation of intra- and extracranial alieries and arterio-
Based 011: Van Gelderen E.M., De Bmijne E.L.E., Agteresch H.J. and Saxena P.R. (1995). 
The effect of nitric oxide donors on haemodynamics and blood flow distribution in the 
porcine carotid circulation. Br. J. Pharmacol. 114; 1303-1309. 
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venous anastomoses leads to increased vascular pulsations, which (rather than increased 
blood flow pel' se) could, at least in part, be responsible for the headache caused by 
nitrovasodilators. 
6.1 Introduction 
Nitric oxide (NO) released from endothelial cells by numerous stimuli participates 
in the regulation of vascular tone (see Moncada el al., 1991; this thesis, chapter I). 
A dilatation of large (extra) cranial arteries and arteriovenous anastomoses has been 
implicated in the pathogenesis of migraine, though the mechanism involved is not fully 
clear (Saxena, 1978; Humphrey & Feniuk, 1991; Ferrari & Saxena, 1993; Lance, 
1993). Recent observations in both animals and man have led to the suggestion that 
NO may also be involved in migraine. Inhibition of NO-biosynthesis resulted in a 
reduced blood flow through porcine systemic and cranial arteriovenous anastomoses, 
thus indicating a NO-dependent vasodilator tone in these shunt vessels (this thesis, 
chapter 4 and 5). Histamine, known to relax isolated cranial blood vessels via release 
of NO from vascular endothelium (Toda, 1990; Fujiwara el al., 1992), induced 
pulsatile headache in migraine patients (Krabbe & Olesen, 1980). Nitrovasodilators, 
such as nitroglycerin and isosorbide mononitrate, which are generally thought to act 
as NO-donor, caused dose-dependent temporal artery dilatations and headache in man 
(iversen, 1992; Iversen ef al., 1992). Moreover, patients with migraine appeared to be 
more sensitive to nitroglycerin as demonstrated by a more pronounced headache and 
cerebral artery dilatation relative to non-migraine subjects (Olesen ef al., 1993; 
Thomsen ef al., 1993). 
The present investigation was devoted to study the effect of NO donors on the 
carotid haemodynamics and the distribution of the conunon carotid artery blood flow 
over mieriovenous and capillary (tissue) fractions in the anaesthetized pig. Some 
reports suggest that S-nitrosothiols may account, as an intermediate, for the 
NO-induced vasorelaxant actions (ignarro, 1990; Myers ef al., 1990; Rubanyi ef al., 
1991). Therefore, we investigated both sodium nitroplUsside (NPR), known to release 
NO spontaneously (Feelisch & Noack, 1987a), and the NO-'precursor' S-nitroso-N-
acetylpenicillamine (SNAP; Ignarro ef al., 1981). To preserve the constrictor tone in 
cranial mieriovenous anastomoses, necessary to study mechanisms involved in opening 
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of arteriovenous anastomoses, a recently described anaesthetic regimen was used 
(Den Boer e/ al., 1993). Some of these results were presented at the winter meeting 
of the British Pharmacological Society (Van Gelderen et al., 1994). 
6.2 Methods 
General 
Domestic pigs (Yorkshire x Landrace; 15-17 kg) were anaesthetized with Lm. 
injection of ketamine (25 mg kg-I) and midazolam (0.3 mg kg-I). Following injection 
of thiopentone (6 mg kg-I), the animals were intubated and connected to a respirator 
(Bear 2E, BeMeds AG, Baar, Switzerland) for intermittent positive pressure ventilation 
with a mixture of room air and oxygen. By adjusting oxygen supply, respiratory rate 
and tidal volume, arterial blood gas values were kept within physiological range (PH 
7.39-7.49; pCO, 37-44; pO, 100-130). Anaesthesia was maintained by a continuous Lv. 
infusion with a mixture of fentanyl (18-38 fig kg·1 h· l) and thiopental (6-12 
mg kg-I h-I). Due to differences in sensitivity of individual animals, infusion rate was 
adjusted in each animal using two criteria: (i) absence of blinking reflex, indicative of 
appropriate anaesthesia and (ii) venous oxygen saturation values below 60%, indicative 
of low arteriovenous anastomotic blood flow. 
A catheter was introduced into the aortic arch via the left femoral artery, 
connected to a pressure transducer (Statham P23, Hato Rey, Puerto Rico) for 
measurement of arterial blood pressure and blood sample withdrawal to determine 
blood gases (ABL-51O, Radiometer, Copenhagen, Denmark). Cardiac output and 
pulmonary arterial blood pressure were measured with a 6F-Swan-Ganz thermodilution 
catheter (Corodyn, Braun Melsungen AG, Melsungen, Germany) introduced into the 
pulmonary artery via the left femoral vein and connected to a cardiac output computer 
(WTI, Rotterdam, The Netherlands) as well as to a pressure transducer. Mean arterial 
(MAP) and mean pulmonary artery (MP AP) pressures were calculated from respective 
systolic (SBP) and diastolic (DBP) blood pressures as: MAP or MPAP ~ DBP+ 
(SBP-DBP)/3. Heart rate was triggered from the blood pressure signals using a 
tachograph as well as counted directly from these signals over a 30 s recording 
interval. Systemic vascular conductance was calculated by dividing cardiac output by 
MAP. The right common carotid artery was dissected free and the total carotid blood 
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flow on the ipsilateral side was measured with a flow probe (internal diameter: 2.5 or 
3 mm) COlmected to a sine-wave electromagnetic flow meter (Transflow 600-system, 
SkalaI', Delft, The Netherlands). Vascular pulsations were calculated from the flow 
signals as the difference in systolic and diastolic blood flow values. Two hubless 
needles (external diameter 0.5 mm), bent at right angles and connected to a 
polyethylene tubing, were inserted into the connllon carotid artery against the direction 
of the blood flow for administration of radioactive microspheres or drugs. The right 
jugular vein was cannulated to collect venous blood samples to determine venous blood 
gases. All catheters were filled with a heparin sodium solution (80 LU. mi'!) to prevent 
blood clotting. During the experiment, physiological saline was infused to compensate 
for fluid loss and body temperature was kept between 37-38'C. The animals were 
allowed to stabilize for at least 45 min before the start of experiments. 
Distribution of common carotid artelY blood flow 
The distribution of common carotid artery blood flow was measured using 
repeated injections of radioactive microspheres (mean±s.d. diameter: 15±1 11m; NEN 
Company, Dreidch, Germany) with different labels e'!Ce, lllSn, lOJRu, "Nb or 46SC) 
(Jolmston & Saxena, 1978). A suspension of approximately 250,000 microspheres was 
vortexed before each measurement and injected into the common carotid artery against 
the direction of the blood flow to ensure uniform mixing. At the end of the experiment 
the animals were killed and the heart, kidneys, lungs and the different intra- and 
extracranial tissues were dissected out, weighed and put in vials. The radioactivity in 
these vials was counted for 10 min in a y-scintillation counter (Packard, Minaxi 
Autoganulla 5000) using suitable windows for discriminating between the different 
isotopes. Radioactivity was counted in entire tissues, except in case of bone, fat and 
skin, where aliquots (more than 50% of total weight) were analyzed. 
Tissue (capillary) blood flow was calculated by multiplying the ratio of tissue and 
total radioactivity by total carotid blood flow at the time of injection. Since 
radioactivity was absent in the heart and kidneys, all radioactive microspheres reaching 
the venous side of the circulation had passed through arteriovenous anastomoses to be 
ultimately sieved in the lungs (see Johnston & Saxena, 1978; Saxena & Verdouw, 
1982). Therefore, the amount of radioactivity in the lungs represents the arteriovenous 
anastomotic fraction of common carotid blood flow. 
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Experimental protocol 
After the stabilization period the animals were randomly assigned to either control 
or treatment groups. At the start of the experiments, baseline haemodynamic 
parameters, blood gases as well as the distribution of the common carotid artery blood 
flow was measured. Thereafter, the first group was treated four times with i.c. 
infusions of saline (control; n=6). The second group was treated with either three (10, 
30, 100 J.lg min'!; n=4) or four increasing doses ofNPR (3, 10,30 and 100 J.lg min'!; 
n=4). In the third group, the potential effect of the solvent (20% v/v ethanol in saline) 
was measured, followed by three doses of SNAP (3, 10, 30 J.lg min'!; n=6). 
Additionally, in this group three animals were treated with SNAP (100 J.lg min'!) to 
determine the effect on carotid and systemic haem adynamic values. The amount of 
ethanol infused during the experimental period (75 min) ranged from 0.97 to l.l ml, 
depending on the weight of the animal. Since solvent infusion did not induce 
significant effects, SNAP induced responses were compared with responses observed 
in the saline (control) group. In all groups infusion rate (125 J.lI min'! IS kg'!) was 
adjusted to correct for differences in animal weight. Each dose was infused for IS min 
in which time period the carotid blood flow signal and systemic haemodynamic 
parameters stabilized; during the last five minutes of each infusion all parameters were 
reassessed and blood samples collected. 
Data presentation and analysis 
All data, calculated with a personal computer (Olivetti PCS 286) using a set of 
specially developed computer programs (Saxena et al., 1980), are presented in the text 
as mean ± s.e. mean. The effect of treatment was analyzed in each group using a 
repeated measurement analysis of variance. When the samples represented different 
populations, the values after the different treatments were compared to baseline values 
by use of Duncan's new multiple range test. Subsequently, the percent changes fi'OIn 
baseline values among the groups were tested using the Duncan's test for multiple 
comparisons. Statistical significance was accepted at a level of p:O;O.05. 
Chemicals 
The chemicals used in this study were: fentanyl citrate (Janssen Pharmaceutic a, 
Beerse, Belgium), heparin sodium (Heparin Leo, LEO Pharmaceutical Products B.V., 
Weesp, The Netherlands), ketamine HCI (Apharmo, Arnhem, The Netherlands), 
midazolam (Dormicum, Roche, Mijdrecht, The Netherlands), nitropmsside sodium 
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(Pharmacy Department, University Hospital Dijkzigt, Rotterdam, The Netherlands), 
S-nitroso-N-acetylpenicillamine (SNAP; RBI, Natick, USA), thiopental sodium 
(Rhone-Poulenc Rorer, Amstelveen, The Netherlands). All chemicals were dissolved 
in sterile saline, except fentanyl citrate and SNAP. Fentanyl citrate was dissolved in 
propylene glycol and subsequently diluted in disti lied water. SNAP was dissolved in 
a mixture containing 20% v/v ethanol (70%) in saline to reach a concentration of 
100 ~g 125 ~I" (highest dose used). This stock solution was subsequently diluted with 
sterile saline to obtain the lower concentrations (3, 10 and 30 ~g mi"). All doses refer 
to their respective salts. 
Table 6.1 Systemic haemodynamic variables measured at baseline and after intracarotid 
infusions with saline (control; 1l=6), nitroprusside sodium (NPR; 11=8, except 3 /.lg min<1 11=4) 
and solvent (S) followed by S-nitroso-N-acetylpenicillamine (SNAP;n~6, except 100 Ilg min" 
n~3l· 
Saline, NPR or SNAP (~g min") 
Baseline S 3 10 30 100 
HR (beals lIIil(l) 
Saline 77±7 77±7 79±8 81±9 81±1O 
NPR 85±5 87±1O 88±5 98±4 130±12*t 
SNAP 80±8 81±8 87±1O IOO±l9 117±19t 124±27t 
MAP (1III11Hg) 
Saline 94±5 93±6 93±6 91±6 89±7 
NPR 91±5 90±5 86±5 81±5 74±6t 
SNAP 82±3 84±6 88±7 85±6 74±6 74±10 
MPAP (IIImHg) 
Saline 21±1.4 22±1.2 22±1.2 22±1.3 22±1.4 
NPR 23±O.6 22±1.5 22±l.O 22±O.9 20±l.O 
SNAP 20±O.8 21±1 21±O.7 20±1.l 19±1.3 20±1.9 
CO (I lIIill· l) 
Saline 1.4±0.1 1.4±O.1 1.4±O.2 1.4±O.2 1.5±0.2 
NPR' 1.7±O.2 1.7±O.3 1.7±O.2 1.8±O.2 1.9±0.2 
SNAP 1.4±O.l l.3±O.1 l.3±O.1 1.3±0.1 1.4±O.1 1.9±O.2 
SVC (1111 lIIill·1 11II11Hg·l) 
Saline 15±1 15±1 15±2 15±2 16±1 
NPR 19±2 19±4 21±3 22±2 26±3 
SNAP 17±2 16±2 15±1 16±3 19±1 26±2 
Data are given as mean±s.e. mean. t, p':::;O.05 versus baseline; *, p:50.05 versus saline. HR, 
heart rate; MAP, mean arterial blood pressure; MPAP, mean pulmonary artery pressure; 
CQ, cardiac output; SVC, systemic vascular conductance. 
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6.3 Results 
Systemic haemodynamics 
The systemic haemodynamic variables of all groups at baseline and followed by 
either saline, solvent, NPR or SNAP are depicted in Table 6.1. There were no 
significant differences between the three groups in systemic haemodynamic values at 
baseline. Neither saline nor solvent (ethanol/saline, 20% v/v) induced any change in 
the systemic haemodynamic variables. Both NPR (100 f!g min· l ) and SNAP (30 and 
100 f!g min· l ) increased heart rate significantly; with the highest dose heart rate 
increased by 57±15% and 44±17%, respectively. Mean arterial blood pressure tended 
to decrease following NPR and SNAP, being significantly different from baseline 
values with the highest dose of NPR only. Neither drug significantly affected other 
systemic haemodynamic variables. 
Carotid haell/odynamics 
Carotid blood flow remained stable throughout the saline infusioils (Figure 6.1). 
Likewise, no changes were observed in baseline carotid blood flow (52±6 ml min' I) 
in the SNAP group following solvent infusion (5l±8 ml min' l ; not shown in figure). 
Both NPR and SNAP induced a dose-dependent. increase in carotid blood flow. The 
maximum increase from baseline, observed with the highest dose (100 f!g min· l ) oflhe 
two compounds, was 79±9% and 85±l8%, respectively. The increase in carotid blood 
flow was associated partly with enhanced vascular pulsations, which were increased 
from baseline by a maximum of 59±17% (NPR) and 109±45% (SNAP) (Figure 6.1). 
At baseline, 23±4% (n=20) of the total carotid blood flow was shunted through 
arteriovenous anastomoses and no differences between groups were observed. The 
extent of shunting in pigs anaesthetized with fentanyl and thiopental is much less than 
that (-75%) previously observed in pigs anaesthetized with pentobarbital (Saxena & 
Verdouw, 1982; Den Boer et al., 1990; Villal6n et al., 1990; this thesis chapter 5). 
The NPR-induced carotid blood flow increase was reflected by a dose-dependent 
increase in total capillary blood flow; maximum increase from baseline was I OO±l1 %. 
No changes were observed in the arteriovenous anastomotic fraction (Figure 6.2). In 
contrast to NPR, SNAP increased both total capillary blood flow and arteriovenous 
anastomotic blood flow. Total capillary blood flow was increased by 7l±19% from 
baseline, being significantly different from saline treated animals from 10 f!g min·1 
onwards. 
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Figure 6.1 Carotid blood flow (a) and pulse aruplitude (b) at baseline (B) and after 
intracarotid infusions with either saline (125 J.ll min'l, 4 times; n=6), nitroprusside sodium 
(NPR; 3 fig min", n~4, and 10,30 and 100 fig min", n~ 8 each) or S,nitroso-N-acetyl-
penicillamine (SNAP; 3, 10,30 fig min"; 1I~6 each, and 100 fig min"; n~3). In case of SNAP 
solvent values (not shown) were not different from baseline values. In both panels, (0), (e) 
and (T) represent saline, NPR and SNAP, respectively. Values are given as mean±s.e. mean. 
t, P:;;0.05 versus baseline (B); *, P:;;0.05 versus saline. 
Arteriovenous anastomotic blood flow increased significantly from baseline following 
SNAP (10 and 30].lg min"); maximum increase (245±151%) was observed with the 
highest dose (Figure 6.2). 
Both NPR and SNAP increased carotid vascular conductance from baseline by 
a maximum of 127±l5% and 178±66%, respectively; being significantly different from 
the saline group from 10 fig min" onwards (Figure 6.3). Arteriovenous anastomotic 
conductance was essentially unaffected by NPR (maximum increase 72±40%; n.s.), 
whereas SNAP enhanced the conductance significantly from baseline by 284±160%. 
Total capillary conductance was equally increased by NPR and SNAP; 30 fig min" of 
either NPR or SNAP increased conductance by 89±7% and 91±21 %, respectively 
(Figure 6.3). 
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Figure 6.2 Total carotid, arteriovenous anastomotic (AVA) and capillary blood flow at 
baseline (B) and after intracarotid infusions with either saline (125 !II min", 4 times; n~6), 
nitroprusside sodium (NPR; 3 !lg min"; n~4, and 10, 30 and 100 !lg min"; n~8 each) or 
S-nitroso-N-acetylpenicillamine (SNAP; 3, 10 and 30 !lg min"; n~6). In each set of panels, 
open and hatched bars represent baseline values and values after increasing doses of saline, 
NPR or SNAP, respectively; in case of SNAP crossMhatched bars represent values after the 
solvent (S). Data are given as mean±s.e. mean. t, p'::::;O.05 versus baseline; *, p'::::;O.05 versus 
saline. 
Regional carotid blood jlow 
As depicted in Figure 6.4, neither saline infusions nor solvent infusion affected 
blood flow distribution to either the total brain, extracerebral or dural tissues. Both 
NPR and SNAP failed to affect total brain blood flow. In contrast, a significant 
increase in extracerebral blood flow was observed following NPR (10, 30 and 100 
!lg min") and SNAP (10 and 30 !lg min"); maximum increases were 106±l2% and 
84±l7%, respectively. Dural blood flow was enhanced dose-dependently by NPR, 30 
and 100 !lg min", with a maximum increase of 368±96%. Likewise, SNAP (10 and 
30 !lg min") enhanced dural blood flow from baseline (I 54±57%). 
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A number of extracerebral tissues (bones, ear, muscle and skin) showed enhanced 
blood flows following both NPR and SNAP (Fignre 6.5). Fmihermore, SNAP 
increased blood flow to the fat (Fignre 6.5) as well as the eyes from a baseline value 
of 30±5 ml min·' to a maximum of 75±20 ml min·' with the highest dose 
(100 Ilg min·'). 
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Figure 6.3 Total carotid, arteriovenous anastomotic (AVA) and capillary conductance at 
basetine (B) and after intracarotid infusions with either saline (125 fli mil,', 4 times; IF6), 
nitroprusside sodium (NPR; 3 fig min·'; n~4, and 10, 30 and 100 fig min·'; n~8 each) or 
S-nitroso-N-acetylpenicillamine (SNAP; 3,10 and 30 J.lg min·'; n~6). In each set of panels, 
ope~ and hatched bars represent baseline values and values after increasing doses of saline, 
NPR or SNAP, respectively; in case of SNAP cross-hatched bars represent values after the 
solvent (S). Data are given as mean±s.e. mean. t, p';0.05 versus baseline; " p';0.05 versus 
saline. 
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Figure 6.4 Blood flow distribution to cerebral and extracerebral tissues and to dura mater at 
baseline (B) and after intracarotid infusions with either saline (125 fll min", 4 times; n~6), 
nitroprusside sodium (NPR; 3 flg min"; n~4, and 10, 30 and 100 flg min"; n~8 each) or 
S-nitroso-N-acetylpenicillamine (SNAP; 3, 10 and 30 flg min"; n~6). In each set of panels, 
open and hatched bars represent baseline values and values after increasing doses of saline, 
NPR or SNAP, respectively; in case of SNAP cross-hatched bars represent values after the 
solvent (S), Data are given as meanis.e. mean. t, p$0.05 versus baseline; " p$O,05 versus 
saline. 
Arteriovenous oxygen saturation difference 
In all groups venous oxygen and carbon dioxide tension remained stable 
throughout the experiments. In contrast to saline, NPR and SNAP reduced the arterial 
partial oxygen pressure by 24±2% and 9±2%, respectively (Table 6.2), The difference 
in arteriovenous oxygen saturation was reduced from baseline with the highest dose of 
NPR, whereas no changes were observed in either saline- or SNAP-treated animals 
(Table 6.2). 
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Figure 6,5 Blood flow to extracerebral tissues at baseline (B) and after intracarotid infusions 
with either saline (125 fll min", 4 times; n~6), nitroprusside sodium (NPR; 3 I'g min"; n~4, 
and 10, 30 and 100 I'g min"; n~8 each) or S-nitroso-N-acetylpenicillamine (SNAP; 3, 10 and 
30 I'g min"; n~6), In each set of panels, open and hatched bars represent baseline values and 
values after increasing doses of saline, NPR or SNAP, respectively; in case of SNAP 
cross-hatched bars represent values after the solvent (S). Data are given as mean±S,e. mean. 
*, p~O.05 versus baseline. 
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Table 6.2 Arterial pO, (A pO,), jugular venous blood pO, (V pO,) and difference in arterial 
and jugular venous oxygen sahlratioll, measured at baseline and after intracarotid injection of 
either saline (control; lF6), nitroprusside sodium (NPR; n~8, except 3 flg min" n~4) and 
solvent (S) followed by S-nitroso-N·acetylpenicillamine (SNAP; n~6). 
Baseline S 
Saline, NPR or SNAP (flg min") 
3 to 30 100 
A pO, (1Il1llHg) 
Saline 121±8 123±7 121±7 117±7 1I4±8 
NPR 1I7±4 1I9±3 109±4 103±4t 89±3t 
SNAP 1I5±4 1I6±3 1I8±5 109±2 104±3t n.d. 
V pO, (1Il1llHg) 
Saline 37±3 38±2 39±2 38±2 37±2 
NPR 35±2 39±5 37±2 38±2 41±3 
SNAP 41±6 39±5 42±6 40±6 42±5 n.d. 
A-V 0, sat (%) 
Saline 45±7 42±7 41±6 42±7 43±6 
NPR 50±5 45±10 42±4 40±4 35±4t 
SNAP 38±9 38±8 36±9 37±8 34±7 n.d. 
Data are given as mean±s.e. mean. n.d.: not determined. t, p':::;;O.OS versus baseline value. 
6.4 Discussion 
General 
This study aimed to investigate the effect of exogenous NO on the carotid 
circulation of the anaesthetized pig with low arteriovenous anastomotic blood flow. In 
the conscious state arteriovenous anastomoses are under a predominantly sympathetic 
constrictor tone and, as a consequence, less than 5% of intracardially injected 
microspheres are sieved in the lungs (Van Woerkens ef al., 1990). During anaesthesia, 
arteriovenous shunting is increased substantially limiting comparison with conscious 
animals. Recently, a mixture of fentanyl and thiopental was reported to preserve tone 
in arteriovenous anastomoses enabling the investigation of effects on arteriovenous 
anastomoses under conditions which resemble the conscious state (Den Boer ef al., 
1993). In accord with the latter study, we observed that approximately 20% of the 
carotid blood flow was directed to arteriovenous anastomoses. It is to be noted that, 
as seems to be the case in humans (Heyck, 1969), basal arteriovenous shunting is 
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higher in the carotid vascular bed than in the systemic vascular bed, which may be 
explained by the relatively greater skin area, together with higher density of 
arteriovenous anastomoses in the head skin, perfused by the carotid circulation (Saxena 
& Verdouw, 1985). 
Systemic and carotid haemodynamics 
Following intracarotid infusions of NPR and SNAP, systemic haemodynamic 
variables were not much affected indicating that the drug effects were primarily 
confined to the carotid part of the circulation. However, we can not fully exclude a 
systemic contribution as heart rate increased (NPR: 100 J.lg min"; SNAP: 30 and 
100 J.lg min") and MAP tended to decrease with NPR. The increase in heart rate is 
most likely reflex mediated to compensate for the expected fall in systemic blood 
pressure, although additional effects may be involved. For example, hypercapnia is 
associated with tachycardia presumably via activation of chemoreceptors in the carotid 
body. Interestingly, NO synthase-containing fibres have been demonstrated in the 
carotid body of rats (Wang et al., 1993; Hohler et al., 1994) and cats (Prabhakar et al., 
1993). Moreover, NPR increases cGMP formation in the carotid body arterioles (Wang 
el al., 1991), whereas inhibition of the endogenous NO biosynthesis increases 
chemoreceptor outflow and reduces cGMP formation (Prabhakar et al., 1993). So far, 
it is not yet known whether exogenous NO stimulates chemoreceptors to reduce their 
outflow. 
Both NO donors induced similar increases in carotid blood flow which were 
accompanied by enhanced vascular pulsations. Likewise, enhanced pulsatility was 
observed in the human carotid and cerebral artery using the NO donor nitroglycerin 
(MacDonald et al., 1989; Thomsen et al., 1993). The mechanism underlying these 
enhanced pulsations is not clear, but it may be related to changes in vascular 
compliance following vasodilatation. Since pulsatility is also increased by 
calcitonin gene-related peptide (MacDonald el al., 1989; this thesis chapter 7), an 
exclusively NO-dependent phenomenon is precluded. 
Carotid blood flow distribution 
Both NPR and SNAP showed a similar arteriolar dilatation as reflected by the 
increase in capillary blood flow and conductance, whereas in contrast to NPR, only 
SNAP enhanced blood flow through arteriovenous anastomoses. The latter finding is 
in accord with our previous observations demonstrating that endogenous NO may 
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participate in the regulation of shunt flow in the carotid circulation (this thesis 
chapter 5). However, the lack of effect on arteriovenous anastomoses with NPR is in 
divergence with this observation and the previously reported tendency of NPR to 
increase blood flow through systemic arteriovenous anastomoses in rabbits (Hof & Hot; 
1989). This discrepancy may be explained partly by the concomitant rise in capillary 
blood flow which could lead to a redirection of carotid blood flow towards the 
capillaries to negate the increase in arteriovenous anastomotic blood flow (,steal' 
phenomenon). Recent experiments in humans (Bruning, 1994) have shown that NPR, 
infused into the brachial artery but in a much lower concentration (5 ng kg"' min·'), 
also failed to increase. at1eriovenous anastomotic blood flow in the fingers. 
The differences observed in the present experiments between NPR and SNAP 
may be explained by differences in the amount of NO released from these compounds. 
At 37'C, approximately 0.2 I1mol min·' is released spontaneously from NPR (Feelisch 
& Noack, 1987a), whereas under similar conditions SNAP releases approximately six 
times more NO (Kodja el ai., 1994). Moreover, it has been suggested that nitrosothiols 
may be actively degraded at vascular membranes (Kowaluk & Fung, 1990) and SNAP 
has been shown to have an in vitro chemical half life of 70 min (Mathews & Kerr, 
1993), although the rate of formation and degradation may differ significantly in 
biological fluids. Therefore, it is conceivable that following repeated infusions SNAP 
accumulates at arteriovenous anastomoses, thus providing sufficient local concentration 
of NO to cause vasodilatation. 
A reduced difference between arterial and venous oxygen saturation has been 
observed in migraine patients (Heyck, 1969), suggesting enhanced shunting of arterial 
blood towards the venous side of the circulation. Likewise, after inhibition of NO 
synthesis this difference was increased together with a reduction in blood flow tln·ough 
arteriovenous anastomoses in anaesthetized pigs (this thesis chapter 5). In the present 
study, the ability of SNAP to enhance arteriovenous blood flow is not reflected by a 
concomitant reduction in the difference in arteriovenous oxygen saturation. Since both 
NPR and SNAP induced a marked arteriolar dilatation, an increase in oxygen 
consumption at the capillary level may pal1ially account for this lack of effect. 
Additionally, a reduced arterial oxygen supply may have limited the amount of oxygen 
shunted towards the venous side. Indeed, a significant reduction in partial oxygen 
pressure together with a slight reduction in arterial oxygen saturation was observed 
with NPR and SNAP. 
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Regional carotid blood flow distribution 
Both NO donors enhanced extracerebral blood flow without changing brain blood 
flow, suggesting that these dmgs do not interfere with autoregulatory processes. 
However, the absence of cerebral blood flow changes does not per se mle out middle 
cerebral artery dilatation as reported in migraine (Friberg et al., 1991), because such 
large vessel dilatations can not be detected with radioactive microspheres. Although, 
the role of extracranial dilatation in migraine headache is often disregarded, dilatation 
and increased pulsations in the extracranial blood vessels have been observed on the 
side of headache (Ray & Wolff, 1940; Iversen et al., 1990). Manual pressure as well 
as ergotamine oppose these effects and relieve pain (Graham & Wolff, 1938; 
Dmmmond & Lance, 1988). 
NPR and SNAP enhanced dural blood flow significantly. Since this tissue may 
be the source of headache pain (Ray & Wolff, 1940), and dural blood vessels are 
irmervated by perivascular trigeminal sensory nerves (Mayberg et al., 1984), it is 
tempting to speculate that enhanced blood flow together with pronounced vascular 
pulsations in this tissue participate in vascular headache. However, it must be pointed 
out that several antimigraine drugs (ergotamine, dihydroergotamine and sumatriptan) 
failed to affect porcine dural blood flow and dural atteriovenous anastomotic shunting 
(Den Boer e/ al., 1992a), and, in contrast to perivascular administration, i. v. 
administration of sumatriptan did not constrict feline pial artery, but increased carotid 
vascular resistance (Connor e/ al., 1992). 
In conclusion, the present findings demonstrate that the NO donors, NPR and 
SNAP, induce arteriolar dilatation together with enhanced vascular pulsations in the 
carotid circulation of the pig. Though arteriovenous anastomotic blood flow did 
increase with SNAP, the pronounced arteriolar dilatation appears to limit the effect of 
exogenous NO on arteriovenous anastomoses, probably due to a 'steal' phenomenon. 
Taken together, these findings support the opinion that dilatation of (extra)cranial 
arteries and arteriovenous anastomoses may lead to increased vascular pulsations, 
which (rather than increased blood flow) could be partly responsible for the headaches 
caused by nitrovasodilators. 
110 
Chapter 7 
Carotid blood flow distribution, haemodynamics and inotropic 
responses following calcitonin gene-related peptide in the pig 
Summary 
The sensory neuropeptide, calcitonin gene-related peptide (a-CORP), has been 
implicated in the pathogenesis of migraine headache. This study aimed to evaluate the 
effects of intracarotid infusions of human a-CORP (10, 30 and 100 pmol kt' min"; 
n~8), as compared to those of saline (four times; n~8) on haemodynamics and blood 
flow distribution within the carotid circulation of the anaesthetized pig, using the 
radioactive microsphere method. Furthermore, the effects of antimigraine drugs, 
dihydroergotamine (l00 Jlg kt', Lv; n=4) or sumatriptan (300 Jlg kg", Lv.; n~4), on 
these parameters were studied in the presence of the infbsion of the highest 
concentration of human a-CORP. Additionally, putative positive inotropic responses 
to human a-CORP (10-'-10.7 M) were investigated in porcine isolated atrial and 
ventricular trabeculae. Human a-CORP increased carotid artery blood flow and 
conductance dose-dependently, together with an enhancement in vascular pulsations. 
These effects were associated with a fall in systemic blood pressure with concomitant 
increases in heart rate and cardiac output. The increase in carotid blood flow was 
reflected by an increase in total capillary blood flow, predominantly to extracerebral 
tissues including the dura, whereas blood flow through atteriovenous anastomoses 
remained stable. Both dihydroergotamine and sumatriptan reduced carotid blood flow 
and its capillary fraction without affecting systemic vascular conductance. In tissues, 
these dmgs reversed blood flow increases due to human a-CORP in most extra cerebral 
tissues, but failed to reduce dural blood flow. 
In porcine isolated atrial and ventricular trabeculae, noradrenaline (10-8_10-5 M) 
increased force of contraction in a concentration dependent manner. In contrast, human 
a-CORP (10-'_10-7 M) failed to increase force of contraction in atrial trabeculae (IF6) 
Based all: Van Oelderen E.M., Dll X.Y., Schaemaker R.O. and Saxena P.R. (1995). Carotid 
blood flow distribution, haemodynamics and inotropic responses following calcitonin 
gene-related peptide in the pig. Ellr. J. Pharmacol. 284; 51-60. 
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and exerted only a moderate concentration-dependent positive inotropic effect in 
ventricular trabeculae (-25% of the response to 10-' M noradrenaline, n~10)_ 
These data indicate that human a-CGRP caused arteriolar dilatation together with 
a fall in blood pressure in the pig. The tachycardia may be reflex-mediated, but the 
peptide also exerts a moderate positive inotropic action on ventricular trabeculae. The 
fall in systemic arterial blood pressure and the marked increase in capillary blood flow 
most likely prevented the opening of arteriovenous anastomoses. Furthermore, the 
anti migraine dlUgs, dihydroergotamine and sumatriptan, were able to reverse blood 
flow changes induced by human a-CGRP in the porcine carotid circulation. 
7.1 Introduction 
In spite of considerable debate concerning the precise mechanism, the 
pathogenesis of migraine is associated with dilatation of large (extra)cranial and 
at1eriovenous anastomoses (Saxena, 1978; Drummond & Lance 1988; Ferrari & 
Saxena, 1993). Recent observations in animals and humans have suggested that both 
calcitonin gene-related peptide (CGRP) and nitric oxide (NO) may act in concert in the 
vascular events observed during migraine attacks. The 37-amino acid peptide, CGRP, 
is' abundantly present in sensory fibres, including fibres innervating the heal1 and 
trigeminal vascular system (Mulderry elal., 1985; Uddman el al., 1986; Suzuki el al., 
1989). The peptide has been shown to be a potent vasodilator exerting differential 
regional haemodynamic effects (Brain el al., 1985; Franco-Cereceda el al., 1987; 
Gardiner el al., 1989). In migraineurs, elevated plasma levels of CGRP have been 
observed in the extracerebral circulation during headache (Goadsby et al., 1990) and 
antimigraine agents like dihydroergotamine and sumatriptan reduced elevated CGRP 
plasma levels in these patients, as well as in cats during trigeminal nerve stimulation 
(Goadsby & Edvinsson, 1993). Likewise, nitrovasodilators, which are generally thought 
to act by releasing NO (Ignarro, 1990), induce more pronounced headache 
(Olesen el al., 1993) and cranial artery dilatation in migraine patients than in normal 
subjects (Thomsen el al., 1993). Finally, nitrovasodilators increase blood flow through 
arteriovenous anastomoses in the carotid circulation of the pig (This thesis, chapter 6) 
and may activate perivascular sensory nerves to release CGRP in cerebral as well as 
cutaneous microvessels (Wei el al., 1992; Holzer & Jocic, 1994). 
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The present study aimed to evaluate the effects of human a-CORP on 
haemodynamics and blood flow distribution within the carotid circulation of the pig, 
using the radioactive microsphere method. Since dihydroergotamine and sumatriptan 
have been shown to reduce carotid blood flow in pigs (Den Boer et al., 1992a,b), we 
also studied the effects of these two dmgs on haemodynamics and carotid blood flow 
distribution during the infusion of human a-CORP. 
Additionally, a-CORP has been shown to increase cardiac output (Lappe et al., 1987; 
Wang et al., 1989; Oardiner et al., 1991) and positive inotropic responses have been 
described in isolated atria of various species (Saito et al., 1986; Sigrist et al., 1986; 
Franco-Cereceda et al., 1987; Du et al., 1994). As preliminary experiments 
demonstrated an enhanced cardiac output following human a-CORP in pigs and as 
little is known about its putative inotropic effects in the pig heart, the effect of 
a-CORP was investigated further in porcine isolated atrial and ventricular trabeculae. 
A preliminary account of some of the results was presented at the 
XIIth International Congress of Pharmacology (Van Oelderen & Saxena, 1994). 
7.2 Methods 
The protocol of this study was submitted to and approved by the Institutional 
Committee for the use of animals. 
General (in-vivo) 
After an overnight fast, sixteen domestic pigs (Yorkshire x Landrace; 15-17 kg) 
were anaesthetized with Lm injection of ketamine (25 mg kg") and midazolam (0.3 
mg kg"). Following injection of thiopentone (6 mg kg") in the middle ear vein, the 
animals were intubated and connected to a respirator (Bear 2E, BeMeds AO, Baar, 
Switzerland) for intermittent positive pressure ventilation. By adjusting oxygen supply, 
respiratory rate and tidal volume, arterial blood gas values were kept within the 
physiological range (PH 7.39-7.49'; pCO, 37-44; pO, 100-130). Anaesthesia was 
maintained by a continuous Lv. infusion with a mixture offentanyl (18-38 J,lg kg" h") 
and thiopental (6-12 mg kg" If'). This anaesthetic regimen was used to preserve the 
vasoconstrictor tone in cranial arteriovenous anastomoses that is necessary to study 
mechanisms involved in opening of arteriovenous anastomoses (Den Boer et al., 1993). 
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Due to differences in the sensitivity of individual animals, the infusion rate was 
adjusted in each animal using two criteria: (i) absence of blinking reflex, indicative of 
appropriate anaesthesia and (ii) venous oxygen saturation values below 60%, indicative 
of low arteriovenous anastomotic blood flow. 
A catheter was introduced into the aortic arch via the left femoral artery and was 
connected to a pressure transducer (Statham P23, Hato Rey, Puerto Rico) for the 
measurement of arterial blood pressure as well as withdrawal of blood samples to 
determine blood gases (ABL-51 0, Radiometer, Copenhagen, Denmark). Cardiac output, 
pulmonary arterial blood pressure and body temperature were measured with a 
6F -Swan-Ganz thermodilution catheter (Corodyn, Braun Melsungen AG, Melsungen, 
Germany) introduced into the pulmonary artery via the left femoral vein and connected 
to a cardiac output computer (WTI, Rotterdam, The Netherlands) as well as to a 
pressure transducer. Mean arterial (MAP) and mean pulmonary altery (MP AP) 
pressures were calculated from the respective systolic (SBP) and diastolic (DBP) blood 
pressures as: MAP or MPAP = DBP+(SBP-DBP)/3. Heart rate was recorded using a 
tachograph triggered from blood pressure signals as well as counted directly from these 
signals over a 30-s recording interval. Systemic vascular conductance was calculated 
by dividing cardiac output by mean arterial pressure. The right conmlOn carotid artery 
was dissected free and the total carotid blood flow was measured with a flow probe 
(internal diameter: 2.5 or 3 mm) connected to a sine-wave electromagnetic flow meter 
(Transflow 600-system, Skalar, Delft, The Netherlands). Carotid vascular conductance 
was calculated by dividing carotid blood flow by mean arterial pressure and vascular 
pulse amplitude was calculated from the flow signals as the difference in systolic and 
diastolic blood flow values. Two hubless needles (external diameter 0.5 mm), bent at 
right angles and connected to polyethylene tubing (internal diameter 0.5 mm), were 
inserted into the common carotid artery against the direction of the blood flow for 
administration of radioactive microspheres or drugs. The right jugular vein was 
camllliated to collect venous blood samples to determine venous blood gases. All 
catheters were filled with a heparin sodium solution (80 I.U. ml'I) to prevent blood 
clotting. During the experiment, physiological saline was infused to compensate for 
fluid loss and body temperature was kept between 37 and 38'C. 
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Dislribution of comlllon carotid arlelY blood flow 
As described extensively by Jolmston and Saxena (1978), the distribution of 
common carotid artelY blood flow was measured using repeated injections of 
radioactive microspheres (mean±s.d. diameter: 15± 1 /lm; NEN Company, Dreieich, 
Germany) with different labels (,"Ce, 113Sn, w'Ru, "Nb or "Sc). Briefly, a suspension 
of approximately 250,000 microspheres was vortexed and injected into the common 
carotid artery at baseline and following the various treatments. Microspheres were 
injected against the direction of the blood flow to ensure uniform mixing. At the end 
of the experiment, the animals were killed and the heart, kidneys, lungs and the 
different intra- and extracranial tissues were dissected out, weighed and put in vials. 
The radioactivity in these vials was counted for 10 min in a y-scintillation counter 
(Packard, Minaxi Autogamma 5000) using suitable windows for discriminating 
between the different isotopes. Radioactivity was counted in whole tissues, except in 
the case of bone, fat and skin, where aliquots (more than 50% of total weight) were 
analyzed. 
Tissue (capillary) blood flow was calculated by multiplying the ratio of tissue and 
total radioactivity by total carotid blood flow at the time of injection, using a set of 
computer programs (Saxena el al., 1980). Since radioactivity was absent in the heart 
and kidneys, all radioactive microspheres reaching the venous side of the circulation 
had passed through arteriovenous anastomoses to be ultimately sieved in the lungs 
(see Johnston & Saxena, 1978; Saxena & Verdouw, 1982). Therefore, the amount of 
radioactivity in the lungs represents the arteriovenous anastomotic fraction of common 
carotid blood flow. 
Isola led alrial and venlricular Irabeculae 
Cardiac tissues were obtained from pigs at the end of control (saline) experiments 
and atrial and ventricular trabeculae were set up for recording of contractions as 
described previously (Schoemaker el al., 1992; Du el al., 1994). Briefly, after excision, 
pieces of atrial and ventricular myocardium were placed in ice-chilled oxygenated 
Krebs buffer (composition in mM: NaC1118, KCI4.7, CaCI, 2.5, MgSO, 1.2, NaHCO, 
25, KHPO, 1.2 and glucose 8.3) and atrial and ventricular trabeculae «I mm 
thickness) were carefully dissected free. The trabeculae were mounted in organ baths 
containing Krebs buffer (gassed with 95% 0, and 5% CO,; 37°C) and isometric 
tension was recorded with a Harvard transducer. Resting tension was set to 750 and 
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1950 mg for atrial and ventricular tissues, respectively, in order to provide optimal 
loading conditions. Tissues were paced at 1 I-Iz, using electrical field stimulation (3 ms, 
voltage 20% above threshold). 
Experimental protocols 
In vivo experiments 
After a 45-min stabilization period, the animals were assigned at random to 
treatment (intracarotid infusions) with either saline (4 times, 125 III mitr', n=8) or 
human a-CGRP (10, 30 and 100 pmol kg-' min", n=8). Each dose was infused for 10 
min to obtain stable blood flow signals. At baseline and after each infusion period, 
haemodynamic variables were collected and radioactive microspheres were injected. 
After the highest dose of human a-CGRP (100 pmol kg" min"), infusion was 
continued and either dihydroergotamine (100 Ilg kg-I, i.v.; n=4) or sumatriptan 
(300 Ilg kg", i.v.; n=4) was injected and all variables were reassessed after 10 min. 
In vitro experiments 
Baseline force of contraction was measured after stabilization, and inotropic 
responsiveness was assessed by making a concentration-response curve for 
noradrenaline (lO'8-lO" M). The maximum concentration of noradrenaline was 
restricted to 10-' M, since tissues were irreversibly damaged after higher concentrations 
(see Schoemaker et al., 1992; Du et ai" 1994). Tissues with a response to 10" M 
noradrenaline smaller than 25 mg were excluded from further analysis. 
After the tissues had been washed six times and allowed to stabilize, a 
concentration-response curve for human a-CGRP (10"_10'7 M) was obtained in both 
atrial and ventricular tissues. Responses to human a-CGRP were expressed as 
percentages of the response to 10" M noradrenaline. Following another wash and 
stabilization period of at least 10 min, a second noradrenaline concentration-response 
curve was made to check the viability of the tissues. 
Data presentation and analysis 
The effect of saline and human a-CGRP treatment in the two groups of 
anaesthetized pigs was analyzed by a repeated-measurement analysis of variance. When 
the samples represented different populations, the values after each treatment were 
compared to baseline values by using Duncan's new multiple range test. Subsequently, 
the percent changes from baseline values among groups were tested using 
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Student's I-test. Baseline values for isolated atrial and ventricular trabeculae were 
compared using an unpaired I-test. The effects of noradrenaline and human a-CGRP 
were analyzed with an analysis of variance for repeated measurements. In all cases, 
statistical significance was accepted at a level of P:s;O.05. 
Drugs 
The compounds used were: dihydroergotamine mesylate r:w ander-Pharma, Uden, 
The Netherlands), fentanyl citrate (Janssen Pharmaceutica, Beerse, Belgium), heparin 
sodium (Heparin Leo, LEO Pharmaceutical Products B.V., Weesp, The Netherlands), 
human a-CGRP (Sal(on Biochemicals GMBH, Hannover, Germany), ketamine HCI 
(Apharmo, Arnhem, The Netherlands), midazolam (Dormicum, Roche, Mijdrecht, The 
Netherlands), noradrenaline bitartrate (Sigma, St. Louis, MO, U.S.A.), sumatriptan 
(Glaxo Research GI'OUP, Ware, U.K.), thiopental sodium (Rhone-Poulenc Rorer, 
Amstelveen, The Netherlands). All chemicals were dissolved in sterile saline, except 
fentanyl citrate which was dissolved in propylene glycol and subsequently diluted in 
distilled water. 
7.3 Results 
Haemodynamics 
Systemic and carotid haemodynamic variables measured at baseline and after 
intracarotid infusions with either saline or human a-CGRP and following injections 
with either sumatriptan or dihydroergotamine in the presence of human a-CGRP 
infbsion (100 pmol kg'! min'!) are depicted in Table 7.1. No differences were observed 
between the two groups at baseline, and infusion of saline caused no significant change 
in these variables. In contrast, human a-CGRP reduced mean arterial blood pressure 
with a maximum decrease of 3 1±4% (100 pmol kg'! min'!). Heart rate, cardiac output 
and systemic vascular conductance increased dose dependently with a maximum of 
78±13%, 44±14% and 104±8%, respectively, whereas no change was observed in 
stroke volume. Carotid blood flow and carotid vascular conductance were enhanced 
following human a-CGRP with a maximum increase of 199±46% (30 pmol kg'! min'!) 
and 277±58% (100 pmol kg'! min'!), respectively (Figure 7.1; Table 7.1). 
117 
Chapter 7 
200 Carotid 
• 
100 
o 
+ + 
II 
'i' 
c 
E Arteriovenous anastomotic 
4
0
0 j ! 
~ ;:: 
-g 
o 
iii 
200 Capillary 
• 
100 + 
o Ii 
B 10 30 100 100 100 
+ + SUM OHE 
Saline (limes) a·CGRP (pmol kg" min") 
Figure 7.1 Carotid blood flow and its distribution over arteriovenous anastomotic and 
capillary fractions at baseline (B) and after intracarotid infusions of saline (four times, n~8; 
left panels) or human a·CORP (10, 30 and 100 pmol kg" min", n~8; right panels), followed 
by either sumatriptan (SUM; 300 flg kg", Lv.; n~4) or dihydroergotamine (DHE; 100 flg kg", 
Lv.; n~4) in the presence of human a·CORP (l00 pmol kg" min"). Data are given as mean 
± s.e.mean, *, P':::;O.05 versus saline values; +, P.:::;O.OS versus human a-CORP. 
Together with the enhanced carotid blood flow, a significant increase in vascular pulse 
amplitude was observed with human a-CORP, 30 and 100 pmol kg" min"; maximum 
increase from baseline 142±19% (Table 7.1). 
Intravenous injections of either sumatriptan (300 flg kg") or dihydroergotamine 
(100 flg kg") in the presence of intracarotid infusions of human a-CORP (100 pmol 
kg" min") reduced mean arterial blood pressure by 42±5% and 33±5%, respectively, 
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Table 7.1 Systemic and carotid haemodynamic variables measured at baseline and after 
intracarotid infusions of either saline (control; n=8) or human a-CGRP (n=8) and following 
injections of either sumatriptan (SUM, 300 flg kg" iv; n=4) or dihydroergotamine (DHE, 
100 pg kg" iv; n=4) in the Eresence of human a-CGRP (100 pmol kg" min"). 
Saline or human a-CORP (pmol kg" min") 
Baseline 10 30 100 100+SUM 100+DHE 
MAP (mmHg) 
Saline 86±4 83±4 85±4 85±4 84±4 
a-CORP 89±2 86±2 76±3* 6l±3* 49±5t 52±4 
HR (beats mil,-') 
Saline 76±6 74±5 74±6 75±5 74±6 
a-CORP 80±10 90±l1 104±9* l39±13* 1l4±24 134±18 
eo (I mill") 
Saline l3±01 13±01 13±01 13±01 14±02 
a-CORP 14±01 17±02 19±02* 19±02* 15±02 16±02 
SV (ml) 
Saline l8±08 l8±08 18±07 l8±08 19±1O 
a-CORP 18±15 19±17 18±17 15±24 15±30 13±30 
sve (1111 mil'-' mmHg") 
Saline l6±1 16±1 16±1 16±1 16±2 
a-CORP 15±1 19±2 25±2* 3l±2* 3l±1 3l±1 
eve (1111 lIIin" IIlIllHg".] 00) 
Saline 60±8 66±9 67±12 70±1O 64±4 
a-CORP 58±4 1l8±13* 193±18* 207±20* 165±21t 145±23t 
eFP (ml lIIiI,-') 
Saline 47±1O 46±1l 45±9 45±8 47±9 
a-CORP 67±7 74±6 108±9* 159±16* 148±7 181±34 
Values represent means±s.e. mean; *) P::;;O.05 versus saline; t, P::;;O.05 versus human a-CGRP 
(100 pmol kg" min"). HR, heart rate; MAP, mean arterial blood pressure; CO, cardiac output; 
SV, stroke volume; SVC, systemic vascular conductance; evc, carotid vascular conductance; 
CFP, carotid flow pulse. 
but induced no further change in the other systemic haemodynamic variables 
(Table 7.1). Both carotid blood flow and carotid vascular conductance were reduced 
by sumatriptan (42±3% and 23±6%, respectively) and dihydroergotamine (33±5% and 
26±4%, respectively) (Figure 7.1; Table 7.1). Carotid flow pulse remained stable 
following either dmg (Table 7.1). 
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Figure 7.2 Tissue blood flow distribution over extracerebral and cerebral tissues at baseline 
(B) and after intracarotid infusions of saline (four times, n~8; left panels) or human a-CORP 
(10, 30 and 100 pmol kg" min", n~8; right panels), followed by either sumatriptan (SUM; 
300 !lg kg", Lv,; n~4) or dihydroergotamine (DHE; 100 !lg kg", Lv.; n~4) in the presence 
of human a-CORP (laO pmol kg" min"). 
Carotid blood flow distribution 
The human a-CORP-induced increase in carotid blood flow was confined to the 
capillary fraction, which was increased from baseline (41±4 ml min") by 237±45% 
(30 pmol kg" min"). At baseline, 2l±5% (n~ 16) of the total carotid blood flow was 
directed towards arteriovenous anastomoses and no differences were observed between 
the two groups. Neither saline nor human a-CORP induced changes in the arterio-
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venous anastomotic fraction (Figure 7.1). Likewise, the increase in carotid vascular 
conductance was reflected by an increase in capillary conductance, which increased 
from baseline (46±4 ml min" nunHg") to a maximum of 330±57% (data not shown). 
Sumatriptan and dihydroergotamine reduced equally the human a-CORP-induced 
increase in capillary blood flow by 42±4% and 44±5%, respectively, whereas neither 
drug affected arteriovenous anastomotic blood flow (Figure 7.1). Similarly, sumatriptan 
and dihydroergotamine reduced capillary conductance by 23±6% and 3S±5%, 
respectively, without changing arteriovenous anastomotic conductance (data not 
shown). 
Human a-CORP enhanced tissue blood flow dose dependently in extracerebral 
tissues by 30S±49% (30 pmol kg" min") without changing total brain blood flow. In 
cranial tissues, dural' blood flow was increased dose dependently from baseline 
(4.0±0.S ml min" 100 g") to a maximum of367±1l 1% (Figure 7.2). Tissue blood flow 
was significantly enhanced in all extra cranial tissues, including the bones, ears, eyes, 
fat, muscles, salivary glands, skin and tongue (Figure 7.3). Major increases were 
observed in the ears and skin, with a maximum increase ofS02±19S% and SOS±l60%, 
respectively (Figure 7.3). 
Sumatriptan and dihydroergotamine reversed human a-CORP-induced increases 
in extracerebral blood flow by 44±4% and 49±4%, respectively. In tissues, dural blood 
flow was slightly reduced by both drugs (Figure 7.2). The two drugs partially reversed 
the increases in blood flow in the ears, skin and muscles, without affecting that to the 
bones and eyes (Figure 7.3). Additionally, dihydroergotamine reversed blood flow 
increases in the tongue, salivary glands and fat (Figure 7.3). 
Myocardial contractility in vitro 
Baseline force of contraction was significantly lower in atrial tissue (50±16 mg, 
n~6) than in ventricular tissue (595±137 mg, IFIO). As shown in Figure 7.4, 
noradrenaline (l 0.8_10.5 M) increased force of contraction in a concentration-dependent 
manner in both tissues. With the highest concentration of noradrenaline (10.5 M), the 
force of contraction increased by 163±50 mg (n~6) and 615±106 mg (n~lO) in atrial 
and ventricular trabeculae, respectively. At the end of the protocol, noradrenaline 
(l0·5 M) induced positive inotropic responses comparable to the initial responses in 
ventricular trabeculae (100±6%, n~lO) whereas noradrenaline responses in atrial 
trabeculae were slightly reduced (S4±7%, n~6) (Figure 7.4). 
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In contrast to noradrenaline, human a-CORP (10-'-10-' M) failed to increase force 
of contraction in the atrial tissue (baseline: 107±26 mg, 10-' M human a-CORP: 
103±25 mg; n=6 each), but exerted a moderate concentration-dependent positive 
inotropic effect in ventricular tissue (Figure 7.4)_ At 10-' M human a-CORP, 
ventricular contractile force increased from 545±110 mg at baseline up to 663±120 mg, 
or 21±3% of the response to 10-5 M noradrenaline (n=lO). 
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Figure 7.3 Tissue blood flow 10 eXlracerebral tissues at baseline (B) and after intracarotid 
infusions of saline (four times, n=8; left panels) or human u-CGRP (10, 30 and 100 
pmol kg-' min-i, n=8; right panels), followed by either sumatriplan (SUM; 300 fig kg-I, i.v.; 
n=4) or dihydroergotamine (DHE; 100 fig kg-I, Lv.; n=4) in the presence of human u-CGRP 
(100 pmol kg-I min-I), Data are given as mean ± s.e.mean. *) PS;O.05 versus saline values; 
+, P';0.05 versus human u-CGRP. 
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Figure 7.4 Concentration-response curves for noradrenaline (NA; upper panels) (first: 0, 
second: V) and a-CGRP (.; lower panels) in porcine isolated right atrial (n~6) and left 
ventricular (n~ 10) trabeculae_ Responses are expressed as percentages of the response to NA 
(l0·5 M) at baseline. Data are given as mean ± S.C. mean. 
7.4 Discussion 
SystemiC haemodynamics 
The systemic haemodynamie effects of human a-CGRP have been described 
extensively in animals and humans (Franco-Cereceda et at_, 1987; Lappe et at_, 1987; 
Gardiner et at., 1989, 1991; Wang et at_, 1989). The fan in systemic blood pressure 
and increase in systemic vascular conductance observed with intra carotid infusions of 
the two highest concentrations (30 and 100 pmol kg-I min-I) of human a-CGRP are in 
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accordance with these reports, but also show that the potent vasodilator action of the 
peptide was not limited to the carotid circulation. Since heart rate increased in parallel 
with the decline in blood pressure, it is reasonable to assume that changes in heart rate 
were baroreflex-mediated. Our unpublished observations in two pigs, anaesthetized 
with pentobarbital and subjected to bilateral vagosympathectomy, support this view; 
intracarotid infhsions of human a-CGRP (up to 100 pmol kg-I min· l ) in these animals 
with markedly inhibited sympathetic tone (see Den Boer et al., 1993) did not increase 
heart 'rate, despite a pronounced fall in alterial pressure. It, however, remains possible 
that in other circumstances (e.g. the use of porcine a-CGRP in pigs) or in other species 
additional mechanisms, such as a direct chronotropic action or release of 
catecholamines, may contribute to the observed tachycardia. Indeed, heart rate 
responses to a-CGRP were attenuated but not completely abolished in dogs afkr 
cardiac denervation (Wang et al., 1989). A direct chronotropic effect of rat a-CGRP 
has also been observed in rat isolated atria (Sigrist et al., 1986), but no tachycardia was 
detected in conscious rats given human a-CGRP (Gardiner et al., 1989). On the other 
hand, catecholamine release was reported in dogs and man (Franco-Cereceda et al., 
1987; Wang'et al., 1989), and ll-adrenoceptor blockade abolished tachycardia in cardiac 
denervated dogs (Wang et al., 1989). 
As previously reported for rats (Lappe et al., 1987), cardiac output increased 
without changes in stroke volume, most likely, reflecting a reduction in afterload, as 
indicated by the fall in systemic blood pressure. However, when systemically infused 
in a comparable dose, human a-CGRP enhanced indices of contractility in conscious 
rats, despite a marked reduction in stroke index, possibly due to the reduction in 
venous pressure (Gardiner et al., 1991). If this was also the case in our experiments, 
the putative positive inotropic action of human a-CGRP (see section myocardial 
contractility in vitro) was masked in pigs by concomitant venodilatation. 
Both dihydroergotamine and sumatriptan failed to reverse human 
a-CGRP-induced systemic haemodynamic changes. Either drug tended to reduce mean 
arterial blood pressure, significantly so only in the case of sumatriptan. Since the latter 
was shown previously to reduce cardiac output in anaesthetized pigs (Den Boer et al., 
1992b), the small change in this variable may have accounted for the additional 
reduction in blood pressure. As no significant changes in systemic vascular 
conductance were observed with either dihydroergotamine or sumatriptan, both drugs 
exerted a selective vasoconstrictor effect in the carotid vasculature. 
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Carotid haemodynamics 
Carotid vascular pulsations 
The increase in carotid vascular pulsations caused by human a-CGRP is partially 
in accord with previous observations using Doppler flow measurements in humans, 
when the peptide enhanced pulsatility in the internal carotid artery, but not in the 
common carotid artery (MacDonald et al., 1989). As argued in chapter 6, these 
increased pulsations most likely reflect changes in vascular compliance following 
vasodilatation, though the precise mechanism is unclear. It is to be noted that local 
pulsatile flow may be influenced by changes in systemic vascular resistance and, 
furthermore, similar changes in pulsatility are also observed with histamine and 
nitrovasodilators, precluding the existence of a specific mechanism (Graham & Wolff, 
1938; Thomsen et al., 1993; this thesis, chapter 6). The inability of either 
dihydroergotamine or sumatriptan to change the carotid vascular pulsations induced by 
human a-CGRP may argue against vasodilatation as the sole underlying mechanism. 
Additionally, it is possible that the dose of the antimigraine drugs was not sufficient 
to oppose the enhanced vascular pulsations during continued infusion of a high dose 
of human a-CGRP. 
Carotid blood jlow distribution 
In keeping with the observations in rats (Gardiner et al., 1989, 1991), human 
a-CGRP elevated common carotid blood flow dose dependently, associated with 
pronounced increases in regional tissue blood flow, indicating arteriolar dilatation. In 
the presence of a high concentration of human a-CGRP, sumatriptan and 
dihydroergotamine reduced carotid blood flow to an extent similar to that reported in 
the absence of the peptide (Den Boer et al., 1992a), suggesting that their 
vasoconstrictor action in this vessel does not depend on the level of circulating human 
a-CGRP. 
As previously reported (Den Boer et al., 1993; this thesis, chapter 6), 
approximately 21% of the carotid blood flow (compared to over 70% in anaesthetized 
pigs, Den Boer et al., 1992a) was shunted through atteriovenous anastomoses, 
indicating that, at baseline, these vessels were largely under sympathetic constrictor 
tone. Despite its potent vasodilator action, human a-CGRP failed to affect blood flow 
through arteriovenous anastomoses. These vessels appear to be imlervated by sensory 
nerves (Gorgas et al., 1977; Hales & Molyneux, 1988) and CGRP-containing fibres 
have been demonstrated immunohistochemically in the proximity of alteriovenous 
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anastomoses in the dog tongue (Hino el al., 1993). Moreover, in a similar dose, CGRP 
increased arteriovenous anastomoses blood flow in the sheep hind limb (Mogg e/ al., 
1992). The lack of effect of human a-CGRP in our study is not explained by the 
difference in peptide used (human a-CGRP versus rat CGRP), since more pronounced 
vasodilator effects have been reported with human a-CGRP than with rat a-CGRP 
(Gardiner e/ al., 1989). As an elevated shunt flow was observed in the sheep hind 
limb, apparently without significant changes in systemic blood pressure and capillary 
flow (Mogg el al., 1992), it is possible that the pronounced increase in capillary blood 
flow in conjunction with the marked rise in systemic vascular conductance prevented 
the opening of arteriovenous anastomoses in the carotid circulation of the pig by way 
ofa 'steal-like' phenomenon. As nitrovasodilators have been reported to enhance blood 
flow through arteriovenous anastomoses under comparable conditions (This thesis, 
chapter 6), it seems unlikely that, in this part of the circulation, nitrovasodilators act 
via the release of CGRP (Wei e/ al., 1992; Holzer & Jocic, 1994). 
The anti migraine drugs, dihydroergotamine and sumatriptan, have been shown to 
reduce blood flow through arteriovenous anastomoses in pigs with a high shunt flow 
(Den Boer e/ al., 1992a). Since arteriovenous anastomoses were largely closed and 
repeated infusions with human a-CGRP failed to increase atieriovenous anastomotic 
blood flow, such a constrictor action could not be detected in the present experiments. 
In the porcine carotid circulation, human a-CGRP increased extracerebral blood 
flow without affecting intracerebral flow. The predominant action on extracerebral 
tissues, most markedly reflected by the major changes in cutaneous tissues (skin and 
ears) SUPpOltS the contention that extracranial vascular dilatation and pulsation indeed 
have a role in migraine headache (Graham & Wolff, 1938; Drummond & Lance, 
1988). However, the absence of cerebral blood flow changes seems to be in conflict 
with the enhanced cerebral blood flow together with elevated CGRP levels in the 
external jugular vein following stimulation of the trigeminal ganglion (Goadsby & 
Edvinsson, 1993) as well as with the increased vessel diameter in the feline cerebral 
microcirculation observed with CGRP (Wei e/ al., 1992). This discrepancy is most 
likely attributable to methodological differences since, in the former study, cerebral 
blood flow was measured by Laser Doppler flowmetry, detecting changes in large 
intracerebral vessels (not detected by microspheres), whereas in the latter study CGRP 
was applied topically, producing relatively high local concentrations. Finally, it may 
be argued that a putative vasodilator action of human a-CGRP in porcine cerebral 
capillaries is effectively opposed by cerebral autoregulation. 
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Within the porcine cranial circulation, dural blood flow was significantly 
enhanced by human a-CGRP. The dura mater, which is innervated by CGRP-
containing nerves (Uddman et al., 1986; Suzuki et al., 1989), is regarded a likely 
source of headache, and plasma levels of CGRP appear to be elevated in the cranial 
venous effluent in migraineurs (Friberg et al., 1994). Thus, it is plausible that enhanced 
dural blood flow, together with increased vascular pulsatHity, contributes to migraine 
headache. However, in spite of an increase in carotid vascular resistance indicating 
vasoconstriction, antimigraine drugs like dihydroergotamine and sumatriptan failed to 
reduce dural blood flow in pigs (Den Boer et al., 1992a), whereas sumatriptan reduced 
feline pial diameter only after topical application (Connor et al., 1992). Moreover, in 
the present study with presumably high levels of CGRP, both sumatriptan and 
dihydroergotamine only slightly reduced dural blood flow and failed to reduce carotid 
vascular pulsations. 
Myocardial contractility in vifro 
To evaluate the putative positive inotropic action of a-CGRP fuliher, we shldied 
its inotropic responses on isolated trabeculae obtained from right atria and left 
ventricles from saline treated animals. As both noradrenaline and a-CGRP act via the 
adenylyl cyclase/cAMP pathway (Brodde et ai., 1992; Sigrist ef al., 1986; Ishikawa 
ef al., 1987), noradrenaline was used to check the inotropic responsiveness and 
viability of the tissues, both at the beginning and at the end of the experiments. As in 
our previous shldies (Schoemaker et al., 1992; Du et al., 1994), tissues not responding 
to noradrenaline at the begitming of the experiment were excluded. All tissues 
responded to noradrenaline at the end of the experiments, confirming that these tissues 
remained viable during the course of the experiment. 
In contrast to noradrenaline, human a-CGRP failed to increase force of 
contraction in porcine atrial tissue but increased contractility in ventricular tissue. So 
far, a positive inotropic action in the atrium rather than ventricles has been observed 
in the rat (Sigrist et al., 1986; Ishikawa ef al., 1987), guinea pig (Saito ef al., 1987) 
and human myocardium (Sigrist ef al., 1986; Du et ai., 1994), suggesting a rather 
uniform mode of action, at least on atrial trabeculae. However, the discrepancy may 
be attributable to species differences. For example, few CGRP specific binding sites 
have been detected in guinea pig ventricles (Ishikawa et al., 1988), whereas these sites 
could be demonstrated in porcine ventricular tissue (Miyauchi et al., 1988). At present, 
no data are available about specific binding sites for CGRP in the porcine atrium. 
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The ability of human a-CGRP to increase the force of contraction in ventricular 
trabeculae is in accord with the detection of binding sites for this peptide as well as 
with the observation of positive inotropic responses in ventricular false tendons 
(Miyauchi e/ al., 1988). Moreover, the magnitude of the inotropic response at 10.7 M 
human CGRP, being approximately 25% of the isoprenaline control curve, was 
comparable with that in our study. Although these moderate ventricular inotropic 
responses support the hypothesis of a positive inotropic effect iu anaesthetized pigs, it 
remains to be established whether such concentrations actually occur in vivo. 
In summary and conclusion, intracarotid infusion of human a-CGRP caused 
arteriolar dilatation in the pig, which was accompanied by hypotension, tachycardia and 
an increase in cardiac output. Within the carotid circulation, vasodilatation was largely 
confined to extracerebral tissues and the marked increase in capillary blood flow 
together with the fall iu systemic blood pressure most likely prevented the opening of 
arteriovenous anastomoses. Furthermore, in the presence of high levels of human 
a-CGRP, the imtimigraine drugs, dihydroergotamine and sumatriptan, reversed blood 
flow changes iuduced by human a-CGRP in extracerebral tissues. 
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General discussion 
A part of the experiments described in this thesis was delineated to study 
haemodynamic responses and changes in local blood flow induced by iuhibition of 
NO biosynthesis in different animal species. The majority of these effects can be 
attributed to abolishion of the NO-mediated vasodilator tone, but additional 
mechanisms like activation of neurohumoral systems may not be excluded. The 
potential contribution of such mechanisms to the systemic and regional haemodynamic 
effects of L-NAME is discussed in general. 
A dilatation of (extra)cerebral arteriovenous anastomoses has been implicated in 
the pathophysiology of migraine headache, but the inital vasodilator stimulus is still 
elusive. Our experiments in the carotid circulation of anaesthetized pigs, a model 
suitable to study vascular responses to antimigraine drugs, indicate that the endogenous 
generation of NO may play a role in the regulation of blood flow through these 
shuntvessels. FUlihennore, clinical experimental data seem to imply that changes in 
NO-mediated pathways occur during migraine headache. The putative relation between 
NO and the vascular changes during migraine headache is therefore addressed in the 
second part of this discussion. 
8.1 Haemodynamic responses and tissue blood flows 
N"-nitro-L-arginine methyl ester (L-NAME) produced differential haemodynamic 
responses and changes in tissue blood flow distribution in anaesthetized animals. In the 
rat, L-NAME exerted a pronounced hypertensive action, independently of the existing 
vascular tone. In contrast, such a pressor response was absent in cats and pigs, although 
tissue blood flows were reduced. This species difference is not due to the type of 
anaesthesia used but may rather be related to differences in compensatory mechanisms, 
such as differences in baroreflex sensitivity and differences in regional production of 
NO. This is illustrated by the finding that in the intact rat, pressor responses to 
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L-NAME are partially compensated by reflex bradycardia whereas in the pig the 
expected rise in blood pressure is opposed by a fall in cardiac output probably due to 
profound pulmonary vasoconstriction. 
Our experiments with L-NAME in anaesthetized animals support the general 
contention that NO is released at a basal rate and, accordingly, plays a role in the 
regulation of local blood flow and blood pressure. Nevertheless, both haemodynamic 
responses and changes in local blood flow distribution following L-NAME were 
attenuated, but not always reversed by the endogenous substrate L-arginine. This may 
suggest that other, NO-independent, mechanisms were involved in the effects of 
L-NAME. Buxton and coworkers (1993) claimed that the L-NAME-induced responses 
are explained by its atropine-like activity (Buxton el al., 1993). However, L-NAME 
did not change the magnitude of the hypotensive responses to acetylcholine in rats and 
cats (see chapter 2) and L-NAME is rapidly dealkylated ill vivo to L-NNA 
(Schwarzacher & Raberger, 1992), which is devoid of antimuscarinic actions (Buxton 
el al., 1993). Moreover, Cheng and colleagues (1994) demonstrated that the 
bradycardic response upon efferent vagal stimulation, a muscarinic receptor-mediated 
reponse not dependent on the release of NO, was not impaired by a high dose of 
L-NAME but abolished by atropine. Therefore, it is unlikely that the effects of 
L-NAME described in this thesis were mediated through blockade of muscarinic 
receptors. The apparent inability of L-arginine to reverse the actions of L-NAME is 
probably best explained by the high affinity of L-NAME for the enzyme NOS, 
requiering a high concentration of substrate to compete for the active site of the 
enzyme. 
Although the haemodynamic effects and changes in regional blood flow during 
inhibition of endothelial NO production in intact anaesthetized animals can be 
attributed to abolishion of the NO-mediated vasodilator tone, it is unclear which 
vasoconstrictor stimulus served as the functional counterpart and, hence, accounts for 
the rise in peripheral resistance and blood pressure. Since vasoconstriction is largely 
dependent on the level of sympathetic tone under normotensive conditions and 
vasoconstrictor responses to adrenergic agonists are potentiated by NO-inhibitors, it is 
likely that in the abscence of NO formation vasoconstriction mediated by circulating 
catecholamines may dominate. In addition, central sympathoexcitatory effects have 
been proposed to palticipate in the hypertensive action of NO-synthesis inhibitors. 
Sakuma el al. (1992) demonstrated that L-NMMA causes a long-lasting increase in 
renal sympathetic nerve activity, susceptible to sympathectomy. Enhanced renal 
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sympathetic activity and hypertensive responses were also observed with micro-
injections of L-NMMA into the nucleus tractus solitarius of intact, and sinoaortic 
denervated and vagotomized animals (Harada el al., 1993). However, HalbrUgge and 
colleagues (1991) reported that the L-NMMA-induced pressor effect in anaesthetized 
animals is accompanied by a reduction, rather than an increase in catecholamine 
release. Furthermore, the pressor response of L-NAME in the rat has been shown to 
be resistant to ganglionic blockade and blockade of adrenergic receptors (Wang & 
Pang, 1991; Chuy el al., 1992). Moreover, our experiments in the pithed rat 
preparation suggest that the hypertensive action of L-NAME does not primairely 
depend on the integrety of the sympathetic nervous system. Thus, it is conceivable that 
activation of the central sympathetic system is of minor importance in our experiments. 
Likewise, the influence of the renin-angiotensin system on the systemic pressor 
responses in anaesthetized animals is unclear. Neither converting enzyme inhibition nor 
angiotensin II receptor antagonism reduced the hypertensive effects of NO synthesis 
inhibition in the rat (Wang & Pang, 1991; Zambetis e/ al., 1991; Sigmon & 
Beierwaltes, 1994). Nevertheless, the angiotensin II receptor antagonist losartan 
attenuatted the L-NAME-induced reductions in tissue blood flows and the increase in 
peripheral resistance in anaesthetized rats (Sigmon & Beierwaltes, 1994). Furthermore, 
while comparing the interaction of L-NAME and angiotensin II receptor blockade in 
conscious and anaesthetized rats, they noted that the ability of losartan to oppose 
regional haemodynamic responses to L-NAME is more obvious in the anaesthetized 
rat than in the conscious rat and proposed that the vasoconstrictor action of angiotensin 
II is the major antagonist of NO-mediated vasodilation when the activity of the renin-
angiotensin system and the level of circulating angiotensin II are elavated. If this 
hypothesis is correct, it is conceivable that angiotensin II may also account for the 
haemodynamic responses observed in the pithed rat preparation, since in this model 
peripheral vascular resistance and blood pressure is maintenained by a high level of 
endogenous angiotensin II (De Jonge e/ al., 1982). 
Our experiments in rats and cats demonstrated that the hypotensive response to 
both acetylcholine and serotonin are mediated largely independent of the generation of 
NO by the vascular endothelium, suggesting a stricking dissimilarity between in vitro 
and in vivo experiments. In case of acetylcholine-evoked hypotension, evidence is 
currently accumulating that apart from its well-kown ability to stimulate vascular NO 
production, acetylcholine produces vasorelaxation via endothelium-dependent smooth 
muscle hyperpolarization. The contribution of smooth muscle hyperpolarization to 
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vascular relaxation seems inversely related to the vessel diameter. Accordingly, 
relaxations to acetylcholine in small resistance vessels are mediated via the release of 
EDHF with only a minor contribution of NO (Adeagbo et al., 1993; Garland e/ al., 
1995). Interestingly, Kilpatrick & Cocks (1994) demonstrated in the porcine coronary 
artery that when NO-synthesis is blocked the relaxant response to endothelium-
dependent vasodilators is preserved by hyperpolarization, indicating that the release of 
EDHF and smooth muscle hyperpolarization may serve as a backup system to control 
arterial diameter. 
8.2 Nitric oxide and migraine 
Inspite of an ongoing debate regarding its relevance as a cause of migraine 
headache, (extra)cranial vasodilatation and arteriovenous anastomoses shunting has 
been reported during the headache phase and the therapeutic effect of serotonergic 
agonists has been related to selective vasoconstriction in the carotid circulation. The 
trigger for local vasodilation is yet unclear and a number of potential candidates have 
been proposed. According to the neurogenic inflanunation theory of Moskowitz (1992), 
neuropeptide release from perivascular nerves of the trigeminal system could account 
for the local vascular changes in migraine. These neuropeptides, substance P and 
CGRP, are indeed potent vasodilators but they do not cause headache when injected 
in humans, and our experiments with intracarotid infusions with CGRP in pigs failed 
to detect significant changes in carotid arteriovenous anastomotic blood flow, indicating 
that this peptide may not be the principal mediator of vascular changes in migraine. 
The observation that inhibition of NOS in cats induced a reduction of the microsphere 
content of the lungs, a measure for blood flow through systemic a1ieriovenous 
anastomoses, led to the hypothesis that NO contributes to the regulation of tone in 
these blood vessel segments and hence may be involved in the vascular events of 
migraine. This concept was evaluated in detail in anaesthetized pigs, demonstrating that 
L-NAME reduced blood flow through systemic a1ieriovenous anastomoses. Intracarotid 
administration of L-NAME reduced blood flow in the carotid aliery, which was 
accompanied by a reduction of flow through extracerebral anastomoses. Since 
a1ieriovenous anastomotic conductance was restored by L-arginine a NO-dependent 
mechanism is likely. Subsequent experiments using NO donors showed that under low 
anastomotic blood flow conditions NO may enhance blood flow in the carotid 
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vasculature including arteriovenous anastomoses. Together, the results from our 
experiments suggest that arteriovenous anastomoses in this part of the circulation, at 
least in pigs, are indeed under NO-mediated vasodilator tone. Recent findings by Van 
Es ef al. (1995), suggest that our results may be applicable to humans. These authors 
reported that the NO-donor sodium nitroprusside increases finger blood flow, which 
is predominantly determined by flow through arteriovenous anastomoses. 
Additional support for the contention that NO is involved in the vascular changes 
of migraine is provided by observations from experimental headache. Various 
vasodilator drugs, including nitrates and nitrites, cause headache as a side effect. For 
this reason, nitrovasodilators have been used to provoke experimental headache in man. 
In healthy volunteers,' isosorbide mononitrite caused a dose-related headache, which 
resembled migraine in some but not all SUbjects. The headache was bilateral and 
pulsating of nature, and was aggravated by physical activity. Furthermore, headache 
was accompanied by a dose-dependent dilatation of the superficial temporal a,tery 
(Iversen ef al., 1992). Secondly, glyceryl trinitrate-induced headache was augmented 
by pretreatment with N-acetylcysteine, a donor of sulphydryl-groups which may 
facilitate the liberation of NO from vasodilators. The potentiating effect on headache 
was paralleled by enbanced dilatory responses in the temporal artery (Iversen, 1992). 
Repeating these experiments in migraine patients, Olesen repotted that infusion 
of glyce,yl trinitrate induced a more intense dose-dependent headache and middle 
cerebral attery dilatations, than in non-migraineurs (Olesen ef aI., 1993, Thomsen 
ef al., 1993). Moreover, some of the migraineurs experienced a second migraine-like 
headache within 24 h, suggesting a delayed release of other mediators. 
As with nitrovasodilators, administration of histamine to migraine patients caused 
headache which was paralleled by vasodilatation and enbanced vascular pulsations on 
the side of the pain (Graham & Wolff, 1938). Although the histamine-induced 
headache was shown to be clinically distinct from migraine headache, headache was 
experienced by migraine patients rather than by control subjects. Subsequent injection 
of the HI receptor antagonist mepyramine abolished histamine-induced headache 
responses (Krabbe & Olesen, 1980). Histamine is known to cause relaxations in 
isolated cranial blood vessels, most likely via endothelial HI receptors to release 
endogenous NO, since relaxations are attenuated by L-NMMA and abolished by 
endothelial denudation (Toda, 1990; Fujiwara el al., 1992). These findings have led 
Olesen ef al. (1993) to conclude that migraineurs are more sensitive to both exogenous 
and endogenous NO. 
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Similar to migraine, attacks of cluster headache are provoked by administration 
of glyceryl trinitrate (Drummond & Anthony, 1985; Dahl et al., 1990). These attacks 
are also accompanied by an increase in temporal artery pulse amplitude on the side of 
the headache, and both headache intensity and temporal pulsations are reduced by 
breathing pure oxygen (Drummond & Anthony, 1985). Furthermore, in both types of 
headache, concentrations of plasma CORP appear to be elevated during the attack 
(Ooadsby et al., 1990; Ooadsby& Edvinsson, 1994). Topical application of 
nitrovasodilators was shown to stimulate the release of CORP from perivascular 
sensory nerve endings in pial arteries as well as cutaneous microvessels 
(Wei et al., 1992; Holzer & Jocic, 1994). If this is also the case in humans, the rise 
in plasma CORP may be the consequence of increased sensitivity or activity of NO-
mediated pathways. Consistent with this view, oxygen was shown to alleviate pain and 
to normalize elevated levels of plasma CORP in patients suffering from cluster 
headache (Ooadsby & Edvinsson, 1994). In this respect, it is interesting to note that 
high oxygen tension facilitates the inactivation of NO and may limit its effect. 
Putative mechanisms 
Since enhanced sensitivity is observed in migraine patients, both following 
endothelium dependent (histamine) and independent (nitrovasodilators) stimuli, this 
effect is likely due to changes downstream of the endothelium. One possible 
explanation is provided by alterations at the level of the second messenger system, such 
as upregulation of the guanylyl cyclase system (Olesen et al., 1993). On the other 
hand, Fozard and Kalkman (1994) reasoned that the release of5-HT in the early stages 
of the attack may activate endothelial 5-HT'B!2C receptors and enhanced sensitivity of 
these receptors could explain the role of NO in migraine. Changes in the metabolism 
and distribution of 5-HT as well as its pharmacology have indeed been related to 
pathophysiology of migraine (see Lance, 1993; Saxena, 1995). Furthermore, 5-HT has 
been shown to induce endothelium-dependent responses in isolated porcine peripheral 
arteries with phatmacological similarities to the 5-HT,c receptor (Sumner, 1991; Glusa 
& Richter, 1993). However, we were unable to detect a NO-dependent vasodilator 
response for 5-HT in pithed rats and, moreover, the presence of this type of receptor 
on (extra)cranial arteries and arteriovenous anastomoses has not yet been shown. 
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Nilroxidergic nerves 
The vascular events in migraine are not easily explained by simple changes in 
basal release of NO from the vascular endothelium and, hence, additional NO-mediated 
pathways may be involved. As noted in chapter 5, L-NAME did not reduce cerebral 
blood flow in pigs and high systemic doses or topical application of NOS-inhibitors 
are requiered to reduce cerebral blood flow (Faraci, 1991; Kovach ef al., 1992; Prado 
ef al., 1992) indicating an action distinct from the endothelium. Within the brain NO, 
derived from neurons and astrocytes, is believed to couple local blood flow to neural 
activity (Ideacola, 1993). In addition, NO may transmit information from 
non-adrenergic and non-cholinergic nerves to (extra)cranial arteries. Both NADPH-
diaphorase histochemistry and immunocytochemical studies using antibodies against 
NOS have identified dense NOS-containing perivascular nerves innervating the circle 
of Willis, large cerebral, pial and temporal arteries in several species (Estrada ef al., 
1993; Iadecola ef al., 1993; Nozaki ef al., 1993; Yoshida ef aI., 1993). In humans, 
immunoreactive fibres were observed within the central nervous system (Springall 
ef al., 1992), but only sparse immunoreactivity was detected in cerebral vessels, 
presumably due to the use of post-mortem material (Nozaki ef al., 1993). Nitroxidergic 
nerves appear to originate from the sphenopalatine ganglion, since immunoreactivity 
was abolished either by efferent nerve section or lesions in this parasympathetic 
ganglion (Nozaki ef al., 1993; Yoshida ef al. 1993). A portion of NOS-positive 
neurons is also immunoreactive to vasoactive intestinal polypeptide (VIP), suggesting 
that NO and VIP may be released from the same nerve terminals (Nozaki ef al., 1993). 
The putative functional role of nitroxidergic nerves in the regulation of local 
blood flow is suggested by experiments performed on isolated cerebral and 
extracerebral blood vessels. That is, relaxations of the dog superficial temporal artery 
upon transmural nerve stimulation are associated with an increase in tissue cGMP-level 
and are effectively antagonized by inhibition of NOS and ganglion blockade (Okamura 
ef al., 1993). NOS-inhibition and destruction of the sphenopalatine ganglion also 
prevented relaxant responses of canine and porcine cerebral and temporal arteries 
induced by the ganglionstimulant nicotine as well as by transmural nerve stimulation 
(Chen & Lee, 1993; Toda ef al., 1993). 
At present, evidence for a physiological role in vivo is limited; stimulation of the 
sphenopalatine ganglion in rats increases cortical blood flow, which is attenuated by 
L-NAME (Morita-Tsuzuki ef al., 1993). Furthermore, heat-induced vasodilatation, 
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sensitive to local nerve block, is reduced by L-NNA in rabbits (Taylor & Bishop, 
1993). However, animal studies have also shown that stimulation of trigeminal fibers 
increases blood flow in the carotid circulation together with a rise in skin temparature. 
These changes in carotid blood flow seem to occur, at least in part, via a para-
sympathetic reflex involving the seventh cranial nerve and the sphenopalatine ganglion 
(Lambert et al., 1984). So far, this reflex vasodilatation has been ascribed 
predominantly to the release of VIP and CORP from perivascular nerves (Ooadsby & 
Macdonald, 1985; Beattie & Connor, 1994), but in view of the co-localization of VIP-
and NOS-immunoreactivity a nitroxidergic vasodilatory component may be considered. 
If this reflex axis is also operative in migraine headache, it is reasonable to assume a 
contribution of nitroxidergic nerves to the local vascular events in migraine. 
The role of these nitroxidergic nerves in the pathophysiology of migraine is yet 
to be defined. In order to discreminate between endothelium-dependent vascular effects 
and neuronal evoked responses the development of selective type I NOS-inhibitors is 
a prerequisite for fhture experiments. This may eventually lead to a novel therapeutic 
approach in the treatment of migraine. However, it is also to be expected that type I 
selective NOS-inhibitors may cause major side effects since this isoform is abundantly 
present within the central nervous system. 
In conclusion, NO contributes differentially to the regulation of local vascular 
tone and, hence, regional blood flow in anaesthetized animals. The ability of 
endogenous NO to change blood flow through carotid arteriovenous anastomoses seems 
relevant for migraine headache. This may lead to the development of novel 
antimigraine therapy. 
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Summary 
The vascular endothelium has been recognized as an important regulatory organ 
with multiple physiological functions. Endothelial cells may contribute to the 
cardiovascular homeostasis via the release of vasoactive substances with opposite 
action, which may influence tone of the underlying smooth muscle and modulate local 
blood flow. The potent vasodilator property of NO has led to the view that alterations 
in the physiology of this molecule may be important under pathophysiological 
conditions and clinical experimental data seem to suggest that NO is involved in the 
aetiology of migraine. 
In chapter 1, the clinical features of the migraine syndrome and the vascular 
changes during migraine attacks are discussed. Vasodilatation of large extracranial, 
basal cerebral blood vessels and, arteriovenous anastomoses can be observed during the 
headache phase of migraine. Local vasodilatation is often accompanied by increased 
vascular pulsatility and the ensuing pain may be due to a depolarization of perivascular 
sensory nerves around these arteries. In addition, local release of vasoactive 
neuropeptides, like calcitonin gene-related peptide (CGRP), may maintain the vascular 
changes during the attack. 
The second part of this chapter describes the discovery, chemical identity and 
origin of endothelium-derived relaxing factor (EDRF), and provides an overview of 
the current knowledge of the various endothelium-derived vasoactive factors. The 
factors mediating vasocontriction include thromboxane and prostaglandin H" the 
endothelins, and angiotensin II. Local vascular tone may be reduced via the release of 
prostacyclin and EDRF. In addition, smooth muscle hyperpolarization, attributed to the 
endothelial release of an unidentified hyperpolarizing factor (EDHF), may also 
participate in vasorelaxation. 
In chapter 2, the haemodynamic effects of the NOS-inhibitor NG-nitro-L-arginine 
methyl ester (L-NAME) and its potential ability to attenuate hypotensive responses to 
the endothelium-dependent vasodilator acetylcholine were investigated in anaesthetized 
rats and cats. L-NAME caused a sustained hypertensive response and a moderate 
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bradycardia in rats. Hypertensiolj was partially reversed by the endogenous substrate 
L-arginine. In contrast, L-NAME failed to modifY systemic haemodynamic parameters 
in cats. Subsequent administration of L-arginine did not exert any significant 
haemodynamic effect in cats treated with L-NAME, but caused a moderate reduction 
in heart rate and increases in cardiac output and stroke volume in saline-treated control 
cats. In the cat, L-NAME reduced tissue blood flows in several abdominal organs. 
Administration of L-arginine produced a significant increase in blood flow in the lungs, 
mesentery, kidneys and liver, which was not observed in cats previously treated with 
L-NAME. The magnitude of the acetylcholine-induced hypotensive response, was 
unaffected by L-NAME. However, the duration of these responses was reduced by 
L-NAME in both rats and cats. 
The results from these experiments reveal a marked difference between the 
haemodynamic effects of L-NAME in rats and cats. They suggest that in cats, unlike 
rats, the contribution of L-arginine-derived NO to the regulation of blood pressure is 
rather limited, although such a pathway may exist in various tissues. FUl1hermore, the 
hypotensive response to acetylcholine in both species seems to be mediated largely via 
NO-independent pathways. 
In chapter 3, the haemodynamic effects of L-NAME were studied in rats with 
low vascular tone. In the pithed rat preparation, L-NAME elavated mean a11erial blood 
pressure to a similar extent as previously observed in anaesthetized rats, without 
changing heart rate. Blood pressure responses to L-NAME were unaffected by the 
a l adrenoceptor and 5-I-IT, receptor antagonist ketanserin. 
As relaxant responses of isolated vascular preparations to 5-hydroxy1ryptamine 
(5-HT) were shown to dependent partly on functional endothelium, we evaluated the 
possible involvement of endothelial NO-release in blood pressure responses to 
5-hydroxy1ryptamine (5-HT). The hypotensive responses to 5-HT in the presence of 
ketanserin were augmented by L-NAME as well by the ai-adrenergic agonist 
phenylephrine. L-NAME also tended to prolong the duration of the response to 5-HT. 
The magnitude of hypertensive responses to 5-HT was unaffected by L-NAME, but 
L-NAME extended the duration of these responses. 
These experiments suggest that L-NAME increases blood pressure in animals with 
a low vascular tone, probably by inhibiting the basal release of NO. However, the 
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hypotensive responses to 5-HT seem to be largely independent of NO-release by the 
endothelium, but the hypertensive responses to 5-HT appeal' to be limited by 
conconnnitant release of NO in the pithed rat. 
In chapter 4, haemodynamic responses evoked by L-NAME were analyzed in 
more detail in the anaesthetized pig. Tissues containing arteriovenous anastomoses were 
identified and the effects of NOS-inhibition on total systemic and regional 
arteriovenous shunting analyzed. 
L-NAME reduced systemic and pulmonary artery conductance and cardiac output, 
but heart rate and mean arterial blood pressure remained unchanged. L-arginine 
reversed the systemic and pulmonary haemodynamic changes induced by L-NAME. 
The difference between blood flows simultaneously measured with 15 and 50 l.un 
microspheres, which can be equated to blood flow through arteriovenous anastomoses 
with a diameter between about 28 and 90 ].lm, was reduced by L-NAME. 
These results suggest that in the anaesthetized pig (i) NO is involved in the 
regulation of both systemic and pulmonary vascular conductance, (ii) the decrease in 
systemic vascular conductance is in part due to constriction of systemic arteriovenous 
anastomoses, and (iii) the decrease in pulmonary vascular conductance, leading to 
reduction of cardiac output. 
The role of NO biosynthesis in the regulation of blood flow through carotid 
arteriovenous anastomoses of the anaesthetized pig is described in chapter 5. Apart 
from the highest dose, L-NAME caused no major changes in the systemic 
haemodynamic variables, whereas L-arginine slightly reduced mean arterial blood 
pressure in control animals. 
L-NAME caused a dose-dependent decline in common carotid artery blood flow 
and conductance, which was entirely confined to the arteriovenous anastomotic pmt of 
the carotid circulation. Subsequent intracarotid injection of L-arginine reversed the 
reduction in total carotid conductance almost completely and that in the atteriovenous 
anastomotic part partially. 
These experiments indicate that the L-arginine-NO pathway contributes little to 
the regulation of tissue perfusion in the porcine carotid circulation. In contrast, NO 
seems to play an important role in shunting arterial blood through arteriovenous 
anastomoses in the anaesthetized pig. 
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In chapter 6, the putative role of nitric oxide (NO) in the regulation of capillary 
and arteriovenous anastomotic blood flow was investigated in the carotid circulation 
of the anaesthetized pig. For this purpose, the effects of intracarotid infusions of two 
NO donors, nitroplUsside sodium (NPR) and S-nitroso-N-acetylpenicillamine (SNAP) 
were studied on systemic haemodynamics, and carotid blood flow as well as its 
distribution. 
Apart from heart rate, which increased after both NPR and SNAP, no major 
changes in systemic haemodynamic variables were observed. Both NPR and SNAP 
increased common carotid blood flow, vascular conductance and vascular pulsations 
dose-dependently. Both NPR and SNAP enhanced total capillary blood flow and 
conductance. In contrast to NPR, arteriovenous anastomotic blood flow and 
conductance were increased by SNAP. At the tissue level, capillary blood flow 
increases following NPR or SNAP were reflected by an increase in both extracerebral 
and dural blood flow without changes in total brain blood flow. 
These results indicate that both NO donors cause arteriolar dilatation together 
with enhanced vascular pulsations in the carotid circulation of the pig. The pronounced 
arteriolar dilatation limits the effect of NO donors on arteriovenous anastomoses, 
probably by way of a 'steal' phenomenon. Together, the findings described in this 
chapter support the contention that dilatation of intra- and extracranial arteries and 
atieriovenous anastomoses leads to increased vascular pulsations, which (rather than 
increased blood flow per se) could, at least in part, be responsible for the headache 
caused by nitrovasodilators. 
Chapter 7 describes the effects of the sensory neuropeptide, calcitonin gene-
related peptide (o:-CGRP) on haemodynamics and carotid blood flow distribution in 
the anaesthetized pig. The peptide has been implicated in the pathogenesis of migraine 
headache and its release, in some vessel segments, is apparently initiated by NO. 
Human o:-CGRP increased carotid artery blood flow and conductance dose-
dependently, together with an enhancement in vascular pulsations. These effects were 
associated with a fall in systemic blood pressure with concomitant increases in heati 
rate and cardiac output. The increase in carotid blood flow was reflected by an increase 
in total capillary blood flow, predominantly to extracerebral tissues including the dura, 
whereas blood flow through arteriovenous anastomoses remained stable. The 
antimigraine drugs, dihydroergotamine and sumatriptan, reduced carotid blood flow and 
its capillary fraction without affecting systemic vascular conductance. These drugs 
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reversed blood flow increases due to human a-CGRP in most extracerebral tissues, but 
failed to reduce dural blood flow. 
These data indicate that human a-CGRP caused arteriolar dilatation together with 
a fall in blood pressure in the pig. The fall in systemic arterial blood pressure and the 
marked increase in capillary blood flow most likely negated the opening of 
arteriovenous anastomoses. Furthermore, the antimigraine drugs, dihydroergotamine 
and sumatriptan, were able to reverse blood flow changes induced by human a-CGRP 
in the porcine carotid circulation. 
In chapter 8, the experimental results of this thesis are addressed in general and, 
in addition, the putative role for NO in the pathophysiology of migraine is discussed. 
The majority of haemodynamic and local blood flow responses to L-NAME can be 
attributed to a reduction of the basal NO-mediated vasodilator tone rather than to its 
proposed antimuscarinic action. The functional counterpart of NO responsible for the 
rise in systemic and local vascular resistance seems to be provided, at least in intact 
animals, by circulating catecholamines. 
The initial stimulus causing vasodilatation during migraine is largely unknown 
and locally released CGRP may not be the principal mediator. Although this 
neuropeptide is a potent vasodilator, it causes no headache in humans and did not 
induce arteriovenous anastomotic shunting in the pig. In contrast, our experiments in 
the pig indicate that arteriovenous anastomotic tone can be regulated by endothelium-
derived NO and clinical experimental studies suggest an upregulation of NO-mediated 
pathways in migraine patients. Nitrovasodilators evoke migraine-like headache, which 
is accompanied by dilatation of extracerebral and basal cerebral arteries. Both headache 
and vasodilatation is more pronounced in migraine patients than in healthy subjects. 
Similarly, headache and local vasodilatation has been observed in migraine patients 
with the endothelium-dependent vasodilator histamine. Since an enhanced sensitivity 
is observed in migraine patients following endothelium-dependent and independent 
generation of NO, this phenomenon is not easily explained by simple changes in basal 
NO-release from the vascular endothelium. A putative contribution of nitroxidergic 
nerves to the regulation of cranial blood flow is proposed. 
In conclusion, NO contributes differentially to the regulation of local vascular 
tone and, hence, regional blood flow in various species. The ability of endogenous NO 
to change blood flow through carotid arteriovenous anastomoses seems relevant for 
migraine headache. This may lead to the development of novel antimigraine therapy. 
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Samenvatting 
Het vasculaire endotheel vonnt een belangrijk regulerend orgaan dat een 
verscheidenheid aan fYsiologische functies vervult. De endotheelcellen dragen bij aan 
het handhaven van de cardiovasculaire homeostasis door de afgifte van vasoactieve 
factoren met tegengestelde werking, welke de tonus van de onderliggende gladde 
spierlaag kunnen veranderen en de bloedstroom lokaal kunnen beinvloeden. Uit de 
potente vasodilatoire werking van stikstof oxide (NO) valt af te lei den dat 
veranderingen in de f}'siologische werking van deze verbinding vooral van belang kan 
zijn onder pathofYsiologische omstandigheden en klinisch experimenteel onderzoek 
duidt op een mogelijke 1'01 voor NO in de aetiologie van migraine. 
In "oofds/uk 1 worden de klinische symptomen van het migraine syndroom en 
de vasculaire veranderingen tijdens een migraine aanval besproken. De hoofdpijn fase 
van een migraine aanval gaat gepaard met een verwijding van grote extracraniele en 
bas ale cerebrale arterien. Bovendien is venvijding van arterioveneuze anastomosen 
beschreven. De lokale vaatvenvijding gaat veelal samen met versterkte vasculaire 
pulsaties en de hoofdpijn kan worden veroorzaakt door een depolarisatie van 
perivasculaire sensore zenuwen. Een lokale vrijzetting van vasoactieve neuropeptiden, 
zoals calcitonin gene-related peptide (CGRP), kan bijdragen aan het onderhouden van 
de vasculaire veranderingen tijdens de hoofdpijn aanval. 
Het tweede gedeelte van dit hoofdstuk beschrijft de ontdekking, de chemische 
karakterisering en de oorsprong van de endotheel-afhankelijke relaxerende factor 
(EDRF), en geeft een overzicht van de huidige kennis van de verschillende endotheel-
afhankelijke vasoactieve factoren. De factoren die lokale vasoconstrictie veroorzaken 
zijn thromboxaan en prostaglandine H2, de endothelines en het angiotensine II. Lokale 
verlaging van de vaattonus wordt gemedieerd via de afgifte van prostacycline en 
EDRF. Daarnaast draagt hyperpolarisatie van de gladde spiercel, via een door het 
endotheel gegenereerde onbekende hyperpolariserende factor (EDHF), bij aan de 
vaatvenvijding. 
In hoofds/uk 2 worden de hemodynamische effecten van de NO-syntheserennner 
NG-nitro-L-arginine methyl ester (L-NAME) en de mogelijkheid met deze verbinding 
de hypotensieve respons, veroorzaakt door de endotheel-afllankelijke vasodilator 
acetylcholine, te remmen beschreven in genarcotiseerde ratten en katten. 
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L-NAME induceerde eenlangdurig hypertensief effect en een bescheiden veri aging van 
de hartfrequentie in ratten. Het hypertensieve effect werd tegengegaan door het 
endogene substraat L-arginine. L-NAME vertoonde echter geen hemodynamische 
respons in katten. Toediening van L-arginine veroorzaakte geen significante 
hemodynamische effeclen in katten welke eerder behandeld waren met L-NAME. 
Daarentegen induceerde L-arginine een geringe verlaging van de hatifrequentie, een 
toename van het hartminuutvolume en slagvolume in katten behandeld met fysiologisch 
zout. 
In de kat verlaagde L-NAME de bloedstroom naar verschillende abdominale 
organen. Toediening van L-arginine resuHeerde in een significante toename van de 
bloedstroom naar de longen, het mesenterium, de lever en nieren. Deze respons was 
mindel' in dieren behandeld met L-NAME. De grootte van de hypotensieve respons 
geinduceerd door acetylcholine werd door L-NAME niet beinvloed, maar de duur van 
deze respons werd door L-NAME bekort in zowel de rat als de kat. 
De resultaten van deze experimenten tonen een uitgesproken verschi! in de 
hemodynamische effecten van L-NAME tussen de rat en de kat. De bijdrage van NO 
aan de regulatie van de bloeddruk lijkt, in tegenstelling tot de rat, beperkt in de kat. 
Een regulatoire werking voor NO lijkt echter weI te bestaan in verschillende weefsels. 
In beide diersoorten lijkt de hypotensieve werking van acetylcholine te worden 
gemedieerd via een NO-onafhankelijk mechanisme. 
In hoo/ds/uk 3 worden de hemodynamische effecten van L-NAME in ratten met 
een lage vasculaire tonus beschreven. In de gepende rat verhoogde L-NAME de 
gemiddelde bloeddruk in een vergelijkbare mate als in de intacte genarcotiseerde rat. 
De verlaging van de hatifrequentie bleef echter achterwege. De bloeddruk effecten van 
L-NAME werden niet beinvloed door voorbehandeling met de 0:, adrenerge en 5HT, 
serotonerge receptor antagonist ketanserine. 
Aangezien de vasorelaxerende werking van serotonine in geisoleerde vasculaire 
preparaten afhankelijk lijkt te zijn van functioneel endotheel, werd de mogelijke 
bijdrage van NO-vrijzetting door het endotheel aan de bloeddruk effecten van 
5-hydroxytryptamine (5-HT) eveneens onderzocht. In de aanwezigheid van ketanserine 
werden de hypotensieve responsen van 5-HT versterkt door zowel L-NAME als de 
o:,-adrenerge agonist fenylefrine. De duur van de bloeddrukdaling werd enigszins 
verlengd door L-NAME. De grootte van de hypeliensieve fespons van 5-HT werd door 
L-NAME niet beinvloed, maar de duur van deze respons werd verlengd. 
143 
Appendix 
Deze resultaten suggereren dat L-NAME de bloeddruk verhoogt in dieren met een 
lage vaattonus, waarschijnlijk via remming van de basale afgifte van NO. De 
hypotensieve effecten van 5-HT zijn daarentegen onafhankelijk van NO-vrijzetting door 
het endotheel. In de gepende rat lijken de hypertensieve responsen van 5-HT te worden 
tegengegaan door een gelijktijdige vrijzetting van NO. 
In de, in hoofdstuk 4, beschreven experimenten werden de hemodynamische 
effecten van L-NAME nader geanalyzeerd in het genarcotiseerde varken. Bovendien 
werd het effect van de renuning van het enzym NOS op de totale systemische- en 
regionale bloedstroom door arterioveneuze anastomosen bestudeerd. 
L-NAME verlaagde de systemische- en pulmonale vasculaire conductantie en het 
hartminuutvolume, zonder veranderingen in hartfrequentie en gemiddelde arteriele 
bloeddruk. De systemische en pulmonale hemodynamische veranderingen werden 
tegengaan door L-arginine. 
Het verschil in bloedstroom, gemeten via simultane injecties met microsferen met 
een diameter van respectieveljk 15 I'm en 50 I'm, werd door L-NAME gereduceerd, 
hetgeen kan duiden op een afuame van de bloedstroom door mierioveneuze 
anastomosen met een diameter tussen 28 en 90 I'm. 
Uit deze resultaten mag worden afgeleid dat in het genarcotiseerde varken (i) NO 
betrokken is bij de regulatie van zowel de systemische als de pulmonale vasculaire 
conductantie, (ii) de afhame van de systemische vasculaire geleidbaarheid deels 
veroorzaakt wordt door een constrictie van systemische arterioveneuze anastomosen en, 
(iii) door een afuame van de pulmonale vasculaire conductantie, resulterend in een 
dating van het hartminuutvolume. 
In hoofdstuk 5, werd de bijdrage van de biosynthese van NO aan de regulatie van 
de bloedstroom door mierioveneuze anastomosen onderzocht in het vaatbed van de 
arteria carotis van het genarcotiseerde varken. 
Behalve in de hoogste dosering, had L-NAME geen invloed op de systemische 
hemodynamische varia belen, terwijl L-arginine de gemiddelde arteriele bloeddruk 
enigszins verlaagde. Remming van de NO-synthese resulteerde in een dosis-
afhankelijke afuame van de bloedstroom door de arteria carotis en de conductantie van 
het carotide vaatbed. De afuame beperkte zich geheel tot het arterioveneuze gedeelte 
van deze circulatie. Toediening van L-arginine herstelde de vasculaire conductantie van 
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de arteria carotis vrijwel geheel en de conductantie van de arterioveneuze fractie 
gedeeltelijk. 
Deze experimenten duiden erop dat de vorming van NO uit L-arginine weinig 
bijdraagt aan de regulatie van de weefseldoorbloeding in het vaatbed van de arteria 
carotis van het varken. Daarentegen lijkt NO een belangrijke invloed te hebben op de 
alVoer van bloed door arterioveneuze anastomosen in het genarcotiseerde varken. 
HooJdstuk 6 beschrijft de effecten van de NO-donoren nitroprusside natrium 
(NPR) en S-nitroso-N-acetylpenicillamine (SNAP) op de capillaire en arterioveneuze 
anastomotische bloed~troom in de carotide circulatie van het varken. 
Met uitzondering van de hartfrequentie, veroorzaakte intracarotide infusie met 
deze nitrovasodilatoren geen systemische hemodynamische veranderingen. De 
bloedstroom door de arteria carotis communis, de vasculaire conductantie, en de 
pulsaties van deze arterie werden zowel door NPR als SNAP dosis-afhankelijk 
verhoogd. Beide NO-donoren induceerde een toename van de totale capillaire 
bloedstroom en conductantie. In tegenstelling tot NPR, werd de bloedstroom door 
arterioveneuze anastomosen en de conductantie in dit deel van de carotide circulatie 
verhoogd door SNAP. De toename van de totale capillaire doorbloeding werd 
weerspiegeld door een toename van de bloedstroom in zowel extracerebrale weefsels 
als de dura, zonder noemenswaardige veranderingen in de overige intracraniele 
weefsels. 
oit deze resultaten voigt dat beide nitrovasodilatoren een arteriolaire dilatatie 
kunnen veroorzaken, welke gepaard gaat met versterkte vasculaire pulsaties in de 
carotide circulatie van het varken. De uitgesproken arteriolaire dilatatie beperkt het 
effect van NO-donoren op arterioveneuze anastomosen, mogelijk als gevolg van een 
zogenaamd 'steal' fenomeen. 
Bovendien lijkt de dilatatie van zowel extra- en intracrani~le arterien, en 
arterioveneuze anastomosen te leiden tot versterkte vasculaire pulsaties. De toegenomen 
pulsaties, meer nog dan de toename in de bloedstroom, zijn mogelijk mede 
verantwoordelijk voor de hoofdpijn veroorzaakt door nitrovasodilatoren. 
HooJdstuk 7 beschrijft een studie naar het effect van het neuropeptide, calcitonin 
gene-related peptide (CGRP) op de verdeling van de carotide bloedstroom en de 
hemodynamische variabelen in het genarcotiseerde varken. Dit neuropeptide kan een 
rol spelen in de pathofysiologie van migraine hoofdpijn en de vrijzetting van dit 
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peptide wordt, althans in somrnige v~ten, gemedieerd door NO. Humaan C(-CGRP 
veroorzaakte een dosis-afhankelijke toename van de bloedstroom en conductantie in de 
arteria carotis, alsmede verhoogde vasculaire pulsaties. Deze effecten gingen gepaard 
met een daling van de systemische bloeddruk en een gelijktijdige toename van de 
hartfrequentie en hethartminuutvolume. De vel'hoogde carotide bloedstroom resulteerde 
in een toename van de capillaire bloedstroom naar voomamelijk extracerebl'ale weefsels 
waaronder de dura. De bloedstroom door arterioveneuze anastomosen in het carotide 
vaatbed bleef onverandel'd. 
De antimigraine middelen, dihydroergotamine en sumatriptan, reduceerden de 
verhoogde bloedstroom in de arteria carotis en het capillaire vaatbed zonder effect op 
de systemische conductie. De door C(-CGRP geinduceerde toename in de weefsel 
doorbloeding werd in de meeste extracel'ebrale weefsels, met uitzondering van de dura, 
eveneens tegengegaan door deze middelen. 
De resultaten uit deze experimenten tonen dat C(-CGRP een arteriolaire dilatatie 
en een bloeddruk verlaging veroorzaakt in het varken. De daling van de systemische 
arteriele bloeddruk en de uitgesproken toename van de capillaire dool'bloeding 
maskeert een eventueel effect van dit peptide op arterioveneuze anastomosen. De 
veranderingen van de bloedstroom in het carotis vaatbed van het varken, onder invloed 
van C(-CGRP, kunnen worden tegengegaan met de antimigraine middelen 
dihydroergotamine en sumatriptan. 
In hooft/uk 8 worden de experimentele resultaten van dit proefschrift in het 
algemeen, en de mogelijke relatie tussen NO en de pathofYsiologie van migraine in het 
bijzonder, besproken. Het merendeel van de hemodynamische effecten en de 
veranderingen in weefseldoorbloeding veroOl'zaakt door de NO-syntheseremmer 
L-NAME kunnen worden toegeschreven aan een afilame van de bas ale NO-
gemedieerde vasodilatoire tonus. Er bestaan geen aanwijzingen voor een 
antimuscarinerge werking van L-NAME in onze experimenten. De functionele 
tegenhangers van NO, welke verantwoordelijk zijn voor de toename van de systemische 
en lokale vaatweerstand, lijken in genarcotiseerde diel'en voornamelijk te bestaan uit 
cil'culerende catecholamines. 
De initiele stimulus welke verantwoordelijk is voor de verwijding van grote 
(extra)cerebrale vaten en arterioveneuze anastomosen tijdens de migraine aanval is 
grotendeels onbekend. Hoewel CGRP een potente vasodilator is, veroorzaakt dit 
nellropeptide geen hoofdpijn bij de mens en kon geen effect op de bloedstroom door 
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arterioveneuze anastomosen worden aangetoond in het varken. De experimenten met 
de NO syntheseremmer L-NAME en de verschillende NO-donoren suggereren 
daarentegen dat NO betrokken is bij de bloedstroomregulatie door deze vaatsegmenten 
en klinische experimenteel werk lijkt te duiden op een verhoogde gevoeligheid voor 
of activiteit van NO-gemedie~rde processen in migraine patienten. Verschillende 
nitrovasodilatoren veroorzaken migraine-achtige hoofdpijn en een verwijding van 
extracerebrale arteri~n en basale cerebrale arteri~n. Deze effecten zijn meer 
uitgesproken in migraine patienten dan in gezonde proefpersonen. Hoofdpijn en lokale 
vaatverwijding is eveneens beschreven in migraine patienten voor de endotheel-
afhankelijke vaatvenvijder histamine. De verhoogde gevoeligheid van migraine 
patienten kan niet worden verklaard door veranderingen in de bas ale vrijzetting van 
NO door het vasculaire endotheel, omdat dit verschijnsel wordt waargenomen na zowel 
endotheel-afhankelijke als onafhankelijke vorming van NO. Een mogelijke bijdrage van 
nitroxiderge zenuwen aan de regulatie van de (extra)crani~le bloedstroom is 
voorstelbaar. 
In het algemeen kan worden gesteld dat de bijdrage van NO aan de regulatie van 
de lokale vaaltonus en de regionale doorbloeding verschilt naar diersoort. Het 
vermogen van endogeen NO om de bloedstroom door carotide arterioveneuze 
anastomosen te beinvloeden lijkt relevant te zijn voor migraine hoofdpijn. Dit kan een 
aanzet vormen tot de ontwikkeling van een nieuwe therapie voor migraine. 
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List of abbreviations 
A23l87 
AC 
ACE 
Ach 
ADP 
Bk 
COX 
a-CORP 
ECE 
ecNOS 
EDCF 
EDHF 
EDRF 
ET 
ETA 
ETB 
FAD 
FMN 
cOMP 
OC 
5-HT 
iNOS 
L-NAME 
L-NNA 
L-NMMA 
L-OHARO 
LV dP/dtma< 
f!m 
NADPH 
ncNOS 
SOD 
TNFa 
VIP 
calcium ionophore 
adenyl cyclase 
angiotensin converting enzyme (kininase II) 
acetylcholine 
adenosine diphosphate 
bradykinin 
cyclooxygenase 
calcitonin gene-related peptide 
endothelin converting enzyme 
endothelial NO-synthase, also denoted isoform III 
endothelium-derived contracting factor 
endothelium-derived hyperpolarizing factor 
endothelium-derived relaxing factor 
endothelin 
endothelin-receptor subtype A 
endothelin-receptor subtype B 
flavin adenine dinucleotide 
flavin mononucleotide 
guanosine 3',5'-cyclic monophosphate 
guanylyl cyclase 
5-hydroxytryptamine, serotonine 
inducible NO-synthase, also denoted isoform II 
N" -nitro-L-arginine methyl ester 
NG-nitro-L-arginine 
N" -monomethyl-L-arginine 
NG -hydroxyl-L-arginine 
left ventricular maximum pressure increase 
micrometer (10.601) 
nicotinamide-adenine dincleotide hydrophosphate 
neuronal NO-synthase, also denoted isofonn I 
superoxide dismutase 
tumor necrosis factor-a 
vasoactive intestinal polypeptide 
181 



